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The increased prevalence of allergic diseases over the decades is a major health concern 
globally. Pharmacotherapeutic treatments of these diseases are largely symptomatic 
treatments. Allergen-specific immunotherapy has been shown to be a curative treatment for 
allergic diseases, but the underlying mechanisms for the efficacy remain elusive. The 
conventional allergen-specific immunotherapy for allergy has been conducted with allergenic 
proteins and a new approach involving allergen gene immunization is being developed over 
the last decade. This study aimed to gain a better understanding of the cellular and molecular 
mechanisms of allergen specific immunotherapy, with the long term goal of improving the 
safety and efficacy of immunotherapeutic  treatments for allergic disease.  
 
The first part of the thesis focused on the mechanistic studies underlying the protein-based 
allergy immunotherapy. A major allergen from Dermatophagoides pteronyssinus mites, 
designated as Der p 2, was used as a model allergen to address the dosage effects of allergen 
on the nature of the immune responses elicited in mice immunized with different dosages of 
the Der p 2 allergen using an adjuvant-free immunization approach. Mice primed with 10 µg 
of Der p 2 (D10) displayed Th2-skewed responses, while priming with 50 µg (D50) showed 
suppressed Th2 responses with elevated TGF-β1 and IL-10 production. The notion of D50 
immunization induced the development of Treg cells and hindered the IL-13-dependent IgE 
synthesis was evident by the suppression of  cell proliferative and cytokines production 
(particularly IL-13) in the Der p 2-specific Th2 cells by the CD4+CD25+ T cells from the  
D50 immunized mice. The IL-13 neutralizing study has revealed the importance of IL-13 in 
 vii
regulating IgE synthesis in this model. Furthermore, attenuated IL-13 gene expression and 
low basal IgE titer were observed in D50 mice after Der p 2 aerosol challenge. Gene 
profiling study has shown that MGAT5 gene might be involved in dosage effects on the 
phenotype of immune responses through the modulation of T cell activation threshold. The 
differential expression of some TGF-β related genes have further validated the induction of 
the TGF-β1 signaling pathway and the regulatory responses induced in D50 mice. Some Th2 
related genes were upregulated in D10 mice but under-expressed in D50 mice, corresponding 
to the differential immune responses induced by the two doses of Der p 2 in these immunized 
mice. The identification of genes associated with the Wingless (Wnt) signaling pathway 
suggests the possible cooperation between the Wnt and TGF-β1 signaling pathways in the 
specification of cell fates during development.  
 
The second part of the thesis aimed to gain further understanding of the mechanisms 
underlying the protective immunity against allergy induced by allergen gene immunization. 
The immunogenicity of Der p 2 gene immunization was studied in mice immunized with 
plasmid DNA constructs encoding for different forms of Der p 2. Results showed that the 
magnitude of the immune responses induced by genetic immunization was partially 
influenced by the H2 haplotype of different mouse strains.  The phenotype of the immune 
responses was significantly influenced and dictated by the design of the DNA construct for 
immunization. The immunological impacts of incorporating signal peptide and targeting 
sequences in DNA constructs for allergic disease were evaluated in mice immunized with 
DNA constructs designated as pCI-2, pCI-52, and pCI-52LA. Mice immunized with pCI-
52LA showed strong Th1-skewed responses, whereas construct pCI-2 induced only moderate 
 viii
levels of Th1 response. Mice immunized with pCI-52 showed a mixed Th1 and Th2 
phenotypes and produced substantial circulating Der p 2 protein. Naive mice adoptively 
transferred with DCs primed by pCI-52 construct, but not with DCs primed by other 
constructs, were sensitized to produce high levels of Der p 2 specific IgE. These data 
revealed the potential risk of incorporating a signal peptide sequence that facilitated a high 
expression level of Der p 2 in the construct design, as such DNA construct could provoke 
masked Th2 responses that mediate allergen sensitization instead of allergy protection. 
However, the additional inclusion of lysosomal-targeting sequences to such a construct could 
improve the safety and efficacy of DNA vaccination against Der p 2 sensitization.  These 
data are useful information for the design of safe and efficacious DNA vaccines for allergy in 
general  
 
Taken together, the new findings from this thesis will make valuable contributions in the 
development of safe and more efficacious therapeutic and prophylactic vaccines for allergy.  
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1.1 History of Allergy 
 
In the 17 century, Philipp Jacob Sachs described a case of generalized urticaria following 
ingestion of strawberries, and of shock after eating fish. Furthermore, German authors 
wrote of weakness, fainting and asthma observed in certain subjects after exposing to 
cats, mice, dogs and horses. In the middle of the 17th century, William Cullen witnessed 
an asthma attack of a pharmacist’s wife while her husband was preparing ipecacuanha. 
This may be the first reported incidence of drug allergy. Asthma and hayfever were well 
described in the middle of the 19th century. Dr. John Bostock, in 1819, first accurately 
described hay fever as a disease that affected the upper respiratory tract. Although of 
unknown origin, oddly enough it had nothing to do with either hay or having a fever. 
Common symptoms include sneezing, a runny or stuffed nose, red, itchy, swollen or 
watery eyes and itching in the nose and throat. In 1873 Charles Blackley performed the 
first skin test by applying pollen through a small abrasion in his skin and proved that 
grass pollen was the cause of hayfever. In 1902, French scientist Charles Richet and Paul 
Portier invented the word 'anaphylaxis' and described it as a severe systemic reaction 
sometimes observed after repeated injection of a substance. Anaphylactic shock occurs 
within minutes after allergen exposure, causing symptoms from swelling of body tissues, 
vomiting, developing cramps, to a sudden drop in blood pressure or even loss of 
consciousness.  
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 The term and concept of “allergy” was originally coined in 1906 by Viennese 
pediatrician, Baron Clemens Von Pirquet, who defined it as a “specifically changed 
reactivity of the host to an agent on a second or subsequent occasion”. He described the 
strange, non-disease related symptoms that some diphtheria patients developed when 
treated with a horse serum antitoxin. An allergic reaction is defined then as the result of 
the body's change when it adversely responds to a harmless antigen. The clinical 
symptoms and signs of asthma were well described by ancient Greek scholars, although 
several other types of breathing difficulty were probably attributed to asthma. A 
significant contribution to the understanding of human allergy came in 1921 from Carl 
Prausnitz and Heinz Küstner. Serum from Küstner, who was allergic to fish, was 
transferred to the arm of Prausnitz. A typical weal and erythema reaction was observed 
on the site after local administration of the appropriate allergen. This passive 
transferability strongly implicated an antibody-mediated reaction. The nature of this 
antibody remained unknown until the Ishizakas in the USA and Johansson and Bennich 
in Sweden independently identified it in 1967. In a WHO conference in 1968, the 
antibody was named immunoglobulin E (IgE) (Kaplan AP et al., 1998; Lipkowitz MA 
and Navarra T, 2001 Harwanegg C et al., 2003). 
 
Atopy and immediate hypersensitivity are often used when describing allergy. Atopy is a 
term first coined by Coca and Cooke in 1923 from the Greek meaning ‘out of place’. 
Atopy is the hereditary tendency of a percentage of the population to make IgE and to 
suffer from allergic diseases such as hay fever, asthma and eczema. Gell and Coombs 
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(1975) described four classes (now five) of hypersensitivities reactions (Type I-V). Since 
then, allergy is classified as Type I hypersensitivity as characterized by classical IgE 
mediation of effects. An allergy or Type I hypersensitivity is hence define as an immune 
malfunction whereby a person's body is hypersensitized to react immunologically to 
typically non-immunogenic substances. In response to repeated exposure to an allergen 
such as pollen, the allergic individual produces IgE antibodies, which then attach to mast 
cells. This is the first step in sensitizing the affected tissue. Upon repeated exposure, 
allergens cross-link IgE antibodies on the surface of the mast cells. It is this binding 
process that triggers the release of histamine and other mediators, thus causing allergy 
symptoms (Kaplan AP et al., 1998; Lipkowitz MA and Navarra T, 2001).  
 




Population based studies have revealed dramatic differences in symptom prevalence of 
allergic diseases in various countries of the world. It has been mentioned that allergies 
occur in approximately one of every six Americans. Of these, 41% are due to hay fever, 
25% to asthma, and the remainder to other allergies, such as atopic dermatitis, urticaria, 
angioedema, and food reactions (Burr M, 1993). The highest asthma prevalence was 
found in Britain, Australia, New Zealand, the USA and some Latin America while lower 
prevalence rates were found in the non-industrialized countries and more rural areas 
(Holgate ST, 2000; Ring J et al., 2001). Asthma is arguably the most serious of the 
 3
allergic diseases in that it is disabling (causing more than 100 000 hospital admissions 
each year in England and Wales) and occasionally fatal. In the early 1960s asthma 
mortality increased dramatically in many countries. The increase was attributed to the 
excessive use of non-selective β agonists, which were subsequently withdrawn from the 
market. More recent increases in asthma mortality reported from Britain, France, and the 
United States may be related to increased prevalence or severity of asthma or inadequate 
health care. Evidence for the latter comes from audits and confidential inquiries that show 
inadequate treatment of asthma in the months leading up to death and during the fatal 
attack and the observation of higher mortality in populations recognized as often 
receiving poor health care (socioeconomically deprived people in Britain; black people in 
the United States). In England and Wales asthma mortality rose between the mid-1970s 
and the mid-1980s but declined steadily during the early 1990s (Burney P and Jarvis D, 
1997). There is an estimated that as many as 10% of the general population and 90% of 
the individual suffering from allergic asthma are sensitive to house dust mites. The 
severity of the problem is on the rise, with at least 45% of young people with asthma 
showing sensitivity (Sporik R et al., 1992; Platts-Mills TAE et al., 1997). 
 
1.2.2 Allergic responses 
 
The immune system of an allergic patient produces an allergy antibody (IgE) in response 
to dust mite allergens. In an immediate hypersensitivity response, an allergen enters the 
body and binds to allergen-specific IgE, which in turn binds to the high-affinity receptor 
Fc receptor, FcεRI, expressed on mast cells and basophils (Turner H and Kinet JP, 1999). 
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Cross-linking of receptors by allergen-bound IgE on mast cells and basophils induces the 
release of inflammatory mediators (for example histamine, leukotriences, and 
prostagladins) and within minutes causes hypersensitivity reactions, such as rhinitis (a 
stuffy, running nose, or hayfever), conjunctivitis (red, irritated eyes), bronchitis (cough 
and congestion) and asthma. In allergic individuals who suffer from chronic 
manifestation of atopy (for example chronic asthma and atopic dermatitis), late phase 
reactions are pronounced. The late phase manesfestion includes These responses are 
caused by the activation of allergen-specific T cells after hours to days, and characterized 
by the infiltration of activated eosinophilic granulocytes and allergen-specific T 
lymphocytes (Neerven RJJ et al., 1999; Blaser K et al., 2004) (Figure 1.1). manifestation 
 
1.3 House dust mite  
 
There are many protein components in household dust that can cause allergies in human. 
The most common allergenic components of house dust, however, are from house dust 
mites. House dust mites are complex organisms that produce thousands of different 
proteins and other macromolecules. These products as well as the extracts of mites are 
capable of inducing allergy symptoms of the respiratory tract. Inhalation of dust mite 
allergens by sensitive individuals can cause allergy diseases such as bronchial asthma, 
allergic rhinitis, atopic eczema, and are occasionally fatal (Platts-Mills TAE and 




 The common house dust mites belong to the family Pyroglyphidae and these mites live 
permanently in homes associated with dust. Pyroglyphidae is the most important family 
although other families such as Glycyphagidae, Acaridae, and Echimyopodidae may be 
important in certain geographic areas. The family of Pyroglyphidae contains about 16 
genera and 46 species (Wharton GW et al., 1976; Hart BJ et al., 1998; Arlian LG et al., 
2000). Only 13 species are recorded from house dust, of which 3, Dermatophagoides 
pteronyssinus (Der p), D. farinae (Der f), Euroglyphus maynei (Eur m), are the most 
frequently reported and found in temperate climates. Another two species have more 
limited distributions, D. siboney, so far restricted to Cuba, and D. microceras, 
predominantly within Europe. Important non-Pyroglyphids distributed globally include 
species traditionally regarded as storage mites such as Chlortoglyphus arcuatus 
(Chlortoglyphidae) and members of the superfamily Glycyphagoidea, especially Blomia 
tropicalis, Glycyphagus domesticus, and Lepidoglyphus destructor (Colloff MJ., 1993; 
Colloff MJ and Stewart GA et al., 1997) 
 
1.3.2 Mite allergens  
 
Most mite allergens are biochemically active molecules present in mite bodies, secreta 
and excreta. Mite bodies and fecal particles contained the greatest proportion of mite 
allergens (Tovey ER et al., 1982; Arlian LG et al., 1987). Allergens originates from fecal 
matter include enzymes that originate from mite’s digestive tract. Other possible 
allergens include enzymes associated with molting process or may be components of mite 
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saliva that is left in the environment on the food substrates where mites feed. After death, 
some of the soluble protein in body fluids released from the disintegrated body could also 
be allergenic (Arlian LG and Platts-Mills TAE, 2001). 
 
The identification and characterization of important dust mite allergens have been done 
since the last decade. They are divided into specific groups on the basis of their 
biochemical composition, sequence homology, titers of human IgE reactivity and 
molecular weight. To date, about 19 groups of allergens have been classified (Arlian LG 
and Platts-Mills TAE, 2001; Thomas WR et al., 2002). Among these allergens, strong 
IgE binding has been demonstrated for the group 1, 2, 3, 9, 12 and 15 allergens. The 
group 1 and 2 allergens are considered as major allergens that give high reactivity with 
mite-sensitive patient sera of about 90% (Heymann PW et al., 1989).  
 
1.3.2.1 Group 1 allergens 
 
The group 1 allergens are polymorphic 25-kDa acidic to neutral proteins recognized by 
most mite-allergic individuals. They have been demonstrated in D.  pteronyssinus, D. 
farinae, E. maynei, D. microceras and D. siboney (Chapman MD et al., 1980; Lind P., 
1986; Chua KY et al., 1988; Kent NA et al., 1992; Stewart GA, 1995; Ferrandiz R et al., 
1995). The allergens are found in the whole body and fecal extracts, and are synthesized 
by cells lining of intestinal gut tract of the mite (Tovey ER and Baldo, 1990; Thomas B et 
al., 1991). The complete sequences of the Der p 1 and Der f 1, an almost complete 
sequence for Eur m 1 and the N-terminal sequence for Der m 1 have been reported (Chua 
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KY et al., 1988; Dilworth RJ et al., 1991; Kent NA et al., 1992). These information 
suggested that group 1 allergens are produced as preproproteins, comprising of a leader 
peptide (18 residues) and a propeptide (80 residues) together with a mature protein (222-
223 residues)(Dilworth RJ et al., 1991). Studies with Der p 1 and Der f 1 show a 
sequence identity of 80%. The divergence is predominant in the N-terminal residues 1-20 
(45%), the C-terminal 201-222 (31%) and central region 91-130 (30%). The deduced 
amino acid sequence of Eur m 1 is about 78% homology with Der p 1 and Der f 1, and 
the divergence of the sequence of Eur m 1 was similar as the divergence between Der p 1 
and Der f 1 (Smith W et al., 1999). A potential glycosylation site at amino acid residue 
52/53 has been detected in all three sequences, but the degree of glycosylation associated 
with these allergens is unclear at present (Colloff MJ and Stewart GA, 1997). Group 1 
allergens belong to the cysteine group of proteolytic enzymes that include the mammalian 
enzymes cathepsin B and H and the plant enzymes actinidin and papain. The overall 
sequence homology between group 1 allergens and plant enzymes is about 31% (Chua 
KY et al., 1988; Topham CM et al., 1994; Platts-Mills TAE et al., 1997).  
 
1.3.2.2 Group 2 allergens 
 
Group 2 allergens are neutral to basic 14-18kDa non-glycosylated proteins recognized by 
majority of mite-allergic individuals. This group has been identified in D.  pteronyssinus, 
D. farinae and L. destructor and D. siboney (Lind P, 1985; Yasueda H et al., 1986; 
Ferrandiz R et al., 1995; Heymann PW et al., 1989;; Valera J et al., 1994). They have 
been shown to induce humoral and cellular responses in 80-90% of mite-allergic 
 8
individuals (Heymann PW et al., 1989). The allergens are synthesized as preproteins with 
leader peptides of 11-17 residues and mature proteins of 125-129 residues (Chua KY et 
al., 1990a; Trudinger M et al., 1991). Der p 2, Der f 2 and Eur m 2 share 85-88% amino 
acid sequence identity. Three disulphide bonds have been determined in Der f 2, namely 
Cys8-119, Cys21-Cys27, and Cys73-78 (Nishyama C et al., 1993). These sites are likely 
to be conserved in all group 2 allergens and are essential for IgE binding (Smith WA and 
Chapman MD, 1996). The existences of Tyr p 2, Lep d 2 and Gly d 2 have also been 
shown in storage mites L. destructor and G. domesticus, in respectively (Schmidt et al., 
1995; Gafvelin G et al., 2001). There is about 37-45% amino acid homology between 
Lep d 2, Gly d 2 and Der p 2 (Gafvelin G et al., 2001). The precise biological function of 
group 2 allergens in situ is unknown although they have been shown to be resistant to 
denaturation by proteases, heat and extremes of pH (Lombardero M et al., 1990). 
Sequence homology searches suggest that the group 2 allergens are associated with the 
mite reproduction (Thomas WR and Chua KY, 1995), although confocal microscopy 
indicated that they were present in the mite gut (Van Hage-Hamsten M et al., 1995).  
 
1.3.2.3 D. pteronyssinus 2  
 
Der p 2 is one of the major allergens of D. pteronyssinus isolated and fully characterized 
by Chua KY et al in 1990b. Most mite allergens in house dust mite are found in the fecal 
particles but Der p 2 does not fit the typical paradigm. It occurs largely in the whole 
extract rather than the spent waste (Platts-Mills TAE et al., 1992). Der p 2 protein is 
encoded by two exons. The first exon encodes for a signal peptide and part of the mature 
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protein. The second exon codes for the remainder mature protein. There is a small intron 
of range 80 to 83bp interrupted the coding region of between codons 8 and 9. Gene and 
protein analysis has demonstrated that there are about 10 isoforms or variants of Der p 2 
with pI values ranging from greater than 7.0 and 5.9. The most abundant sequence was 
the variant Der p 2.0101 which was the first sequence described for Der p 2 (Chua KY et 
al., 1996). Most changes to the sequence involved a pattern of substitution where residues 
40, 48, 111 and 114 were replaced from VTMD in Der p 2.0101 to LSLN in Der p 
2.0104. Natural Der p 2 is best represented by a mixture of the sequence Der p 2.0101 
and Der p 2.0104 (Smith WA et al., 2001; Thomas WR et al., 2002).   
 
From the study of O’ Hehir RE and colleagues (1993), the regions of Der p 2 most 
frequently identified by T cell responses were within residues 61-68 and 78-104, and a 
major region was found within the peptide 111-129 residues (O’Brien RM et al., 1995).  
IgE epitope mapping of Der p 2 showed that peptide fragments 42-80, 64-105 and 81-129 
bound specific IgE (Kobayashi I et al., 1996). The tertiary structure of recombinant Der p 
2 has been determined by nuclear magnetic resonance spectroscopy (Mueller GA et al., 
1998). Der p 2 allergen comprised a number of β-pleated sheets together with random 
coil structure. It has some similarity to immunologlobulin fold and to the regulatory 
domains of transglutaminase. Der p 2 can easily be produced as recombinant allergens in 
the E. coli in fused forms (Chua KY et al., 1991; Tame A et al., 1996). This protein can 
also be secreted from Saccharomyces cerevisiae in a form essentially indistinguishable 
from the native allergen (Hakkaart GA et al., 1998).  
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1.4 Cells associated with allergic responses  
 
1.4.1 T lymphocytes 
 
T lymphocytes arise from hematopoietic stem cells in the bone marrow and migrate to the 
thymus gland to mature. During its maturation, it expresses unique T cell receptor (TCR) 
on its membrane which recognizes antigen only in association with cell membrane 
proteins known as major histocompatibility complex (MHC) molecules. All T cells can 
be distinguished by their display of two membrane glyocoproteins, with either CD4 or 
CD8. In general, there are three subpopulations of T cells, namely T helper (Th), T-
cytotoxic (TC) and the third type is called T-suppressor (Ts) or T regulatory (Treg) cell. 
CD4+ T cells are generally Th cells and are class II MHC restricted, while CD8 T cells 
are generally Tc cells and are class I MHC restricted. Ts or Treg cells are identified by 
the expression of CD4 and CD25 markers, and postulated to be involved in the tolerance 
of immune response (Marrack P and Kappler J, 1986; Grey HM et al., 1989). 
 
1.4.2 Th1 cells and Th2 cells  
 
In response to the recognition of an antigen-MHC complex, Th cell secretes various 
growth factors known as cytokines which plays an important role in activating B cell, Tc 
cells, macrophages, dendritic cells and other cells that participate in immune response. Th 
cells can be divided into two distinct subsets of effector cells based on their functional 
capabilities and lymphokine profiles. Since the original findings of Th1/Th2 CD4+ T 
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cells subsets by Mosmann TR et al. (1986), the study of the Th1/Th2 CD4+ T cell 
dichotomy has become an active research field in itself.  
 
Generally, Th1 clones are defined by their production of interferon (IFN)-γ and tumour 
necrosis factor (TNF)-β, which promote macrophage activation, production of opsonizing 
and complement-fixing antibodies, antibody-dependent cell cytotoxicity, and delay-type 
hypersensitivity (DTH) (Mosmann TR and Coffman RL, 1989). Induction of Th1 
expansion is under the influence of IFN-α, interleukin (IL)-12 and transforming growth 
factor (TGF)-β produced by B cells and macrophages (Romagnani S, 1992), while 
differentiation of Th1 cell is promoted by IFN-γ produced by T cell or natural killer (NK) 
cells (Maggi E et al., 1992). IL-12, which is a powerful IFN-γ inducer, appears to be the 
most important natural initiator of Th1 responses by acting either directly or indirectly 
through IFN-γ production (Maggi E, 1998).  
 
Th2 subclass secrete IL-4, IL-5 and IL-13, that provide optimal help for antibody 
responses, including IgE and IgG1 isotype switch facilitation to IgA synthesis, and 
promote mast cell and eosinophil growth, differentiation and activation (Romagnani SJ, 
1995). IL-4 is the most dominant factor in determining the likelihood for Th2 polarization 
in cultured cells (Maggi E et al., 1992). Other cytokines IL-10, IL-6 and IL-1 have also 
been shown. In vitro study has demonstrated PBMC cultures from allergic individuals 
produced more IL-10 than from non-allergic subjects (Heaton T et al., 2005). The level 
of IL-10 production has also shown correlation with the severity of asthmatics responders 
(Matsumoto K et al., 2002). It is well accepted that allergic diseases are typified by a 
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difference in the Th1/Th2-type cytokine response. Allergen-specific Th2 is directly 
involving in the orchestrating the immediate hypersensitivity reaction and late phase 
reaction.  Allergic patients exemplified a Th2 cytokine profile would implicate class 
switching of B cells toward IgG1 and IgE production, and differentiation and survival of 
eosinophil granulocytes (Wierenga EA et al., 1990; Kapsenberg ML et al., 1991; 
Parronchi P et al., 1991; Neerven RJJ, 1999). IFN-γ inhibits the development of Th2 cells 
and therefore inhibits the production of IL-4 and IL-13. IFN-γ also acts directly on B 
cells to repress epsilon (ε) germline transcription thus inhibit IgE production. The effect 
of IFN-γ on isotype class switching is specific to the IgE and IgG1 isotypes (Xu L et al., 
1994). 
 
The early production of IL-12 and IFNs favors Th1 development (Hsieh CS et al., 1993; 
Maggi E et al. 1992). IL-12 is the most powerful Th1-inducing agent. It is mainly 
produced by dendritic cells under the stimulation provided by exogenous signals and is 
upregulated by both CD40 ligand/CD40 interaction and in the presence of IFN-γ (Armant 
M et al., 1996). Interestingly, IFN-γ, but not IFN-α, plays an important role in mice, 
whereas both IFN-γ and IFN-α, promote the Th1 differentiation in human (Maggi E et al. 
1992; Parronchi P et al., 1992). The production of IL-4 by naïve T cells is highly 
dependent on B7 molecules (Lenschow DJ et al., 1996). Naïve CD4 T cells seem to be 
receptive to CD28-dependent IL-4 production only if they receive a weak TCR signal 
(Tao X et al., 1997). Therefore, naïve T helper cells themselves are able to produce small 
amount of IL-4 from their initial activation, and the concentration of IL-4 that 
accumulates at the level of the T helper cell response increasing lymphocyte activation. 
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The inducing effect of IL-4 dominates over other cytokines, so that if IL-4 levels reach a 
necessary threshold, differentiation of the T helper into Th2 phenotype occurs 
(Romagnani S, 2001).  
 
The factors responsible for the polarization of the specific immune response into a 
predominant Th1 or Th2 profile have been extensively investigated. Strong evidence 
suggests that Th1 and Th2 cells do not derive from distinct lineage, but rather from the 
same T helper cell precursor under the influence of both environmental and genetic 
factors acting at the level of antigen presentation (Abbas AK et al., 1996; Romagnani S., 
1997). Among the environmental factors, a role for the route of antigen entry, the 
physical form of immunogen, the type of adjuvant, and the dose of antigen have been 
suggested. The genetic mechanisms that concur in controlling the type of T helper cell 
differentiation still remain elusive. The environmental and genetic factors mixed together 
can influence the Th1/Th2 differentiation mainly by modulating a group of contact 
dependent factors and the predominance of a given cytokine in the microenvironment of 
the responding T helper cell. Among contact-dependent factors, the most important are 1. 
nature of interaction of the TCR with MHC-peptide complex which can probably control 
features of differentiation, T cell activation, clonal expansion and survival. The antigen 
doses and whether a peptide is a potent agonist, mixed antagonist, or partial agonist 
influence the development of Th1 or Th2 cells in vivo (Constant SL and Bottomly K, 
1997; Badou A et al., 2001), 2. Signals from APCs through costimulatory molecules such 
as CD28 and inducible costimulator (ICOS) are also critical regulators (Cua DJ et al., 
1996; Constant SL and Bottomly K, 1997; Maldonado-lopez R et al., 1999; Yoshinaga 
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SK et al., 1999; Akiba H et al., 2000) and 3. Cytokines and transcription factors that 
exert potent influences on the efficiency of Th1 and Th2 development (Le Gros G et al., 
1990; Paul WE and Seder RA, 1994; Glimcher LH and Singh H, 1999).  
 
1.4.3 T regulatory cells 
 
Regulatory (“suppressor”) T cells were first described in 1971 by Gershon and Kondo 
who demonstrated their ability to transfer antigen-specific tolerance to naive animals. 
Due to the lack of substantial evidence, many investigators subsequently dismissed the 
entire concept of suppression as an artifact of the complex and poorly reproducible 
biologic assays used to demonstrate its presence, several experimental observations 
remained difficult to interpret without postulating some form of active down-regulation 
of the immune response (Moller G, 1988; Janeway CA Jr, 1988). In 1995, a phenotypic 
description of one class of regulatory T cells finally became available. Sakaguchi et al 
showed that when CD4+ T cells from normal Balb/C mice were depleted of the fraction 
expressing the CD25+ marker and injected into Balb/C athymic nude mice, all recipients 
developed multiple autoimmune diseases. In addition, the deleterious effects of CD4-
CD25+ T cells could be prevented by the coadministration of CD4+CD25+ T cells. Since 
then, CD4+CD25+ T cells, which occur naturally in peripheral blood and originate from 
the thymus (Jordan MS et al., 2001), have been the subject of intense scrutiny and have 
been shown to contribute to peripheral self-tolerance in rodents (Thornton AM and 
Shevach EM, 1998; Gavin MA et al., 2002; Kohm AP et al., 2002), and humans 
(Dieckmann D et al., 2001; Ng WF et al., 2001; Stephens LA et al., 2001) Their ability to 
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actively transfer unresponsiveness in vitro and in vivo distinguishes them from other 
mechanisms of peripheral tolerance including T cell anergy (Schwartz RH et al., 1996). 
Treg cells have been categorized into cytokines producing or cell-contact dependent 
suppressive immunity. Studies exploring the role of Treg cells in allergic disease have 
primarily focused on inducible Tr1 or Th3 cells, distinctively characterized by their 
ability to secrete IL-10 and TGF-β respectively. Whether these distinctions represent 
developmental or functional differences, or both, remains unclear. The antigen specific 
responses of Tregs have been termed cell-contact dependent, as they require physical 
contact between the Tregs and APCs and the responding T cells (van Oosterhout and 
Bloksma, 2005).  
 
Studies from at least three separate groups have shown impaired naturally occurring 
CD4+ CD25+ Treg-mediated inhibition of allergen-specific Th2 responses in allergic 
patients during active hayfever season (Ling EM et al., 2004; Grindebacke H et al., 2004) 
or in individuals who mount vigorous Th2 responses to allergen (Bellinghausen I et al., 
2003). Furthermore, depletion of CD4+ CD25+ T cells from the peripheral blood of 
healthy individuals reveals enhanced proliferative and Th2 cytokine responses to various 
allergens including milk, nickel and grass (Taams LS et al., 2002; Ling EM et al., 2004; 
Cavani A et al., 2003) implying that naturally occurring CD4+ CD25+ Tregs play an 
active role in suppressing allergen specific Th2 responses. Recent evidence also suggests 
an increased frequency or ratio of CD4+ CD25+ IL-10-secreting T cells in healthy 
individuals compared with individuals with allergic or asthmatic disease (Tiemessen MM 
et al., 2004; Akdis M et al., 2004). It is unclear whether these cells represent naturally 
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occurring CD4+ CD25+ Treg or IL-10 producing Treg cells that may have been induced 
to increase CD25 expression upon activation in culture, highlighting the lack of 
appropriate markers to distinguish the different Tregs in humans. Furthermore, IL-10-
secreting Tregs are impaired in patients with severe asthma who do not respond to steroid 
treatment (glucocorticoid resistant) (Taams LS et al., 2006). In situations where tolerance 
is ‘naturally’ induced, for example in children who grow out of their allergy to cow’s 
milk or in bee keepers who receive multiple stings, an association with the increases in 
IL-10-producing and CD4+ CD25+ Tregs have been reported (Akdis CA et al., 1998; 
Karlsson MR et al., 2004). These studies suggest both naturally occurring CD4+ CD25+ 
Tregs and IL-10-secreting Treg populations actively control immune responses to 
allergen in healthy individuals and that their function might be impaired in disease, 
particularly during chronic antigen exposure (Robinson DS et al., 2004), suggesting that 
novel therapeutic strategies may need to target both Treg populations. 
 
1.4.4 B cells 
 
B lymphocytes mature within the bone marrow and leave marrow expressing a distinctive 
antibody molecule known as B-cell receptor (BCR) on their membrane. Since majority of 
the B cells express MHC II molecules, these cells are classified as APCs. A naïve B cell 
upon encountering the antigen for which its membrane bound antibody is specific, the 
cell begins to divide rapidly, and the progeny differentiate into memory cells and effector 
cells called plasma cells. Memory cells have a longer life span and continue to express 
membrane-bound antibody with the same specificity as the original parent cell. Plasma 
cells do not express membrane bound antibody but produce antibody in a form that can 
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be secreted. A membrane molecule designated B220 is a marker of B cell lineage that 
remain throughout the life span of B cell. Due to their potential for high affinity antigen 
binding, B cells are uniquely endowed with the capacity to accumulate low 
concentrations of antigen on their surface, endocytose it, process it and present in the 
context of antigenic peptide in association with MHC II on their surface for T cell (Klaus 
G et al., 1990; Lanzavecchia A et al., 1990).  
 
The differentiation of B lymphocyte into IgE expressing cells is dependent upon three 
types of signals. The first signal is delivered through the B cell antigen receptor and is 
pivotal in determining the antigenic specificity of the response (Oshiba A and Gelfand 
EW et al., 1999). The second signal is provided primarily by cytokines derived from Th2 
cells, ie IL-4 and IL-13 (Del Prete G et al., 1988; Gauchat, JF et al., 1990; Punnonen J et 
al., 1993; Defrance T et al., 1994; Pawankar R et al., 1997). These cytokines are under 
tight regulation and their role appears to be the stimulation of transcription through the Ig 
constant region genes. Finally, the third signal is provided via the interaction between the 
constitutively expressed CD40 molecule on B lymphocytes and CD154 (CD40 ligand), a 
molecule expressed on T lymphocytes following activation (Pawankar R et al., 1997; 
Challa A et al., 1999). The molecular mechanisms whereby cytokine induced germline 
transcription at the Cε locus will be discussed later.  
 
1.4.5 Dendritic cells 
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Dendritic cell (DC) is considered as the most potent APC that possess unique ability in 
initiating T cell response. DC acquired its name for their highly branched morphology 
that resembles dendrites of nerve cell. They are predominantly found in the T cell-
dependent areas of lymphoid tissue, as well as in other tissues and organs (Methlay JP et 
al., 1990; Steinman RM, 1991; Steinman RM et al., 1997). In mouse spleen, DC express 
high levels of class I and class II MHC, CD11c (Methlay JP et al., 1990), mannose-
receptor-like protein DEC-205 (Jiang W et al., 1995) as well as adhesion (CD11a and 
CD54) and accessory molecules (CD40, CD80 and CD86) (Steinman RM, 1997). DCs in 
culture exist in two functional and phenotypically distinct states, immature and mature 
(Mellman I and Steinman RM, 2001). Immature DCs located in the nonlymphoid tissues 
are adept at endocytosis, process antigens and apoptotic cells through a variety of 
receptors. Along their migration to lymphoid tissues, they lose ability to capture antigens, 
and become mature DCs. DC maturation includes up-regulation of the expression of 
MHC II bearing pathogen-derived peptides and determining the specificity of the T cell 
response (signal 1), as well as the expression of  costimulatory molecules, such as CD80 
and CD86, that determine the ability of naive T cells to expand (signal 2) (Cella M et al., 
1997; Reid SD et al., 2000; Banchereau J et al., 2000).  
 
More recently, it was realized that DC also select the type of immune response by 
expressing a selective set of T cell polarizing molecules (signal 3), either soluble or 
membrane-bound, that determine the balance between Th1, Th2 or regulatory T cell 
development. The ability to induce the different types of T cell responses is determined 
by DCs with different functional properties, the corresponding functional DC subsets are 
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called dendritic cell type 1 (DC1), dendritic cell type 2 (DC2), or DC regulatory, 
respectively (Shortman K & Liu YJ, 2002). The differentiation signals that determine 
different functional subpopulations of DCs are better defined in the human than in the 
mouse (Maldonado-Lopez R et al., 1999; Pulendran B et al., 1999; Rissoan MC et al., 
1999; Shortman K & Liu YJ, 2002; Boonstra A et al., 2003). Data from human DCs 
derived by in vitro culture indicated that the functional DC subsets, DC1 and DC2, would 
arise from the myeloid or plasmacytoid bone marrow precursors, respectively (Rissoan 
MC et al., 1999). In mice, the functional DC1 and DC2 subsets may have both types of 
bone marrow precursors, namely myeloid or plasmacytoid (Maldonado-Lopez R et al., 
1999; Pulendran et al., 1999). Therefore, in mice and possibly in humans, the determinant 
of the DC1, DC2, DC regulatory subsets may not only be the early bone marrow 
precursor but instead can be determined by the differentiation signals that the DCs 
receive from stromal cells (Zhang M et al., 2004) and from inflammatory cells in the 
tissues (Cella M et al., 2000; Boonstra A et al., 2003). Indeed, in mouse lungs, studies on 
bone marrow derived DC subsets have shown that DCs from myeloid bone marrow 
precursors induced Th2 responses (Lambrecht BN et al., 2000) and DCs from 
plasmacytoid bone marrow precursors inhibited asthmatic responses and Th2-mediated 
lung injury (De Heer HJ et al., 2004). 
 
1.5 Immunoglobulin E  
 
1.5.1 Signals involved in IgE synthesis  
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IgE synthesis occurs after a complex process of allergen uptake and processing and the 
subsequent presentation of allergen in the context of MHC II molecules to T cells. T cells 
direct B cells to switch to immunoglobulin synthesis from IgM or IgG to IgE by means of 
two critical signals. The first signal is delivered by IL-4 or IL-13, which bind to receptors 
on B cells (their receptors use the same signal transduction pathway [signal transducer 
and activator of transcription 6 (STAT6)]. The second signal is delivered when CD40 on 
B cell binds to its ligand on T cells, the CD40 ligand. These two signals bring about cell 
DNA rearrangement and splicing, preferentially favoring the production of IgE 
(Bacharier LB and Geha RS, 2000).  
 
The crucial role of IL-4 in the induction of murine IgE synthesis has been confirmed in 
vivo in 1991 (Kuhn R et al). Suppression of in vivo polyclonal IgE responses could be 
achieved by injection of an anti-IL-4 antibody, and no IgE synthesis could be detected in 
IL-4 deficient mouse mutants obtained by IL-4 targeting. Stimulation of murine B cells 
with IL-4 and LPS induced the appearance of 1.7-1.9 kb ε germline transcripts (Rothman 
P et al., 1991). The role of IL-4 in induction of human IgE production has also been 
demonstrated in an in vitro model based on the use of T cell clones (Del Prete G et al., 
1988). Phytohemagglutinin (PHA) or anti-CD3 antibody stimulated T cell clones, or their 
supernatants which contains high IL-4 content, were able to provide substantial help for 
IgE synthesis by normal B cells. Furthermore, neutralizing anti-IL-4 antibody markedly 
suppressed IgE synthesis by B cells.  
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IL-13 shows 30% homology with IL-4 and its share similar IgE switching activity with 
IL-4 (Punnonen J et al., 1993). IL-13 induces ε germline mRNA expression in highly 
purified B cells, which accounts for its ability to drive B-cell switching to IgE isotype. 
IL-13 seems to be two- to five-fold less potent than IL-4 in inducing IgE production, and 
has neither additive nor synergistic effects with IL-4 in the induction of IgE or IgG4 
isotypes. Mice with targeted deletions of the gene encoding IL-4 or IL-13 have impaired 
Th2-cell responses and decreased production of IgE, but IL-4-/-, IL-13-/- double-mutant 
mice have a much serious Th2-cell impairment and virtual absence of IgE-antibody 
responses (de Vries JE et al., 1993; Barner M et al., 1998). It has been shown that IL-4 
and IL-13 shared a common receptor subunit and triggered similar signaling pathway. IL-
4 binds the IL-4 receptor α-chain (IL-4Rα) that is contained in both IL-13R and IL-4R. 
IL-13R has a unique IL-13-binding chain (IL-13Rα1 or IL-13Rα2). IL-4R also contains 
the common cytokine receptor γ-chain (γc). IL-4R triggers the activation of the Janus 
family tyrosine kinases JAK1 (through IL-4Rα), JAK3, IRS1 and TYK1 (through γc). IL-
13R activates JAK1 (through IL-4Rα) and TYK2. The activated JAKs phosphorylate 
tyrosine residues in the intracellular domains of IL-4Rα, which act as STAT6-binding 
sites. STAT6 is phosphorylated, dimerizes and translocates to the nucleus, where it can 
activate transcription of the IgE promoter. The kinetics of IL-4 production is remarkably 
short as compared to IL-13, suggesting that IL-13 may also play a role in the regulation 
of enhanced IgE synthesis in atopy (Zurawski G et al., 1994).  
 
1.5.2 Regulation of ε-chain germline transcription 
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The binding of IL-4 or IL-13 to their receptors on B cells leads to the activation of the 
transcription factor Stat6 and the induction of ‘germline’ transcription at the Cε locus. 
The Iε promoter contains binding sites for several transcription factors, including Stat6, 
NFκB (two sites), BSAP (Pax5) and C/EBP. Although activated Stat6 is clearly the 
critical regulator in Cε germline transcription, mutational analyses of the promoter have 
demonstrated that the NFκB and BSAP elements must also be present for normal 
function (Rothman P et al., 1991; Delphin SJ et al., 1995; Thienes CP et al., 1997). Stat6 
and NFκB actually synergize in activating the promoter and this may be related to a 
physical interaction (Shen CH and Stavnezer J., 1998). Isotype switching is impaired in 
NFκB-p50–/– mice (Sha WC et al., 1995). Qiu and Stavnezer (1998) have shown that 
BSAP overexpression will drive Iε transcription and promote IgE isotype switching. 
PU.1-binding element overlapping the distal NFκB site has been characterized as well 
(Stütz AM and Woisetschlager M, 1999). Like NFκB, PU.1 can also synergize with Stat6 
in activating the promoter; Stütz and Woisetschläger (1999) report that either PU.1 or 
NFκB function suffices o support Stat6-driven ε-germline transcription. Some interesting 
observations have identified an important negative regulator of the Iε promoter and 
germline transcription. BCL-6, a POZ/zinc-finger transcription factor expressed in B 
cells, has a DNA target site similar to that of Stat6. Rothman and co-workers 
demonstrated that BCL-6 can bind to Stat6-binding sites and repress the induction of e-
chain germline transcripts by IL-4 (Harris MB et al., 1999) 
 
1.5.3 Sequential or Direct Switch of heavy chain genes –primary route to IgE 
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There is good evidence that the production of IgE can occur through sequential switching 
events from μ to γ4 to ε (Vercelli D et al., 1998, 2002) (In mice the intermediate is IgG1.) 
In this model the production of IgG4 without IgE antibody would be seen as a restricted 
or truncated Th2 response. It is proposed that the modified Th2 response results from a 
failure of the direct switch mechanisms combined with increased generation of IgG4 
memory. In the animal models it appears that weak antigenic stimulation (ie, low dose, 
without microbial adjuvant factors, or both) favors the development of IgE plasma cells 
through direct switch from μ to ε (Sudowe S et al., 1997). This mechanism occurs 
without much clonal expansion or the formation of a B memory population. Further 
evidence suggests that these responses can give rise to a long-lived plasma cell 
population without effective production of B memory cells. Stronger stimulation results 
in memory cells switched to IgG/IgG4, which potentially can switch to IgE. However, 
because of the problems outlined above, the survival of IgE memory cells is severely 
compromised. In mice long-lived IgE antibody responses like those in human subjects 
can be induced, but they are also relatively insensitive to subsequent antigenic 
stimulation (Benner R et al., 1981; Holt PG et al., 1984; Manz RA et al., 2002). It is 
proposed that these responses in both mice and human subjects represent long-lived 
plasma cells without B memory (Aalberse RC et al., 2004). 
 
1.6 Experimental models of allergy asthma 
 
1.6.1 Animal models 
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The establishment of experimental model of allergic asthma that closely resembled 
human asthma is important as they contribute in gaining insights into the pathogenesis of 
allergy and in defining the potential strategies for therapeutic intervention (Sakai et al., 
1999; Garnier et al., 2002). Indeed, much understanding of response to allergens comes 
from the study of animal models, particularly in mice (Clarke et al., 1999; Mojtabavi et 
al., 2002), guinea pigs (Itoh et al., 1996; Santing et al., 2001) and rats (Haczku et al., 
1995; Carvalho C et al., 1999). Murine models are most commonly employed, mainly 
attributed to the availability of transgenic and gene-targeted animals, and also due to wide 
variety of specific reagents available for phenotypic and functional analysis of the 
cellular and mediator response (Pauwels RA et al,, 1997; Willis Karp M, 2000). The key 
contribution of CD4+ T cells to the pathogenesis of asthmatic inflammation and the 
critical roles played by the Th2 cytokines have been emphasized by several murine model 
reports (Mojtabavi N et al., 2002; Gavett SH et al., 1994; Garlisi CG et al., 1995). Other 
murine studies have focused on the cellular sources of these cytokines, signal pathways 
involved, mediators and adhesion molecules involved in leukocyte recruitment (Nagai H 
et al., 1993; Henderson WR et al., 1996).  
 
1.6.2 Parameters of immunization protocols 
 
The choice or route of antigen administration for either sensitization or challenge in an 
animal model can have drastic effects on the development of immune responses and the 
resulting data interpretation. For instance, delivery of OVA solely by intranasal route 
produced neither local responses (eg. airway hyperresponsiveness [AHR]) nor systemic 
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responses (eg. plasma IgE) (Zhang Y et al., 1997) while a repeated inoculation by 
nebulization has shown an increased in circulating levels of IgE and AHR (Renz H et al., 
1992). These differences probably also reflect differences in vehicle, dose or frequency of 
challenge employed in each respective immunization. A major factor in the elicitation of 
an effective T cell response is in the dosage of antigen used in the priming stages. There 
are reports suggesting that antibody production is regulated in antigen-dose manner. 
Repetitive administrations of minute doses of antigen evoked a high IgE and low IgG1 
production, whereas large doses stimulated a reciprocal antibody titer (Kolbe L et al., 
1991, 1994). Others showed that the inductions of Th1- or Th2-type responses were 
elicited by high versus low doses of antigen (Guery JC et al., 1996; Sakai K et al., 1999). 
Constant and Bottomly (1997) concluded that there was no clear-cut conclusion on the 
dose and type of immunity developed but pointed out that the type of antigen used was 
critical in influencing the nature of immune reaction. The use of adjuvant during priming 
phase to boost the immune response of an allergen has been demonstrated to influence 
immune reactions. The administration of OVA together with alum compound could 
induce a Th2 response, however when used alone, such a relative simple structure protein 
is not particularly antigenic (Brewer JM et al., 1996, 1999). Others demonstrated that 
adjuvant induced non-specific stimulation of IgE and IgG antibody production, and 
selective biase towards antibody subclass production (Beck L and Spielgelberg HL, 1989; 
Avramidis N et al., 2002). The choice of genetic background of the mouse strain engaged 
could have varying degree of response. For instance, the measurement of AHR in nine 
different mice strains of commonly used laboratory mice have shown that AKR/J and A/J 
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strains had the greatest degree of AHR, while C57BL/6J, SJL/J, and C3H/HeJ strains 
having the least response (Levitt RC et al., 1990).  
 
1.7 Immunotherapy for Allergy 
 
1.7.1 Therapeutic strategy 
 
The prevalence of allergic diseases has increased significantly over the past few decades, 
despite the introduction of increasingly potent and effective drugs. Therapies for allergic 
disease include allergen avoidance, pharmacotherapy and specific immunotherapy. 
Immunotherapy, which has shown to provide long-term, antigen-specific and protective 
immune response, is the only aetiology treatment that can possibly prevent or cure the 
allergic diseases (Holgate ST, 2000). Thus, the aim of allergen immunotherapy is to 
vaccinate with an allergen or its derivatives to produce selective inhibition of allergen 
specific responses.  
 
1.7.2 Conventional specific immunotherapy (SIT) 
 
Specific allergen immunotherapy (SIT) with allergen extracts, which typically involves 
repeated subcutaneous injection of increasing amounts of allergic extracts, has been 
practiced ever since its introduction by Noon Land Cantab BC in 1911. However, even 
though the clinical efficacy of SIT is well documented by the clear reductions in 
symptom/medication scores, early and late-phase skin responses, and strongly increased 
allergen threshold levels in provocation tests (Bousquet J et al., 1998), the mechanisms 
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behind these effects are only now emerging from studies using unmodified allergen 
extracts for SIT (Durham SR and Till SJ, 1998). So far SIT is the only causal allergy 
treatment as evidenced by the sustained clinical effects several years after treatment 
discontinuation (Walker SM et al., 1995; Durham SR and Till SJ, 1998; Jacobsen L et al., 
1997), and it can be seen as a vaccination regime aimed to induce clinical tolerance to an 
antigen against which there is an excessive, unwanted immune response (Robinson DS et 
al., 2004). In addition, SIT has been shown to reduce the risk of developing new 
sensitizations, and has been suggested to inhibit the progression from rhinitis to asthma 
(Des RA et al, 1997; Moller C et al., 2002). 
 
1.7.2.1 Immunological Effects of SIT 
 
The immunological changes leading to these clinical effects of immunotherapy include a 
reduction in eosinophil infiltration and activation levels (Furin MJ et al., 1991; Wilson 
DR et al., 2001) as well as enhanced Th1 activation and IL-12 production by APC 
(Durham SR et al., 1996; Hamid QA et al., 1997) at the site of allergen exposure. Apart 
from a shift from Th2 to Th1 responses (Secrist H et al., 1993, Jutel M et al., 1995), 
recent reports have described a general reduction in allergen-specific T cell activation as 
a result of the production of the inhibitory cytokines IL-10 and TGF-β by Treg cells 
(Akdis CA et al., 1998; Jutel M et al., 2003). This increased IL-10 (and TGF-β) 
production has been suggested by Akdis and Blaser (1999) to be the hallmark of 
successful immunotherapy, and the induction of T cell regulation has been investigated 
intensively during the last number of years. In addition, increases in CD4+CD25+ Tregs 
have also been used as an indication of enhanced T cell regulation induced by SIT 
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(Francis JN et al., 2003). At the level of antibody production, the most consistent finding 
related to SIT is an increase in allergen-specific non-IgE antibodies and an initial rise in 
the allergen-specific IgE production followed by a return to pretreatment levels combined 
with a bluntting of the seasonal increase in the IgE production (Jarolim E et al., 1990; 
Ebner C et al, 1997). The production of regulatory cytokines by Tregs are probably 
causally related to the production of blocking antibodies via the induction of isotype 
switching to IgG4 or IgA induced by IL-10 or TGF-β, respectively. This has led to a 
model proposed by Robinson DS et al (2004) for the combined effects of Treg and 
blocking antibodies that explains most of the recently published findings regarding 
mechanisms of SIT. However, as the role of T cell regulation in SIT is not demonstrated 
in all studies (Bolhaar ST et al., 2004), additional mechanisms may yet be involved. The 
mechanisms induced by SIT might be related to changes induced by exposure to high 
allergen levels, as is hypothesized in the ‘modified Th2 response’ theory (Platts-Mills et 
al., 2001). Consequently, if exposure to high allergen concentrations by itself leads to the 
production of allergen-specific non-IgE antibodies, the immunological changes observed 
after SIT may be primarily related to the induction of these blocking antibodies. Through 
inhibition of IgE mediated allergen presentation this could lead to the cellular changes 
observed via a change in the activation threshold for the allergen-specific Th2 cells. The 
blocking of IgE-mediated allergen presentation will reduce the involvement of B cells as 
APC, which in turn leads to T cell activation through the presentation of the allergen by 
professional APC such as dendritic cells or macrophages. This will primarily take place 
in a non-receptor-mediated fashion that requires higher allergen concentrations, favoring 
Th1 development (Carballido JM et al., 1997).  
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 1.7.2.2 Antibody responses following SIT  
 
In 1935, Cooke RA et al demonstrated that serum from patients treated with SIT 
contained a ‘protective substance’ that inhibited the early-phase reaction in the skin. The 
thermo-stable protective antibodies in serum were found to mainly reside in the IgG 
fraction (Loveless MH, 1940; Lichtenstein LM et al., 1968), and are now also known as 
‘blocking antibodies’ because of their ability to inhibit the interaction between allergen 
and IgE. Other studies have shown that IgA antibodies are also blocking (Platts-Mills TA 
et al., 1976). However, only low levels of IgA are present in serum. The first 
investigations of the serum IgG subclasses induced by SIT showed that the increase in 
allergen-specific IgG was mainly in the IgG4 subclass (Devey ME et al., 1976; van der 
Giessen M et al., 1976). Other studies have shown that in addition to IgG4, SIT also 
induces increases in IgG1 whereas only minor changes are found in IgG2 and IgG3 (Ball 
T et al., 1999; Mothes N et al., 2003). Many studies have compared quantitative changes 
in serum IgG and IgG4 levels during SIT with clinical improvement, but the results have 
been conflicting (Djurup R et al., 1987; McHugh SM et al., 1990; Golden DB et al., 
1992). In rush venom SIT, clinical improvement was even found before the appearance 
of allergen-specific antibodies (van der Zwan JC et al., 1983). To date, serum levels of 
blocking IgG4 antibodies have been measured against allergen extracts, which may make 
it harder to directly link the IgG levels to clinical benefit. Flicker and Valenta (2003) 
have pointed out that the effect of blocking antibodies should ideally be studied using 
single major allergens rather than extracts to exclude the effects of irrelevant IgG 
antibodies. This is especially relevant when correlations between IgG4 levels and clinical 
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efficacy are studied, as IgG induced by irrelevant proteins in the extracts will cloud the 
real effect of the blocking antibodies directed to major allergens to which the IgE is 
directed (Flicker S and Valenta R, 2003). It has further been suggested that functional 
properties such as affinity and epitope specificities of the in duced IgG, especially IgG4, 
should be investigated, as changes in these properties may be more relevant for the 
clinical effect of the antibodies (Wachholz PA et al., 2003; Larsen JN et al., 2000). Only 
minor differences were found when measuring the avidities of IgG to different allergens, 
and SIT did not induce any appreciable avidity changes (Adkinson NF et al., 1979). 
Likewise, in birch pollen SIT no or minor changes were found in the Bet v 1 K d values 
of polyclonal IgG (Svenson M et al., 2003). Furthermore it has been demonstrated that 
the blocking effect of specific IgG4 is not superior to that of other IgG subclasses 
(Ejrnaes AM et al., 2004). Even though it is highly relevant, only few studies have 
addressed the presence of antibodies in the affected organs. In one study, SIT induced 
increases in IgG but not in IgA in nasal secretions; however, the changes in IgG were 
small as compared to the changes in serum (Deuschl H et al., 1977). In another study, 
increases in both IgA and IgG were found in nasal secretions following SIT, the 
antibodies inhibited peripheral blood basophil histamine release, and there was a 
correlation between antibody levels and inhibition of histamine release (Platts-Mills TA 
et al., 1976). In a recent clinical study on birch SIT, Reisinger et al. (2005) showed that 
apart from the induction of serum IgG specific for birch, IgG was also induced topically 
in nasal secretions. This presence of IgG4 in the nasal secretions was significantly 
associated with reduced nasal sensitivity to birch allergen determined by nasal allergen 
provocations. 
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 1.7.3 Genetic vaccine  
 
DNA vaccination was introduced in 1990 by a study that demonstrated the induction of 
protein expression upon direct intramuscular injection of plasmid DNA without the need 
for a special delivery system (Wolff JA et al). The protein expression within the muscle 
cells suggested that naked DNA delivered in vivo could be used to express foreign 
proteins inside a cell, and thus also potentially to induce an immune response against the 
expressed proteins. In 1992, Tang DC et al and others demonstrated the simplicity of this 
method in eliciting immune response to foreign antigens. The protective efficacy of a DNA 
vaccine in an animal challenge model was initially demonstrated in the mice immunized 
with DNA encoding an internal conserved protein of influenza A nucleoprotein (NP) 
which elicited both NP-specific antibodies and MHC class I–restricted CTL response 
(Ulmer JB et al., 1993). Upon either mitogenic or antigen-specific restimulation in vitro, 
the CTL were capable of lysing target cells that were either virally infected or pulsed 
with the MHC-class I–restricted peptide. The development of the CTL was striking 
because this demonstrated the power of the technology to elicit class I–restricted CTL by 
simple means, yet permitted generation of entire proteins (rather than peptides), enabling 
determinant selection to occur in the host. This study suggests that DNA vaccine offer a 
simple alternative to other methods for generating CTL such as immunization with 
peptides (which may be limited in their applicability to genetically diverse populations), 
or live attenuated viruses (which in certain cases, e.g. vaccinia or HIV, may be restricted 
in use due to concerns about their safety).  
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Subsequently, reports on the intramuscular immunization with DNA plasmids encoding a 
variety of antigens such as influenza HA, HIV glycoprotein 120 and gag, malaria and M. 
tuberculosis antigen 85 demonstrated the broad applicability and efficacy of this method 
in vaccination (Montgomery DL et al., 1993; Fuller DH et al., 1994; Justewicz DM et al., 
1996; Ulmer JB et al., 1993; Wang R et al., 1998; Calarota S et al., 1998; Chen Z et al., 
1999; Okuda K et al., 2001; Tollefsen S et al., 2002; Otten GR et al., 2006; Pardini M et 
al., 2006). This approach generates memory T lymphocyte responses manifested by 
proliferation of antigen-specific T cells and secretion of cytokines during in vitro culture 
of splenocytes from vaccines. Proliferation of lymphocytes from immune animals ranged 
from 3 times to 100 times greater than cells cultured without antigen, whereas 
proliferation of splenocytes from control vaccinee cultures ranged from one- to threefold. 
Supernatants from these cultures contained high levels of IL-2 and interferon with little 
or no IL-4 or IL-5, indicating that these DNA vaccines elicited Th1-like cytokine 
responses. Selective removal of lymphocyte populations for the NP and Env studies 
indicated that CD4 T lymphocytes were the primary responding cells in these assays. 
These responses were maintained in vaccines for at least a year (longest time point 
tested), indicating that long-lived memory responses were generated. Taken together, 
these results suggest that generation of Th1-like T cell help may be a general property of 
DNA vaccines.  
 
DNA vaccines consist of plasmid vectors (derived from bacteria) that contain 
heterologous genes (transgenes) inserted under the control of a eukaryotic promoter, 
allowing protein expression in mammalian cells. An important consideration when 
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optimizing the efficacy of DNA vaccines is the appropriate choice of plasmid vector. The 
basic requirements for the backbone of a plasmid DNA vector are a eukaryotic promoter, 
a cloning site, a polyadenylation sequence, a selectable marker and a bacterial origin of 
replication. A strong promoter may be required for optimal expression in mammalian 
cells. Some promoters derived from viruses such as cytomegalovirus (CMV) or simian 
virus 40 (SV40) have been used. A cloning site downstream of the promoter should be 
provided for insertion of heterologous genes, and inclusion of a polyadenylation (polyA) 
sequence such as the bovine growth hormone (BGH) or SV40 polyadenylation sequence 
provides stabilization of mRNA transcripts (Davis HL et al., 1997; Gurunathan S et al., 
2000; Garmory HS et al., 2003). 
 
1.7.3.1 Regulatory elements 
 
Various reports have described the strength of promoter/enhancers or other 
transcriptional elements in DNA vaccines (Mukhtar M et al., 1996; Lee AH et al., 1997; 
Kwissa M et al., 2000; Gill DR et al., 2001). In general, virally-derived promoters have 
provided greater gene expression in vivo than other eukaryotic promoters. In particular, 
the CMV immediate early enhancer-promoter (known as the CMV promoter) has often 
been shown to direct the highest level of transgene expression in eukaryotic tissues when 
compared with other promoters. This was demonstrated in a plasmid expressing human 
immunodeficiency virus type 1 (HIV-1) Gag/Env under the regulation of the CMV 
promoter/enhancer as compared to an equivalent plasmid utilising the endogenous AKV 
murine leukemia long terminal repeat (Galvin TA et al., 2000). Analysis of the immune 
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responses in macaques injected with the plasmids showed that the CMV-containing 
plasmid elicited higher Gag- and Env specific humoral and T cell proliferative responses, 
reflecting the greater transcriptional activity of the CMV promoter. It has been 
demonstrated that inclusion of the CMV intron A improved the level of expression of 
transgenes by the CMV promoter or other promoter/enhancers (Chapman BS et al., 
1991). It is thought that the beneficial effect of introns on expression is primarily due to 
an enhanced rate of polyadenylation and/or nuclear transport associated with RNA 
splicing (Huang MT et al., 1990).  
 
1.7.3.2 Kozak sequences 
 
The sequences flanking the AUG initiator codon within mRNA influence its recognition 
by eukaryotic ribosomes. 'Kozak' consensus sequence has been shown to be important for 
optimal translational efficiency of expressed mammalian genes (Kozak M, 1987, 1997). 
It has been proposed that this defined translational initiating sequence (-6 
GCCA/GCCAUGG +4) should be included in vertebrate mRNAs located around the 
initiator codon (Kozak M, 1987). It has also been suggested that efficient translation is 
obtained when the -3 position contains a purine base or, in the absence of a purine base, a 
guanine is positioned at +4 (Kozak M, 1997). Prokaryotic genes and some eukaryotic 
genes do not possess Kozak sequences. Therefore, the expression level of these genes 
might be increased by the insertion of a Kozak sequence. 
 
1.7.3.3 Immunostimulatory CpG motifs  
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 The backbone of a DNA vaccine vector could be further modified to enhance 
immunogenicity via the manipulation of the DNA to include certain sequences, so that 
the DNA itself will have an adjuvantising effect. DNA vaccine vectors that contain many 
immunostimulatory CpG motifs within the bacterial backbone may deliver an adjuvant-
effect that, overall, induce a Th1-like pattern of cytokine production (Sato Y et al., 1996; 
Hartl A et al., 1999). Specifically, DNA motifs composed of an unmethylated CpG 
dinucleotide flanked by two 5’purines (optimally GpA) and two 3’ pyrimidines 
(optimally a TpC or TpT) activated the innate immune system to produce a series of 
immunomodulatory cytokines (Klinman DM et al., 1996). In vitro, CpG motifs present in 
bacterial DNA can activate the immune system in a number of ways including activation 
of monocytes and macrophages to secrete cyctokine (Spawesser T et al., 1997), B cells 
proliferation and immunoglobulin secretion (Krieg AM et al., 1995), improved antigen 
presentations with enhanced expression of MHC and costimulatory molecules eg. MHC 
I, MHC II, CD86 and CD80, and activation of natural killer (NK) cells (Ballas ZK et al., 
1996) and dendritic cells (Spawesser T et al., 1998).  
 
1.7.3.4 DNA vaccine for allergy  
 
Over the last decade, an increasing number of publications reported on successful 
preventive and therapeutic approaches in rodent models of type I allergy. An overview of 
DNA-based studies with respect to prevention and/or treatment of allergy is given in 
Table 1.1 (Weiss R et al., 2006).  
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 In 1996, Raz et al. published the first study demonstrating that immunization with a 
plasmid encoding the model allergen β-galactosidase (β-Gal) induced a Th1-type 
response that dominated over an ongoing protein-induced Th2 response in an antigen-
specific manner. Both CD4+ and CD8+ T cells from DNA-immunized animals have been 
shown to contribute to the suppression of IgE antibody production by affecting the 
primary response and/or by propagating the Th1 memory response in a passive cell 
transfer system (Lee DJ, 1997; Peng HJ et al., 2002).  
 
The first evidence for the antiallergic effect of DNA vaccines with a clinically relevant 
allergen was achieved by intramuscular injection of rats with plasmid DNA encoding the 
dust mite allergen Der p 5 (Hsu CH et al., 1996). DNA-based immunization with this 
construct not only resulted in its long-term expression and the induction of specific 
immune responses, but also prevented the induction of IgE synthesis. This study also 
demonstrated the efficacy of DNA vaccines to counteract allergen-induced pathological 
changes of the lung. Prevaccination with plasmid DNA encoding the allergen led to a 
significant decrease in histamine release in bronchoalveolar lavage (BAL) fluids and 
AHR in rats challenged with aerosolized allergen. This suppression was persistent and 
could also be transferred into naive rats by CD8+ T cells from gene-immunized animals. 
Since then, a variety of model allergens as well as clinically relevant molecules have 
been used for DNA-based immunization against type I allergy. Among them, Betv 1, the 
major allergen of birch pollen, is the most extensively studied molecules (Hochreiter R et 
al., 2003; Hartl A et al., 1999; Hochreiter R et al., 2001; Hartl A et al., 2004). These 
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studies have demonstrated that DNA-based immunization with a construct encoding Betv 
1 mounted Th1-biased specific immune responses and protected against allergic 
sensitization. Moreover, in therapeutic approaches, treatment of sensitized animals with 
DNA vaccines decreased IgE production, IgE-dependent mediator release and reduced 
anaphylactic activity as measured by passive cutaneous anaphylaxis assays, thus clearly 
indicating that DNA immunization induces a sustaining shift from a Th2-type response 
towards a balanced Th1/Th2-type response. Similar results have been demonstrated with 
DNA vaccines encoding allergens of house dust mite (Kwon SS et al., 2001; Peng HJ et 
al., 2002; Jacquet A et al., 2003; Wolfowicz CB et al., 2003; Jarman ER et al., 2004; 
Huangfu T et al., 2006). Most of these studies have demonstrated the effect of DNA 
vaccination by measuring immunological parameters. However, there are increasing 
number of papers dealing with the influence of DNA vaccines on lung parameters (Hsu 
CH et al., 1996; Kwon SS et al., 2001; Kumar M et al., 2001; Maecker HT et al., 2001; 
Jacquet A et al., 2003; Jarman ER et al., 2004; Darcan Y et al., 2005; Li GP et al., 2005; 
Huangfu T et al., 2006), because allergic asthma is one of the most serious problems of 
the upper respiratory tracts encountered by atopic patients. It is characterized by airway 
obstruction, mucus hypersecretion and inflammation of the airways, including infiltration 
and activation of eosinophils in the bronchial mucosa. Overall, these publications have 
shown that DNA-based vaccines offer an intriguing long-term solution to counteract the 
early events in allergic inflammation of the lung.  
 
While it is well known that DNA vaccination is a powerful method to induce CD8+ T 
cell responses, concerns have been raised, that induction of CD8+ immune responses in 
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the lung might lead to exacerbation of lung pathology in asthma. These reservations 
mainly derive from studies investigating the role of viral infections in asthma. It has been 
shown that viral infection can sensitize mice to inhaled antigen (O’Donnell DR et al., 
1998). Respiratory viruses can recruit T cells nonspecifically to the lung (Fraenkel DJ et 
al., 1995) where they may enhance inflammation by releasing cytokines that recruit mast 
cells, basophils and eosinophils. Indeed, there is evidence that the local Th2 environment 
in the lung of asthmatic individuals can switch virus-specific CD8+ T cell responses to 
IL-5 production, thereby inducing airway eosinophilia (Coyle AJ et al., 1995). Although 
these data advise caution on the generation of CD8+ T cell responses in the asthmatic 
lung, there is also evidence for inhibition of IgE and normalization of airway 
responsiveness by CD8+ T cell-derived IFN-γ or dendritic cell IL-12 induction 
(McMenamin C et al., 1993; Renz H et al., 1994; Thomas MJ et al., 2001, 2002; Stock P 
et al., 2004).  
 
Additionally, several investigators showed that increased numbers of CD8+ T cells in the 
lungs of DNA vaccinated mice correlated with a reduced influx of inflammatory cells 
(Kwon SS et al., 2001). A direct involvement of CD8+ T cells in the prevention of lung 
pathology was demonstrated by transfer (Hsu CH et al., 1996) or depletion studies 
(Maecker HT et al., 2001). Taken together, DNA-based vaccines can, at least in the 
mouse model, efficiently protect from IgE expression, experimental airway inflammation 
and AHR by induction of Th1-biased immune reactions. Secretion of IFN-γ and 
subsequent suppression of Th2 cytokines seems to be the central mechanism involved in 
the antiallergic response. So far, the available data demonstrated that expression of 
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significant amounts of Th1-related cytokines such as IFN-γ in the BAL elicited no 
detrimental effects on lung pathology, suggesting that DNA vaccination is a safe method 
in preventing the induction of serum IgE but also from airway sensitization by exposure 




1.8.1 Beginning of microarray 
 
Modern microarray analysis was introduced in 1995 by a Stanford University research 
team led by Pat Brown and Ron Davis. Their seminal publication was titled “Quantitative 
monitoring of gene expression patterns with a complementary DNA microarray” and has 
since been cited over 1,500 times (Schena MD et al., 1995). The authors illustrated the 
use of a robotics system to spot DNA oligonucleotides onto glass slides in ordered arrays, 
creating microarray slides or “gene chips.” Labeled cDNAs made from varied samples of 
Arabidopsis thaliana (mustard plant) mRNA were hybridized to DNA on the chips. Only 
45 oligonucleotide sequences were spotted in this first experiment, representing a tiny 
fraction of the entirety number of the genes present in Arabidopsis, however the work 
inspired many new researches and shortly after, the whole genomes of species such as 
yeast, bacteria, mice, and humans were being spotted onto glass slides. In 1997, Lashkari 
et al. demonstrated that laboratory yeast strains sometimes discard DNA fragments, 
encoding whole sets of genes. Researchers soon realized that culturing cells in common 
rich broths selects for the fastest growing cells, offering an advantage for cells that have 
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discarded genes that are unnecessary for rapid growth. DeRisi et al. (1997) showed the 
concerted induction and repression of numerous genes and pathways as yeast responded 
to environmental changes such as the depletion of glucose. By looking for the upstream 
regulatory elements and transcription factors shared by genes regulated in concert, the 
microarray data were able to characterize gene regulatory pathways. These early articles 
clearly identified the power of microarray analysis, and many laboratories decided to 
include this technology to their repertoire. DeRisi and Brown developed and put up a 
manual for building an array printer from scratch, branded as The Mguide (1999), and 
laboratories throughout the world were benefited. Today, commercial array printers and 
scanners are commonly available, as are commercial pre-spotted slides. As a result, the 
use of microarrays in basic and applied research is growing at a remarkable pace. 
 
1.8.2 Gene profile technology 
 
Microarray technology is based on a process of hybridizing complementary probe and 
target strands of nucleic acids. Gene chips are produced containing 30,000 or more spots 
on a single slide (~ 100 μm spacing), each spot containing DNA oligonucleotides or 
cDNA clones specific for a known gene. These gene chips are probed with fluorescently 
labeled mRNA or cDNA, and comparisons of gene induction and repression are made 
using alternate-colored labels for distinct RNA samples (Schena MD et al., 1995). 
Microarrays can simultaneously compare the expression of all known genes in each 
paired sample, offering a powerful tool for the analysis of gene expression patterning. 
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Microarray analysis consists of three major components: array fabrication, target 
preparation and hybridization, and data collection and analysis (Figure 1.2).  
 
1.8.2.1 Array Fabrication 
 
The basic step in microarray production involves spotting a minute volume of DNA 
solution from a microtiter plate onto a glass microscope slide coated with poly-L-lysine 
or aminosilane (Schena MD et al., 1995; The Mguide, 1999; Hegde P et al., 2000; 
Freeman WM et al., 2000; Bowtell DL et al., 1999). The spotted DNAs are typically 
oligonucleotides or PCR-amplified cDNA clones. This process is repeated until as many 
as 30,000 DNA spots are applied to precise locations on the slide. After printing, the 
DNA is covalently cross-linked to the glass slide. Arrays manufactured by Affymetrix 
(Santa Clara, CA) use photolithography and solid-phase chemistry to synthesize small 
oligomers on the surface of a glass slide. These sets of oligomers offer a measure of 
binding specificity during hybridization. Affymetrix arrays compare control and 
experimental gene expression profiles using two separate arrays, which are scanned 
separately. The signal from a reference or control is then compared with that of an 
experimental sample using appropriate software. The terminology of array fabrication has 
become a point of confusion in recent years. The synthesized oligonucleotides in 
Affymetrix microarrays are referred to as probes, and the labeled mRNA or cDNA that 
are hybridized to them are called targets. cDNA arrays are referenced differently such as 
immobilized cDNA targets, and labeled probes (Brewster JL et al., 2004).  
 
1.8.2.2 Probe Preparation and Hybridization 
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 The first and most important step in probe preparation is isolation of total or poly(A) 
RNA from control and experimental sources. The purified RNA must always be 
visualized by denaturing gel electrophoresis to validate the integrity of the ribosomal 
RNA bands. Once extracted from the two populations, the RNA samples are typically 
labeled with fluorescent dyes in order to generate probes. Fluorescently labeled probes 
can be prepared by several different methods including direct or indirect cDNA labeling, 
cDNA labeling with fluorescent dendrimers, direct mRNA labeling, and direct or indirect 
labeling of amplified RNA (Van Gelder RN et al., 1990; The Mguide, 1999; Hegde P et 
al., 2000; Schena M, 2003; Richter A et al., 2002). RNA amplification may be the 
method of choice when isolating RNA from limiting samples, such as those from tissue 
biopsies.  
 
Microarray protocols required cDNA synthesis using commercially available reverse 
transcriptase. In the direct cDNA labeling method, fluorescently modified 
deoxynucleotides are incorporated during the first strand cDNA synthesis from an RNA 
template using reverse transcriptase (The Mguide, 1999; Hegde P et al., 2000; Richter A 
et al., 2002). In the indirect cDNA labeling method, aminoallyl-modified nucleotides are 
incorporated during the reverse transcription reaction, and fluorescent dyes are 
subsequently coupled to the reactive amino groups in the cDNA. Because the amine-
modified nucleotides resemble unmodified nucleotides more than the fluorescently 
labeled nucleotides used for direct labeling, the reverse transcription reaction is more 
efficient. One disadvantage of the indirect labeling method is that the procedure takes 
 43
more time to perform. A newer method uses fluorescent dendrimer complexes to label 
cDNA (Schena M, 2003; Richter A et al., 2002). After cDNA synthesis, a fluorescent 
dendrimer with hundreds of dye molecules per complex is hybridized to the cDNA.  
 
The labeled probes prepared from the two RNA sources are co-hybridized to the same 
DNA chip. Chips are often prehybridized with a solution containing bovine serum 
albumin to block nonspecific binding of labeled probe to the surface. Hybridization and 
wash solutions must be evenly distributed over the chip to maximize interactions between 
probe and target sequences and minimize background fluorescence. During hybridization 
the chips are stored in a humidified, temperature controlled, darkened environment 
(Brewster JL et al., 2004).  
 
1.8.2.3 Data Collection and Analysis 
 
The hybridized array is typically scanned with a system that uses lasers as a source of 
excitation light and photomultiplier tubes as detectors (Schena M, 2003). This system is 
capable of differentiating the fluorescently labeled probes. After scanning, a grid must be 
placed on the image and the spots representing the arrayed genes must be identified. The 
background fluorescence is calculated locally for each spot and is subtracted from the 
hybridization intensities. Differentially expressed genes are identified by comparing the 
fluorescence intensity of control and experimental probes hybridized to each spot 
(Freeman WM et al., 2000; Bowtell DL, 1999; Knudsen S, 2002; Schena M, 2003; 
Campbell AM et al., 2003). 
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 A scatter plot is a very useful representation of the expression data; the signal intensities 
of the experimental and control samples are plotted along the x- and y-axes, and the ratio 
values are plotted as a distance from the diagonal (Schena M, 2003). The diagonal 
separates spots with higher activity than the control sample from spots with lower activity 
than the control. The scatter plot provides a visualization of the fluorescence ratios 
obtained from the experimental and control samples. One can then easily choose points 
that represent a several fold increase or decrease in gene expression and focus additional 
analyses on these genes. With just one experimental condition and a control, the data 
analysis is limited to a list of regulated genes ranked by the fold-change or by the 
significance of the change determined in a t test. Normalization of data must be 
performed to compare separate arrays. With multiple experimental conditions (e.g. time-
points or drug doses), the genes are often grouped into clusters that behave similarly 
under the different conditions. Complex computational methods such as hierarchical 
clustering or k-means are used to analyze the massive amounts of data generated by these 
experiments. Gene clusters are visualized with trees or color-coded matrices by placing 
genes with similar patterns of expression into a clustered group. Image processing and 
analysis software is commercially available, and several packages are available as 
freeware (www.bio.davidson.edu/projects/GCAT/GCATprotocols.html , 
www.tigr.org/softlab, and www.nhgri.nih.gov/DIR/LCG/15K/HTML/img_analysis.html) 
(Brewster JL et al., 2004).  
 
1.8.2.4 Data Validation, Quality, and Statistical Issues 
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 Many of the initial papers on expression analysis using DNA arrays relied on data whose 
validity was not proven. A number of issues have arisen, for example, errors in the cDNA 
collections used to produce the PCR products that are supposed to represent specific 
genes (Halgren RG et al., 2001), or in the sets of sequences used by manufacturers to 
derive oligonucleotide chips. The practice of systematically replicating measurements 
and of providing a statistical estimate of the variability in the data set has become a 
general practice only recently (Lee ML et al., 2000). Software suites dedicated to data 
acquisition and validation now exist, and publication criteria have become more 
stringent; efforts are being made to define the information that should be provided with 
microarray results in order to make these data compatible to others, for example the 
MIAME (Minimum Information on A Microrarray Experiment) system developed by the 
European Bioinformatics Institute together with a wide group of users in various fileds 
but using the same technique  (www.ebi.ac.uk/microarray) (Brewster JL et al., 2004). 
 
1.8.2.5 Limitations of Expression Analysis and Confirmation of Results 
 
Microarray analysis of gene expression does have limitations that researchers must 
consider. In gene expression, the correlation between induced level of mRNA expression 
and induced levels of protein are not always proportionally aligned. Translational and 
post-translational regulatory mechanisms that affect the activity of various cellular 
proteins are not tested with DNA microarrays, though the emerging field of proteomics is 
beginning to address this issue. Other limitations of microarray analysis include the 
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impact of alternative splicing during transcript processing and the limited detectability of 
unstable mRNAs. Differential gene expression results must be confirmed through direct 
examination of selected genes. These analyses are typically at the level of RNA blot or 
quantitative RT-PCR to examine transcripts of a specific gene (Alwine JC et al., 1977), 
and/or detection of protein concentration using immunoblots. Additional studies often 
include alteration of gene function with targeted mutations, antisense technology, or 
protein inhibition. 
 
1.8.2.6 Microarray technology in allergy research 
 
Microarray technology has made possible many new discoveries at a genome-wide scale 
regarding the underlying genetic bases of diseases, diagnosing of diseases and 
discovering and validating drug targets. The ability to probe the entire genome and enable 
researchers to find novel, interesting research theme is an exciting phenomenan in 
biology. DNA microarrays can be used to compare gene expression in cells or tissues 
taken from patients and controls, or from patients before and after some form of 
treatment. For example, in a microarray study of pooled nasal biopsies from patients with 
allergic rhinitis, a group of transcripts were described. The corresponding proteins were 
analyzed in nasal fluids from the same patients (Benson M et al., 2002). In recent studies 
of atopic dermatitis and nasal polyps, individual, rather than pooled, samples have been 
examined. Selected genes have been verified with real-time PCR or 
immunohistochemistry (Nomura I et al., 2003; Fritz SB et al., 2003; Benson M et al., 
2004). In these studies distinctive gene expression patterns were also identified, e.g. a 
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Th2-like pattern in atopic dermatitis. Interestingly, microarray analyses of Th2 cells from 
patients with allergy also show up-regulation of gene families such as chemokines and 
chemokine receptors (Wohlfahrt JG et al., 2003; Lund R et al., 2003). 
 
Microarray analysis has been used to elucidate the effects of specific cytokines relevant 
to allergy. For example, the Th2 cytokine IL-13 was shown to induce distinct 
transcriptional programs in human airway epithelial cells, smooth muscle cells and 
fibroblasts (Lee JH et al., 2001). These studies indicate a unique feature of microarrays, 
i.e. to identify whole groups of functionally related genes, rather than individual genes. In 
the same way, whole pathways can be examined; in a study of allergic rhinitis decreased 
expression of TGF-β induced genes had been observed (Benson M et al., 2002). A new 
pathway was also identified in gene expression profiling of lung tissue from mice with 
experimental asthma, i.e. genes associated with L-arginine metabolism, specifically the 
cationic amino acid transporter 2, arginase I, and arginase II (Zimmermann N et al., 
2003). Another study includes delineating the cytokine profiles of interleukin IL-4 
transgenic mice with a skin inflammatory disease resembling human atopic dermatitis 
(Chen L et al., 2004).  
 
Alternative approach to identify relevant transcripts is to combine microarray data with 
genetic studies. Linkage disequilibrium have identified chromosomal regions that may 
contain candidate genes for allergic disease. Since such a region may contain hundreds of 
other genes, identification of the actual candidate gene is difficult. However, 
polymorphisms in regulatory elements of candidate genes are common and may lead to 
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altered gene expression (Yan H et al., 2002). Such alterations may be detected using 
DNA microarrays. Thus, the search for candidate genes may be narrowed down by 
searching for changes in gene expression in chromosomal susceptibility regions with 
DNA microarrays. In a very elegant study, this approach led to the identification of 
complement factor 5 as a candidate gene in a transgenic model of allergen-induced 
airway hyper-responsiveness (Karp CL et al., 2000).  
 
More recent gene profiling researches have also identified new transcripts using different 
approach. For instance, using peripheral blood, unstimulated CD4+ T cells of atopic 
dermatitis patients has shown differentially expressed genes involved in tissue homing, 
proliferation, and apoptosis (Hijnen D et al, 2005). Differentially expressed genes 
observed in the allergen-stimulated peripheral blood mononuclear cells of allergic 
patients have revealed their potential as diagnostic markers for allergic contact dermatitis 
(Hansen MB et al., 2005). The combination of focused transgenic model IL-13/Epi (IL-
13–overexpressing transgenic mice with STAT6 expression limited to epithelial cells), 
DNA microarray analyses, and translational studies provides a powerful approach for 
analyzing the contributions of specific mediators and cell types and focusing the attention 
on a limited number of genes associated with specific pathophysiologic aspects of asthma 
(Kupperman DA et al., 2005). Benson M et al (2006) identified disease-associated 
pathways in the late-phase reaction (LPR) of the in vivo model of allergic inflammation. 
This study revealed that LPR showed increased activity of IL-4– and CCL4- dependent 
pathways and downregulation of the TGF-β–induced pathway. Notably, kinetic analysis 
of allergen responses in PBMC revealed an early wave of novel atopy-associated genes 
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involved in signaling which were coexpressed with IL-4 and IL-4R, followed by a later 
wave of genes encoding the classical Th2 effector cytokines. These novel activation-
associated Th2 genes up-regulate in response to another atopy-associated physiological 
stimulus bacterial superantigen, but remain quiescent in nonphysiological responses in 
primary T cells or cell lines driven by potent mitogens, and thus may account for their 
failure to be detected in earlier microarray studies (Bosco A et al., 2006). 
 
Overall, microarray experiments in allergy research have resulted in the identification of 
new transcripts and/or novel pathways for further studies in more established 
experimental models. It is possible that the coming studies will help to find new disease 




Figure 1.1: Allergic mechanisms.  
In pre-disposed individuals, initial exposure(s) to allergen leads to the activation of 
allergen-specific Th2 cells and IgE synthesis, which is known as allergic sensitization. 
Subsequent exposures to allergen cause inflammatory-cell recruitment and activation and 
mediator release, which are responsible for early (acute) allergic responses (EARs) and 
late allergic responses (LARs). In the EAR, within minutes of contact with allergen, IgE-
sensitized mast cells degranulate, releasing both pre-formed and newly synthesized 
mediators in sensitized individuals. These include histamine, leukotrienes and cytokines, 
which promote vascular permeability, smooth-muscle contraction and mucus production. 
Chemokines released by mast cells and other cell types direct recruitment of 
inflammatory cells that contribute to the LAR, which is characterized by an influx of 
eosinophils and Th2 cells. Eosinophils release an array of pro-inflammatory mediators, 
including leukotrienes and basic proteins (cationic proteins, eosinophil peroxidase, major 
basic protein and eosinophil-derived neurotoxin), and they might be an important source 
of IL-3, IL-5, IL-13 and granulocyte/macrophage colony-stimulating factor. 
Neuropeptides are also proposed to contribute to the pathophysiology of allergic 
symptoms. (TCR, T cell receptor). 
 
[Adapted from Hawrylowicz CM and O’Garra A, 2005] 
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Figure  1.2. Standard eukaryotic gene expression assay.  
The basic concept behind the use of GeneChip arrays for gene expression is simple: 
labeled cDNA or cRNA targets derived from the mRNA of an experimental sample are 
hybridized to nucleic acid probes attached to the solid support. By monitoring the amount 
of label associated with each DNA location, it is possible to infer the abundance of each 
mRNA species represented. Although hybridization has been used for decades to detect 
and quantify nucleic acids, the combination of the miniaturization of the technology and 
the large and growing amounts of sequence information, have enormously expanded the 
scale at which gene expression can be studied. Adapted from “GeneChip Arrays for Gene 
Expression Analysis,” a description on Affymetrix, Inc.  
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[Adapted from Weiss R et al., 2006]  
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1.9 Rationales and specific aims of the study 
 
1.9.1 Rationales of the study 
 
Allergic and asthmatic diseases represent a big health problem in industrialized countries, 
where as much as 30% of the populations suffer from diseases such as rhinitis, 
conjunctivitis, atopic dermatitis, and bronchial asthma (Crameri R and Rhyner C, 2006).  
Exposure to aeroallergens such as house dust mites is one of the risk factors for allergen 
sensitization and the development of allergic diseases (Platt-Mills TAE, 1997). Allergic 
cascade is a tremendously redundant process with numerous cell types, mediators, and 
pathways involved in the development of allergic inflammation. This redundancy has 
provides investigator with many potential targets in therapeutic intervention. Thus, 
understanding cellular and molecular mechanisms in prophylactic and therapeutic 
treatment for allergic diseases in animal models is essential to facilitate the development 
of new vaccination strategies, and to ascertain any unfavorable consequences before 
application in human trials.  
 
Practiced for nearly a century, allergen immunotherapy (SIT) continues to be used 
worldwide to manage allergic diseases (Larche M et al., 2006).  Allergen-SIT faces 
several problems related to content of the vaccine, type of the adjuvant, route of 
application, long duration of treatment, side effects, and limited efficacy (Akdis CA, 
2006). Currently, allergen-SIT is performed by repeated subcutaneous injections of 
increasing amounts of allergic extracts; it has been shown to trigger antigen-specific IgG 
but not IgE production. However, the major drawback of using crude extract to induce 
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sensitization is that it might cause severe (and often life-threatening) anaphylactic 
reactions as well as new IgE sensitization induced by other toxin proteins present in the 
extract (Abrahamson MJ et al., 1995; Greidener DK, 1996).  
 
The problem associated with the use of natural allergens and extracts for allergy 
treatment can be overcome by using recombinant allergens (Akdis CA, 2006). Animal 
models of allergy have been largely engaged in defining the potential strategies for 
therapeutic intervention. In 1971, this therapeutic intervention was demonstrated in 
animals through repeated high doses that induced a low transient IgE titer, whereas 
repeated minute doses could generate high and persistent IgE antibody response (Vaz EM 
et al). Subsequent studies confirmed such observations by using different complex model 
antigens (Kolbe L et al., 1991; Arps V et al., 1998; Sudowe S et al., 1995, 1997; Garnier 
CV et al., 1997; Sakai K et al., 1999). Despite extensive studies performed on each 
model, the mechanistic action that dictates such phenomena is not well-defined. As such, 
it is important to have a complete comprehension of the mechanism influenced by the 
allergen dosage that is intended to reduce IgE synthesis in allergic individuals.   
 
The most advanced, although still experimental, strategy aimed at the downregulation of 
the allergic response is based on the development of DNA vaccines (Kowalski ML et al., 
2006; Weiss R., 2006). These vaccines are composed of plasmid DNA, which encodes 
allergen molecules directly in the transfected cells of a target organism, resulting in the 
production of antigens in the host. When these vaccines were injected into animals, either 
prior to or after allergen challenge, it resulted in decreased Th2-mediated responses, 
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enhanced Th1-mediated responses, and suppressed the allergic response. This strategy 
uses nucleic acid vaccines that contain CpG motifs to skew the immune response towards 
a predominantly Th1 response instead of a pro-allergic Th2 response. Nucleic acid 
vaccines are an attractive alternative to conventional protein vaccines because of their 
ability to induce de novo production of antigens in a given tissue after DNA delivery 
(Sato Y et al., 1996; Hartl A et al., 1999; Spawesser T et al., 1997; Garmory HS et al., 
2003). Inoculation of plasmid DNA is a simple way to immunize but is characterized by 
low immunogenicity, which has hampered the development of effective DNA vaccines 
for human use. Several approaches have been untaken to enhance immune response to 
DNA vaccines, including applying in vivo electroporation technology that aids 
transfection efficiency and incorporating signal sequence in the plasmid to enhance 
immunogenicity of the expressed protein (Widera G et al., 2000; Drew DR et al., 2000; 
Jiang C et al., 2002; Otten G et al., 2004). While many remarkable responses have been 
reported in DNA vaccination in various animal models, the underlying mechanism is still 
only partially understood. Mechanistic studies continue to support the idea that 
immunotherapy by genetic immunization expands allergen-specific Th1 immunity and 
suppresses the Th2 responses that resulting clinical allergies.  
 
Understanding the cellular and molecular mechanisms in immunotherapy will provide 
essential information for future clinical studies. For a complete understanding of the 
mechanistic actions of these two approaches, the murine models of protein and gene 
vaccinated animals were established using the Der p 2 allergen. The house dust mite 
extract corresponds to the naturally encountered allergen Dermatophagoides 
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pteronyssinus and consists of all mite components, including Der p 2. (Thomas WR et al., 
2002). Der p 2 is believed to be the major allergenic component of dust mite on the basis 
of the stability and prevalence of Der p 2-speciifc IgE antibodies in mite allergic patients 
(Chua KY et al., 1990; Yasueda H et al., 1996; Heymann PW et al., 1998; Tsai JJ et al., 
2000). On the basis of its significant allergenicity, Der p 2 was therefore chosen in this 
study.  
 
1.9.2 Specific aims of the study 
 
The specific aims are: 
1. To examine the immune responses of mice immunized with differential dosage of Der 
p 2 allergen. 
1.1 To investigate the cellular mechanisms that dictate the dosage effects on the 
differential immune responses in Der p 2 immunized mice 
1.2 To identify the genes associated with dosage response using DNA microarray 
Approach. 
2. To study the immune responses of mice immunized with plasmid DNA constructs 
containing Der p 2 gene via intramuscular route. 
2.1 To evaluate the immunogenicity of Der p 2 encoding DNA constructs in mice with 
different genetic background. 
2.2 To evaluate the phenotypes of immune responses primed by Der p 2 encoding 
DNA constructs with or without signal peptide and/or cellular targeting sequences. 
 
 Chapter 2  
 
Evaluation of the immune responses induced by immunization with different 




The prevalence of allergic disease has increased dramatically over the past two decades 
despite the fact that conventional allergen immunotherapy has been practiced for the 
treatment of allergic disease for nearly 100 years (Umetsu DT and DeKruyff RH, 2006). 
This therapy, which involved repeated subcutaneous injection of increasing amounts of 
allergic extracts, has shown to trigger antigen-specific IgG but not IgE production. It has 
been widely used and beneficial for the treatment of insect venom allergy and rhinitis 
(Graft DF, 1987; Norman PS, 1988) but is less effective in allergic asthma as the use of 
whole allergen extract has some potential side effects. It can induce severe systemic 
reactions such as asthma exacerbation and anaphylactic reactions, due to the cross-linking 
of allergen-specific IgE on mast cells (Abrahamson MJ et al., 1995; Greidener DK, 
1996). The use of purified recombinant protein allergens rather than allergy extracts for 
allergen immunotherapy may permit the allergen dose to be safely increased (Akdis CA, 
2006). As such, it is important to completely comprehend the mechanism modulated by 
the allergen dosage that is intended to reduce IgE synthesis in allergic individuals.   
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 Animal models of allergy have been largely created to define potential strategies for 
therapeutic intervention. The effect of antigen dose on the induction of IgE in animal 
models has been raised by Vaz EM et al. (1971), in which repeated high doses induced a 
low transient IgE titer while minute doses generated a high and persistent IgE antibody 
response. Subsequently, murine models using complex model antigens i.e., phospholipase 
A (PLA) (Kolbe L et al., 1991), keyhole limpet haemocyanin (KLH) (Arps V et al., 
1998; Sudowe S et al., 1995, 1997), and ovalbumin (OVA) (Guery JC et al., 1996; Sakai 
K et al., 1999) also confirmed that the amount of antigen used for immunization affects 
the quality of humoral responses. These studies, in consensus, illustrated that IgE 
responses were markedly attenuated with elevated levels of IgG1/IgG2a production, 
while multiple low doses induced high IgE titers and decreased levels of IgG1/IgG2a 
production (Arps V et al., 1998; Kolbe L et al., 1991; Sakai K et al., 1999). Despite 
extensive studies performed on each model, the explanations for the antibody response 
and mechanism underlying this response are vague. Although some investigators 
proposed that the antibody response is manipulated by the differential polarization of Th1 
or Th2 cells (Guery JC et al., 1996; Sakai K et al., 1999), others claimed no difference in 
CD4+ T cell cytokine profile between mice that had been immunized with different doses 
of antigen (Arps V et al., 1998). To date, the exact mechanism that dictates this 
phenomenon remains poorly understood.  
 
IgE class switch has been documented to be regulated by IL-4 or IL-13, of which they 
possess overlapping roles but do not appear to be interchangeable in vivo (Punnonen J et 
al., 1993; Zurawski G et al., 1994; Sudowe S et al, 2000). Evidence of IL-13 as an IgE 
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 class switch factor, participating in the synthesis or maintenance of IgE in the absence of 
IL-4 expression, is emerging (McKenzie GJ et al., 1998; Barner M et al., 1998; 
McKenzie GJ et al., 1999; Herrick CA et al., 2000; Fallon PG et al., 2001; Herrick CA et 
al., 2003). Its distinctive role was illustrated in the murine system where both IL-13-
deficient and IL-4R-deficient mice displayed impaired Th2 cell development and reduced 
basal IgE levels (McKenzie GJ et al., 1998; Barner M et al., 1998; McKenzie GJ et al., 
1999). Furthermore, mice expressing IL-13 transgene mounted antigen-specific IgE-
mediated allergic responses in the absence of IL-4 expression (Fallon PG et al., 2001). 
Notably, in an OVA epicutaneous sensitization study, the IL-4 deficient mice displayed a 
Th2 response similarly as wild type mice, but IL-13 deficient mice and IL-4 deficient 
mice upon depletion of IL-13 showed an impaired Th2 activation (Herrick CA et al., 
2000, 2003). Taken together, it is hypothesized that IL-13 may play a critical role in the 
regulation of IgE production in allergen dosage murine model sensitized by a 
subcutaneous route.  
 
To study the mechanism that dictated the antigen dosage-priming phenomenon, an 
immunization regime was established in the mice by priming via subcutaneous injection 
with 10 μg (D10) or 50 μg (D50) of rDer p 2 protein in the absence of an adjuvant. To 
answer the question on whether the development of Th1/Th2 cells could modulate the 
quality of antibody response, the immune responses of the Der p 2 allergen immunized 
mice were evaluated. Since this immunization was a cutaneous targeting approach, the 
role of IL-13 in IgE synthesis was also investigated in the Der p 2 allergen immunized 
mice.  
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 2.2 Materials and methods 
 
2.2.1 Preparation of recombinant Der p 2 
 
The cDNA of mature Der p 2 was amplified by polymerase chain reaction (PCR) from 
the plasmid pGEX-2T-Der p 2 (Chua KY et al., 1990) using the sense primer 5′-
GCCTCGAGAAAAGAGATCAAGTCGATGTCAAA-3′ and anti-sense primer 5′-
GCGAATTCTTAATCGCGGATTTTAGC-3′. The 5′ XhoI and 3′ EcoRI sites were used 
for directional in-frame cloning with the α-factor signal sequence driven by the alcohol 
oxidase gene promoter in pPIC9 vector. The PCR reaction was carried out at 94°C for 30 
sec, 50°C for 30 sec, 72°C for 1 min for 30 cycles with pfu DNA polymerase (Promega, 
Madison, WI, USA) and the insert in pPIC9 was completely sequenced. The pPIC9-Der p 
2 was linearized with BglII and transformed into P. pastoris strain GS115 by lithium 
chloride method as described in the Pichia expression manual (version E) (Invitrogen 
Corporation, Carlsbad, CA, USA). The His+Muts clones were selected for Der p 2 protein 
expression. Then, the yeast media containing the rDer p 2 protein were applied to a 
Sephadex G25 molecular sieving column (5 × 20 cm; Pharmacia, Uppsala, Sweden) 
equilibrated with 20 mM sodium acetate, pH 5.5. rDer p 2-containing fractions were 
pooled and applied to a SP-Sepharose fast flow column (2.6 × 15 cm; Pharmacia, 
Uppsala, Sweden) equilibrated with the previous buffer. Bound proteins were eluted with 
600 ml of a linear sodium chloride gradient from 0 to 500 mM. The purity of 
recombinant Der p 2 (rDer p 2) was examined by SDS-PAGE followed by silver staining. 
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 2.2.2 Mice  
 
Female CBA/CaH mice (6-8 weeks old) were purchased from the Sembawang 
Laboratory, Singapore and housed under conventional conditions in the Animal Holding 
units at The National University of Singapore. All animal experiments were performed 
according to the guidance approved by Institutional Guidelines for Animal Care and 
Handling (IACUC). Before each treatment, mice were anaesthetized by an intraperitoneal 
injection with 50-100 μl of a mixture containing 1.25 mg/ml of midazolam (Roche, 
Basel, Switzerland), 2.5 mg/ml fluanisone and 0.079 mg/ml fentanyl citrate (JANSSEN 
PHARMACEUTICAL, Beerse, Belgium). 
 
2.2.3 Immunization regimen 
 
Mice were primed by subcutaneously injected with 10 μg (D10) of rDer p 2 protein in 
100 μl of PBS per mouse or 50 μg (D50) of rDer p 2 protein in 100 μl of PBS per mouse 
on days 0, 4 and 8 (figure 2.1a). Mice were bled weekly and sera were analyzed for Der p 
2 specific IgG1, IgE and IgG2a antibodies by ELISA. To study the early priming 
response, primed mice were sacrificed on day 10 and the spleen and lymph nodes were 
harvested for in vitro culture study. The lymph nodes were harvested from the superficial 
cervical, axillary, brachial and inguinal regions. Protein immunized mice were also 
sacrificed on day 10 for the enrichment of splenic CD4+CD25+ T cells.  
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 In another study, protein primed mice were boosted with 10 μg of rDer p 2 protein on day 
28, and given aerosol challenge on days 56, 58, 60 and 62 (figure 2.1b). In the aerosol 
challenge, mice were kept unrestrained in a desiccator chamber and given continuous 
flow of aerosol rDer p 2 protein generated by an ultrasonic nebulizer (model UltraNEB 
99, DeVilbiss Health Care, Somerset, PA). Four dosages of 0.1 mg/ml of rDer p 2 protein 
in PBS were given for 30 mins at two days interval. Control mice were subjected to 
aerosol rDer p 2 protein inhalation alone or naïve mice. Mice were bled weekly and sera 
were analyzed for Der p 2 specific IgG1, IgE and IgG2a antibodies by ELISA. On day 
64, mice were sacrificed for splenocyte cultures.  
 
To generate antigen-specific Th2 cells, mice were patched by an epicutaneous route as 
previously described (Wang LF et al., 1996). Briefly, 50 μg of rDer p 2 protein in 100 μl 
of PBS was first applied to 1 cm2 gauze on the patches, which was then applied to the 
shaved skin and secured with an elastic bandage. The patching was performed on days 0 
and 14 and each patch was applied for 4 days. At day 21, treated mice were sacrificed, 
and their spleens were collected for short-term T cell culture to establish the antigen-
specific Th2 cells.  
 
2.2.4 Detection of Der p 2-specific immunoglobulin responses 
 
ELISA Costar plates (Corning, Inc., Corning, NY) were coated with 50 μl of rDer p 2 
protein diluted in coating buffer (0.1M NaHCO3, pH 8.3) to a concentration of 5 μg/ml 
and incubated at 4°C overnight. After washing the plate with 0.05% Tween (Sigma, St. 
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 Louis, MO USA)/PBS (PBST), 100 µl of blocking buffer (1% Bovine Serum Albumin 
(Sigma)/PBS) was added and incubated at room temperature for 2 hrs. The plate was 
washed again. Fifty microliters of the diluted mouse sera were added to the wells and 
incubated at 4°C overnight. The plate was washed and incubated with 50 µl of 
biotinylated rat anti-mouse IgG1 (LO-MG1-2), IgG2a (LO-MG2a-7) or IgE (LO-ME-3) 
(Serotec Ltd, Oxford, England) antibodies for 1 hr at room temperature. The antibodies 
were diluted in blocking buffer at a final concentration of 250 ng/ml. Next, the plates 
were washed and incubated with 50 µl of ExtraAvidin-alkaline phosphatase (Sigma) 
(1:2000) for 1 hr at room temperature. Finally, the reactions were developed with 50 µl of 
Sigma Fast pNitrophenyl phosphatase substrate (Sigma) and optical density was 
measured at 405 nm on a microplate reader (Tecan, Ges.m.b.H, Austria). Standard curves 
were generated using anti-mouse Igκ light chain antibody (187.1) and commercial 
standards of purified mouse IgG1 (107.3), IgG2a (G155-178) or IgE (C38.2) (BD 
Bioscience PharMingen). ELISA units were defined as the OD405nm reading 
corresponding to the signal generated with 1 ng/ml of detected antibody in a sandwich 
ELISA with anti-mouse Igκ as the capture antibody. The detection limits of the IgG1, 
IgG2a and IgE assays were 0.2, 0.4 and 0.2 ELISA units, respectively. The sera dilutions 
were ranged from 1:100 to 1:40,000 for IgG1, 1:100 to 1:10,000 for IgG2a, and 1:5 for 
IgE assays. 
 
2.2.5 Preparation of single cell suspension 
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 Spleens or lymph nodes were harvested from mice and placed in Petri dishes in the 
presence of 10 ml of 1X Hanks Balanced Salt Solution (HBSS) (Sigma). Single cell 
suspension was made by disrupting the tissues using two frosted slides. Red blood cells 
(RBCs) were lysed by adding 1.5 ml of RBC lysis buffer (10 mM Tris, 0.83% NH4Cl, 
pH8.3) for 90 sec. The cells were washed 3 times with 1 X HBSS and the cell number 
was determined by using a hematocytometer. The cells were suspended in complete 
RPMI medium (supplemented with 10% heat-inactivated bovine calf serum (StemCell 
Technologies, Vancouver, Canada), 1 mM sodium pyruvate (HyClone, South Logan, UT, 
USA), 2 mM L-glutamine, antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin), 
5.5×10-2 mM 2-β mercaptoethanol (Gibco BRL, Life Technologies, Paisley, UK), 
 
2.2.6 Splenic and lymph nodes cell cultures 
 
Splenocytes or lymph nodes cells were cultured in a complete RPMI-1640 medium and 
incubated at 37˚C in the presence of 5% CO2. To determine the cytokine production of 
freshly isolated splenic cells, 100 µl of cells (3×106 cells/ml) were stimulated in the 
presence or absence of 100 μl of rDer p 2 protein (20 μg/ml) in a 96-well U bottomed 
plate (Nunc, Roskilde, Denmark). To determine the cytokine production of freshly 
isolated lymph nodes cells, 50 µl of lymph nodes cells (6×106 cells/ml) and 50 μl of 
APCs (6X106 cells/ml) were added to 96-well U bottomed plate, followed by 100 µl of 
rDer p 2 protein (20 μg/ml). To establish the short-term T cell culture, splenocytes were 
cultured in 24-well (4×106 cells/well) or 6-well (2×107 cells/well) plates in the presence 
of 10 μg/ml of rDer p 2 protein for 10 days. At days 3, 5 and 7, cells were supplemented 
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 with fresh medium containing 10 U/ml of recombination mouse IL-2 (R&D Systems, 
Minneapolis, MN, USA). To determine the cytokine profile of short-term culture T cells, 
50 µl of T cells (2X106 cells/ml) collected after Ficoll-Pague centrifugation (as describe 
below) and 50 μl of APCs (6 X106 cells/ml) were added to 96-well U bottomed plate, 
followed by 100 µl of rDer p 2 protein (20 μg/ml). The supernatant were collected at 
different time-points for the cytokine ELISA assay as described below. 
 
2.2.7 Removal of dead cells from short-term culture cells by Ficoll-Pague 
centrifugation  
 
Ten days after cultured with rDer p 2 antigen, the cells were collected and suspended in 5 
ml of 1 X HBSS. This cell suspension was transferred to a 15 ml tube. Three milliliters of 
Ficoll-Pague plus (Amersham Biosciences Corp, Piscataway, NJ) was added to the 
bottom of the tube without disturbing the interface of the two layers. Next, the cells were 
centrifuges for 20 min at 800 X g without brake. After that, the live cells were collected 
from the interface, washed 3 times with 1 X HBSS, and suspended in complete RPMI 
medium.  
 
2.2.8 Preparation of antigen presenting cells  
 
APCs were derived from the mitomycin C-treated splenocytes of naive mice. Mitomycin 
C (Roche Diagnostic GmbH, Mannheim, Germany) was dissolved in PBS at a 
concentration of 0.5 mg/ml. Splenocytes were washed twice with 1 X HBSS and 
 66
 suspended in PBS to a concentration of 5X107 cells/ml. Mitomycin C was added to the 
cells at a final concentration of 50 μg/ml and incubated in the dark at 37ºC for 20 min. 
Next, the cells were washed 3 times with 30 ml of 1X HBSS and suspended in complete 
RPMI medium.   
 
2.2.9 Enrichment of splenic CD4+CD25+ T cells 
 
The splenic CD4+CD25+ T cells were enriched by using CD4+CD25+ Regulatory T-Cell 
Isolation Kit (Miltenyl Biotec, Bergisch Gladbach, Germany). Firstly, 1X108 splenic cells 
were added to 400 µl of staining buffer (0.5% BSA/2mM EDTA/PBS, pH7.2) and 
incubated with 100 µl of Biotin-Antibody Cocktail containing biotin-conjugated 
antibodies against CD8a (Ly-2; isotype: rat IgG2a), CD11b (Mac-1; isotype: rat IgG2b), 
CD45R (B220; isotype: rat IgG2a), CD49b (DX5; isotype: rat IgM) and Ter-119 
(isotype: rat IgG2b) for 15 min at 4°C. Next, the mix was supplemented with 300 µl of 
buffer, followed by 200 µl of anti-biotin microbeads and 100 µl of CD25-PE antibody. 
The mix was incubated for additional 15 min in the dark at 4°C. The cells were then 
washed by adding 5 ml of buffer and centrifuged at 300 x g for 10 min. The supernatant 
was removed completely and cell pellet was suspended in 500 µl of buffer. The cell 
suspension was loaded onto a column which was placed in the magnetic field of a cell 
sorted AutoMACs (Miltenyl Biotec). Using the program “depletion”, the magnetically 
labeled non-CD4+ T cells were retained in the column, while the unlabeled CD4+ T cells 
run through. The unlabelled cells were collected at the outlet port "neg1" and centrifuged 
at 300 x g for 10 min. The pellet was suspended in 1 ml of staining buffer and incubated 
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 with 100 µl of anti-PE microbeads for 15 min in the dark at 4°C. The cells were then 
washed with 5 ml of buffer and centrifuged at 300 x g for 10 min. The supernatant was 
completely removed and suspended into 500 µl of buffer. The magnetically labeled cells 
were loaded onto a column of the AutoMACS. Using separation program “positive 
selection 2”, the enriched CD4+CD25+ T cell fraction was collected at the outlet port 
“pos2”. To determine the cell purity, 1X105 cells were stained with rat FITC-conjugated 
anti-mouse CD4 antibody (RM4.5), PE-conjugated anti-mouse CD25 antibody and 
PerCP-conjugated anti-mouse CD3 antibody (145-2c11), and the purity was determined 
by flow cytometry (FACScan/Calibur and CellQuest software)(Becton Dickinson and 
company, San Jose, CA). From the analysis, at least 98% of isolated cells were 
CD4+CD25+ T cells.  
 
2.2.10 Preparation of cytokine and proliferation assay  
 
Antigen-specific Th2 cells were derived from epicutaneous patched mice. This was 
performed by culturing the splenocytes for 10 days in the presence of rDer p 2 protein 
and the dead cells were removed as described in sections 2.2.5, 2.2.6 and 2.2.7. Antigen-
specific Th2 cells (1x105 cells), enriched CD4+CD25+ T cells (1x105 cells) and APCs 
(3x105 cells) were cultured in combination or individually in the presence or absence of 
10 μg/ml of rDer p 2 protein. To determine the cytokine response, culture supernatants 
were harvested at 72 hr and assayed for cytokine IL-4, IL-5 and IL-13 production. For the 
proliferation study, cells were incubated for 5 days and pulsed with 1 μCi of [3H]-
thymidine (NEN Life Science, Boston, MA) at the last 18 hr. Cells were harvested to a 
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 glass fiber filter (Skatron instruments AS, Lier, Norway). After adding the scintillation 
fluid (Amersham Biosciences Corp) and the proliferation was measured by the liquid 
scintillation counter (Beckman Coulter, Inc. Fullerton, CA). The proliferation index is 
expressed as the ratio of Th2 cells alone.   
 
2.2.11 Cytokine ELISA 
 
Purified antibodies to mouse IFN-γ (RA-6A2), IL-4 (BVD4-1D11), IL-5 (TRFK5), IL-9 
(D9302C12), IL-10 (JES052A5, R&D Systems, Minneapolis, MN, USA), IL-13 (38213, 
R&D Systems) and TGF-β1 (A75-2) antibodies were diluted in coating buffer to a final 
concentration of 2 μg/ml. All antibodies and recombinant proteins were purchased from 
BD Bioscience PharMingen (San Diego, CA, USA), unless otherwise stated. Costar high 
binding 96-well ELISA plates were coated with 50 μl of the diluted antibodies and 
incubated at 4°C overnight. After washing with 0.05% Tween/PBS, the plates were 
blocked with 100 µl of blocking buffer at room temperature for 2 hrs. The plates were 
then washed and incubated with 50 µl of supernatant overnight at 4ºC. The supernatant 
were used as neat or diluted in blocking buffer to a range of 1:2 to 1:100. For quantitation 
purpose, 50 µl of the mouse recombinant cytokines were prepared in two-fold serial 
dilution in blocking buffer and included in each plate. The plates were then washed and 
added with 50 µl biotinylated polyclonal antibodies to mouse IFN-γ (XMG1.2), IL-4 
(BVD6-24G2), IL-5 (TRFK4), IL-9 (D8402E8), IL-10 (R&D Systems), IL-13 (R&D 
Systems) or TGF-β1 (A75-3). The concentration for biotinylated IFN-γ, IL-4 and IL-5 
were 2 µg/ml, IL-10 was 400 ng/ml, IL-13 was 200 ng/ml and TGF-β1 was 200 ng /ml. 
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 Next, the plates were washed and incubated with 50 µl of ExtraAvidin-alkaline 
phosphatase (Sigma) (1:2000) for 1 hr at room temperature. Finally, the reactions were 
developed with 50 µl of Sigma Fast pNitrophenyl phosphatase substrate (Sigma) and 
optical density was measured at 405 nm on a microplate reader The detection limit for the 
IFN-γ, IL-4, IL-5, IL-9, IL-10, IL-13 and TGF-β1 assays were 20 pg/ml, 10 pg/ml, 20 
pg/ml, 150 pg/ml, 25 pg/ml, 40 pg/ml and 20 pg/ml, respectively. The results shown were 
deducted from background readings of those without antigen stimulation. 
 
2.2.12 Enrichment of short-term culture splenic CD4 + T cells  
 
Short-term splenocytes cultures were prepared and dead cells were removed as described 
in sections 2.2.5, 2.2.6 and 2.2.7. To enrich CD4+ T cells, 5X107 live cells were washed 
with staining buffer and incubated with 50 μl of biotinylated anti-CD4 (PharMingen) at 
4°C for 15 min. The cells were washed with staining buffer and incubated with 50 μl 
streptavidin-conjugated microbeads (Miltenyi Biotec) at 4°C for 15 min. CD4+ T cells 
were enriched by using cell sorted AutoMACs and the program “positive selection 2”. To 
check for purity, a portion of cells was stained with FITC-conjugated anti-mouse CD4 
antibodies (RM4.5) and Per-CP-conjugated anti-mouse CD3ε (145-2c11) antibodies. The 
purity of CD4+ T cells was analyzed by flow cytometry (FACScan/Calibur and 
CellQuest software). The CD4+ T cells showed at least 95% purity.  
 
2.2.13 Total RNA extraction  
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 Total RNA was extracted from the enriched splenic CD4+ T cells by using RNeasy Mini 
kit (Qiagen Inc, CA) according to the manufacturer’s protocol. The quality of RNA was 
verified by the detection reading of Optical Density (O.D.) 260/280, which fell within a 




Total RNA was reverse transcribed into cDNA using Moloney-Murine Leukaemia Virus 
(M-MVL) Reverse Transcriptase (Promega) as recommended by the manufacturer. 
Briefly, 1 µg of total RNA was mixed with 1 µg of oligo dT (Research Biolaboratory, 
Singapore), and topped up with DEPC water to a final volume of 30 µl. The mix was 
incubated at 70ºC for 10 min and put on ice immediately. The mix was then added with 1 
µl of dNTPs (10 mM) (Promega), 8 µl of 5 X MMLV buffer, 1 µl of recombinant RNase 
inhibitor (40 U/µl) (Promega) and 1 µl of MMLV reverse transcriptase (10 U/µl), and 
then incubated at 42ºC for 1 hr. The cDNA was stored at -80ºC.  
 
2.2.15 Quantification of cytokine gene expression level by conventional PCR 
 
To quantify the cytokine gene expression level, HPRT was normalized in each sample to 
standardize the amount of cDNA sample used in each PCR. One to 2 µl of the cDNA was 
added to a reaction mixture containing 1 µl of sense and anti-sense cytokine primers (10 
pmol), 1 µl of dNTP (10 mM) and 1 µl of Taq DNA polymerase (2.5 U/µl) (Promega) 
and 5 µl of 10X PCR buffer. Each sample was brought to a final volume of 50 μl with 
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 ddH20. The mix was incubated in a DNA thermal cycler (Perkin Elmer Gene Amp PCR 
system 9700, PE applied biosystems, USA) for a total of 30 cycles. Each cycle consists of 
30 sec at 94˚C, 30 sec at 58˚C, and 1 min at 72˚C. An initial 5 min incubation at 94˚C and 
a final extension of 10 mins at 72˚C were included in each reaction. All primers were 
purchased from Research Biolaboratory, Singapore. The cytokine primers sequences are 
listed in Table 2.1. 
 
2.2.16 IL-13 depletion study  
 
 Mice were administered 20 μg of rat anti-mouse IL-13 monoclonal antibodies (mAbs) 
(38213, R&D Systems) via an intravenous route. Thirty minutes later, mice received a 
subcutaneous injection of D10 of rDer p 2 protein. The treatments were performed at 
days 0, 4, 8 and 28. For the control group, mice were given 20 μg of rat IgG2B isotype 
(141945, R&D Systems) and similarly injected with D10 of rDer p 2 protein. Mice were 
bled and the sera collected were assayed for Der p 2-specific antibody titers.  
 
2.2.17 Statistical Analysis 
 
Data are expressed as means ± s.e.m. Differences between groups were considered 
statistically significant when P-values were < 0.05, using a Mann-Whitney U-test.
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 Table 2.1: Primer sequences for cytokine genes 
 
Gene Primer sequence 
Sense 5’ GTTGGATACAGGCCAGACTTTGTTG 3’ HPRT (300 bp) 
(Accession no. 
 NM_013556) Anti-sense 5’ GAGGGTAGGCTGGCCTATGGG 3’ 
Sense 5’CATTGAAAGCCTAGAAAAGTCTG 3’  IFN-γ (245 bp) 
(Accession no. 
 BC119065) Anti-sense 5’ CTCATGAATGCATCCTTTTTCG 3’ 
Sense 5’ CATCGGCATTTTGAACGAGGTCA 3’ IL-4 (215 bp) 
(Accession no. 
 BC027514) Anti-sense 5’ CTTATCGATGAATCCAGGCATCG 3’ 
Sense 5’ GAAAGAGACCTTGACACAGCTG 3’  IL-5 (254 bp) 
(Accession no. 
 BC125366) Anti-sense 5’ GAACTCTTGCAGGTAATCCAGG 3’ 
Sense 5’ CCAGTTTTACCTGGTAGAAGTGATG 3’ IL-10 (317 bp) 
Accession no. 
BC120612)  Anti-sense 5’ TGTCTAGGGTCCTGGAGTCCAGCAGACT 3’ 
Sense 5’ ATGGCCATGTGGGAGCTGGAG 3’  IL-12 (334 bp) 
Accession no. 
NM_008352) Anti-sense 5’ TTTGGTGCTTCACACTTCAGG 3’ 
Sense 5’ CCCTGTGCAACGGCAGCAT 3’  IL-13 (241 bp) 
(Accession no. 




 2.3 Results  
 
2.3.1 Humoral responses of allergen dosage murine model 
 
To show that allergen dosages could modulate the immune responses of rDer p 2 protein 
immunized mice, the humoral and cellular responses of protein primed mice were 
evaluated. Mice immunized with the D10 dose have shown enhanced IgE levels (~ 3.5 
ELISA units) with low IgG1 levels (~ 1700-3000 ELISA units) while those immunized 
with the D50 dose responded with an  elevated high IgG1 concentration (6500-10,000 
ELISA units) and low IgE titers (~1.5 ELISA units) (figure 2.2a-b). The level of IgG2a in 
D50 immunized mice increased to ~ 120 ELISA units as compared to the basal level of ~ 
40 ELISA units in the D10 immunized mice (figure 2.2c). As the humoral responses of 
these mice were specifically stimulated by the Der p 2 allergen itself, but independent of 
the adjuvant interference, investigations were initiated to evaluate the early priming 
mechanism that dictated the antibody response of these immunized mice. 
 
2.3.2 Distinct cytokine responses were elicited in cell cultures of Der p 2 protein 
immunized mice 
 
To characterize the phenotypes of immune responses driven in these mice, the cytokine 
profiles of lymph nodes cells and splenocytes cultures of the protein immunized mice 
were examined. In the lymph nodes cell cultures, D10 immunized mice showed 
significantly elevated production of IL-4 (110-150 pg/ml, p < 0.05, figure 2.3a) and IL-9 
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 (180-230 pg/ml, p < 0.05, figure 2.3b) as compared to the D50 immunized mice (IL-4 : 9-
30 pg/ml; IL-9: 43-48 pg/ml) and PBS group (IL-4: 20-23 pg/ml, IL-9: 23-38 pg/ml), 
indicating that a typical Th2-skewed phenotype was induced in D10 immunized mice. 
However, no significant difference in the IL-13 level of these mice (figure 2.3c) was 
observed. D10 immunized mice showed a significant and suppressive effect on IFN-γ 
production while D50 group showed a slight IFN-γ production as compared to the PBS 
controls (figure 2.3d, p < 0.05). The large amount of accumulated IFN-γ production 
detected in PBS group was non-antigen specific and the cell type responsible for the 
production was unclear. It was ruled out that D50 immunized mice solely induced Th1-
skewed response as they showed markedly increase in IL-10 and TGF-β1 production as 
compared to the D10 and PBS groups (IL10: 80-155 pg/ml in D50 vs 20-25 pg/ml in D10 
vs undetected in PBS group, figure 2.3e; TGF-β1: 80-125 pg/ml in D50 vs undetected in 
D10 and PBS group, figure 2.3f).  
 
The notion of D10 immunized mice inducing a strong Th2 phenotype was further 
supported by the cytokine profiles of the splenocyte cultures, which  showed high levels 
of IL-4, IL-9 and IL-13 as compared to both D50 and PBS groups (IL-4 : 118 ± 46 pg/ml 
in D10 vs 37 ± 19 pg/ml in D50 vs undetected in PBS, figure 2.4a; IL-9 : 126 ± 82 pg/ml 
in D10 vs 46 ± 21 pg/ml in D50 vs undetected in PBS, figure 2.4b; IL-13 : 121 ± 21  
pg/ml in D10 vs 60 ±  12  pg/ml in D50 vs  undetected in PBS, figure 2.4c). IL-13 
production in lymph nodes cells culture of all groups was insignificant as compared to the 
significant increase found in the splenoctye culture of D10 immunized mice. This is 
possibly due to the different stages of response induced within the two tissue 
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 compartments. Similar to the lymph nodes cell cultures, the IFN-γ production at 72 hr 
was suppressed in both D10 and D50 immunized mice as compared to PBS group (~ 0-66 
± 160 pg/ml in D10 and D50 vs 780 ± 130 pg/ml in PBS group, figure 2.4d). A large 
amount of accumulated IFN-γ was detected in the PBS group (~ 6800 ± 3000 pg/ml) at 
96 hr, and some levels were detected in the D50 group (~ 4400 ± 370 pg/ml). The source 
of non-antigen specific IFN-γ production was unclear. D10 immunized mice showed 
higher IL-10 production as compared to D50 immunized mice (330 ± 42 pg/ml in D10 vs 
150 ± 30 pg/ml in D50, figure 2.4e). A higher IL-10 production was observed in the 
splenocyte cultures of D10 immunized mice but not in the lymph nodes cells cultures. 
This might be explained by the two compartments containing different cell types. The IL-
10 detected in the spleen of D10 mice was probably contributed by cells such as 
macrophages that are involved in the development of Th2 response, while the majority T 
cells in the lymph nodes compartment may not be capable of producing IL-10. The 
development of Treg cells in D50 immunized mice was further supported by the 
moderate IL-10 and high TGF-β1 production in the splenocyte cultures as compared to 
D10 and PBS group (TGF-β1 : 870  ±  382 pg/ml in D50 vs 193 ± 311 pg/ml in D10  and 
107  ±  323 pg/ml in PBS, figure 2.4f). In both splenic and lymph nodes cell cultures, IL-
5 production fell below the detectable limit in all groups (data not shown).  
 
The cytokines profile of D50 immunized mice exhibited suppression in Th2 cytokines 
response with slight production of IFN-γ. This priming might not solely be the result of 
biased Th1 response as previously reported (Sakai K et al., 1999; von Garnier C et al., 
2002) since high TGF-β1 and moderate IL-10 levels were detected. The development of 
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 Treg cells might be involved as IL-10 and TGF-β1 have suppressor cytokine functions 
and frequently occur together during a regulatory T cell response (Kitani A et al., 2003). 
Furthermore, Treg cells have the capacity to secrete high amounts of TGF-β and small 
amounts of IFN-γ (de Moraes LV et al., 2003). 
 
2.3.3 CD4+CD25+ T cells of D50 immunized mice suppressed the proliferative 
response and cytokine production of antigen-specific Th2 cells 
 
To further characterize the T cells activated by D50 immunization, the effect of antigen-
specific Th2 cells upon co-culture with splenic CD4+CD25+ T cells of protein 
immunized mice was assessed by measuring the proliferative response of Th2 cells. A 
significant fall of at least 65% in the proliferation response of antigen-specific Th2 cells 
was seen in D50 group as compared to D10 group (32.1 ± 15.7 % vs 97.6 ± 11.2 %, p < 
0.05, figure 2.5a), illustrating the suppressive function of D50 derived CD4+CD25+ T 
cells in antigen-specific lymphoproliferative response. In addition, the antigen-specific 
Th2 cell cytokines profile showed that the CD4+CD25+ T cells from the D50 immunized 
mice have the capacity to inhibit the synthesis of Th2 cytokines as compared to the 
CD4+CD25+ T cells from the D10 immunized mice and Th2 cells alone, particularly on 
IL-13 (41 ± 20 pg/ml in D50 vs 120 ± 20 pg/ml in D10 and 115 ± 8 pg/ml in Th2 cells 
alone, p < 0.05, figure 2.5b), followed by IL-4 (81.5 ± 7.5 pg/ml in D50 vs 103.4 ± 13.9 
pg/ml in D10 and 117.9 ± 22.3 pg/ml in Th2 cells alone, figure 2.5c) and IL-5 (37.6 ± 9.0 
pg/ml in  D50 vs 74.3 ± 20.1 pg/ml in D10 and 62.6 ± 11.7 pg/ml in Th2 cells alone, 
figure 2.5d).  
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 2.3.4 Humoral responses of allergen protein boost and aerosol challenge mice  
 
To further evaluate the significance of protein priming, allergen protein primed mice 
were subjected to allergen protein boost and aerosol challenge, and the humoral 
responses were assessed. D10 immunized mice showed a drastic increase in IgE 
production one week after boosting with 10 µg of rDer p 2 protein (17.6 ± 6.6 ELISA 
units, p < 0.05, figure 2.6a) as compared to D50 group (2.8 ± 1.1 ELISA units). 
Subsequently, a significantly high level of IgE production was persisted in D10 
immunized mice while D50 immunized mice displayed markedly low basal IgE level (5.9 
± 2.2 vs 1.5 ± 0.6 ELISA units at day 42, 2.8 ± 1.0 vs 0.15 ± 0.05 ELISA units at day 56, 
p < 0.05). Conversely, the level of IgG1 production in D10 immunized mice was notably 
lower as compared to the D50 group (9236 ± 3490 vs 40,915 ± 15,464 ELISA units at 
day 35, p < 0.05, figure 2.6b). Thereafter, a constant IgG1 level of about 18,000 ELISA 
units was observed in D10 group, while D50 immunized mice displayed enhance IgG1 
production ranging of 83,390 ± 31,520 ELISA units on day 42 (p < 0.05) and 58,864 ± 
22,860 ELISA units on day 56. The IgG2a production of D10 immunized mice remained 
at a basal level of about 40-150 ELISA units throughout the experiment while D50 group 
upon allergen protein boost showed significant increase to 740 ± 262 ELISA units at day 
42 (p < 0.05, figure 2.6c). The booster injection with D10 of rDer p 2 protein could 
trigger a marked increase in IgE production in D10 immunized mice while no significant 
IgE boosting effect was seen in D50 immunized mice. Instead, D50 immunized mice 
responded with distinctly high IgG1 production and a slight increase in IgG2a 
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 production. The suppressive effect of IgE production persisted in the D50 immunized 
mice even after allergen protein boost and aerosol challenge. 
 
2.3.5 D50 model suppressed the aerosol challenge-induced IL-13 gene expression  
 
To investigate the T cells responses of the aerosol challenge mice, the CD4+ T cell 
cytokine mRNA expression profiles were quantified by conventional RT-PCR analysis 
(figure 2.7). IL-12 was not detected and there was not much difference in the expression 
levels of IL-4 and IFN-γ between the groups of mice. There were, however, differences in 
their expression of other Th2 cytokines especially effector cytokines. Interestingly, the 
IL-13 gene expression level was significantly attenuated in D50 immunized mice.  
 
2.3.6 Depleting serum IL-13 abrogated antibody response in D10 murine model 
 
To address the effect of IL-13 on dosage dependent antibody response, systemic IL-13 
was depleted in D10 immunized mice by injecting anti-IL-13 mAbs or isotype control 
before each protein immunization. Mice that received anti-IL-13 mAbs showed impaired 
IgE production as compared to the control group at day 35 (2.6 ± 1.0 vs 7.4 ± 1.2 ELISA 
units, p < 0.05, figure 2.8a). Thereafter, their IgE profiles were sustained in both groups 
(0.9-1.3 ELISA units in mice that received anti-IL-13 mAbs vs 2.9-3.3 ELISA units in 
control group, p < 0.05). IgG1 production also showed significant reduction in the group 
that received anti-IL-13 antibodies as compared to control group (1000 ± 398 vs 23,300 ± 
9900 ELISA units at day 49; 1070 ± 396 vs 17,412 ± 8286 ELISA units at day 56, p < 
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 0.05, figure 2.8b). No significant difference in IgG2a production was observed in both 
groups (figure 2.8c). This blocking assay has illustrated the independent role of IL-13 in 
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Figure 2.1: Schematic diagrams on the experimental protocols. 
Mice were primed by subcutaneous injection with 10 μg (D10) or 50 μg (D50) of rDer p 
2 protein via subcutaneous route on days 0, 4 and 8. Treated mice were sacrificed on day 
10 for splenocyte and lymph nodes cells cultures, or for the isolation of splenic 
CD4+CD25+ T cells (a). In another study, protein immunized mice were boosted with 10 
μg of rDer p 2 protein on day 28, and subjected to aerosol inhalation with 0.1 mg/ml of 
rDer p 2 protein in PBS for 30 min on days 56, 58, 60 and 62. Immunized mice were bled 
weekly and sera were collected until day 64 for the detection of Der p 2 specific antibody 
production. Treated mice were sacrificed on day 64 for T cell cytokine analysis. Control 
mice were subjected to aerosol inhalation alone (InEx) or naïve mice (Naïve), and 
sacrificed on the same day (b).  
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Figure 2.2: Specific immunoglobulin responses of mice immunized with rDer p 2 
protein. Mice were administered D10 or D50 of rDer p 2 protein on days 0, 4, and 8 via 
subcutaneous route and monitored for Der p 2 specific IgE (a), IgG1 (b) and IgG2a (c) 









































































































































































Figure 2.3: Cytokine profiles of lymph nodes cell cultures.  
Mice were subcutaneously injected with D10 or D50 of rDer p 2 protein on days 0, 4 and 
8. On day 10, lymph nodes were harvested and cultured with 10 μg/ml of rDer p 2 protein 
in the presence of antigen presenting cells. Supernatants were harvested at 72 hr, 96 hr 
and 120 hr for the detection of cytokines IL-4 (a), IL-9 (b), IL-13 (c), IFN-γ (d), IL-10 (e) 
and TGF-β1 (f) production by ELISA. Results shown are representative of 2 independent 
experiments, mean ± s.e.m., n = 4 per group. *compared with PBS, # compared with 
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Figure 2.4: Splenocytes cytokine production of protein immunized mice.  
Mice were primed with D10 or D50 of rDer p 2 protein, or with PBS via subcutaneously 
route on days 0, 4 and 8. Spleens were harvested on day 10, cultured with 10 μg/ml of 
rDer p 2. Supernatants were collected at 72 hr, 96 hr and 120 hr, and assayed for IL-4 (a), 
IL-9 (b), IL-13 (c), IFN-γ (d), IL-10 (e) and TGF-β1 (f). Results shown are representative 
of two independent experiments, mean ± s.e.m., n = 4-5 per group. * compared with PBS, 





























Figure 2.5 Effect of antigen-specific Th2 cells upon co-cultured with the 
CD4+CD25+ T cells of protein immunized mice. In the proliferation assay, antigen-
specific Th2 cells were co-cultured with CD4+CD25+ T cells of protein-primed mice and 
assayed for the incorporated thymine [H3] on day 5. Proliferation index is expressed as 
the ratio to Th2 cells alone (a). Culture supernatants were harvested at 72 hr and assayed 
for IL-13 (b), IL-4 (c) and IL-5 (d). Data shown the average of three independent 
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Figure 2.6 Specific immunoglobulin responses of mice immunized with rDer p 2 
protein and aerosol challenge. Mice were subcutaneously injected with D10 or D50 of 
rDer p 2 protein on days 0, 4 and 8. Treated mice were boosted with 10 μg of rDer p 2 
protein on day 28, and subjected to aerosol inhalation with 0.1 mg/ml of Der p 2 in PBS 
for 30 min on days 56, 58, 60 and 62. The Der p 2-specific titers of IgE (a), IgG1 (b) and 
IgG2a (c) were determined by ELISA. Results shown are mean ± s.e.m, n = 8 per group. 



























Figure 2.7: RT-PCR analysis of cytokine expression profiles of splenic CD4+ T cells. 
rDer p 2 protein primed mice were subjected to aerosolized Der p 2 allergen exposure 
and sacrificed on day 64. Control groups were untreated mice (Naive), or mice receiving 
aerosolized inhalation exposure to Der p 2 allergen alone (InEx). Cells were stimulated 
with antibodies against CD3 and CD28 for 24 hr, and total RNA was isolated for the 
analysis of cytokine expression. Each band shows the amplified cytokine product from 
pooled spleens of eight mice.   
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Figure 2.8: Effect of IL-13 blockade in mice primed with 10 μg of rDer p 2 protein. 
Mice were given 20 μg of anti-IL-13 mAb or isotype control antibody on days 0, 4, 8, 
and 28 via intravenous route at least thirty minutes before subcutaneous injection with 
D10 of rDer p 2 protein. Der p 2 specific IgE (a), IgG1 (b), and IgG2a (c) were 
determined by ELISA. Results shown are mean ± s.e.m, n = 3 per group, *  p < 0.05. 
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 2.4 Discussion 
 
This study has established an experimental model in which an indoor aeroallergen, Der p 
2, is capable of triggering specific, dosage-dependent immune response in adjuvant-free 
approach. This system recapitulated the effects of antigen dosage on IgE and IgG1 
production (Kolbe L et al., 1991; Arps V et al., 1998; Sudowe S et al., 1995, 1997; von 
Garnier C et al., 2002), while circumventing the possible interference caused by the use 
of an adjuvant i.e. non-specific antibody stimulation that was selectively biased towards 
antibody subclass production (Mancino D and Ovary Z, 1980; Beck L and Spielgelberg 
HL, 1989), induction of a strong antigen-specific Th2 response (Brewer JM et al., 1999; 
Avramidis N et al., 2002), or a Th1 dominated response (Avramidis N et al., 2002). This 
approach eliminated the interference of adjuvant and offered a clean allergen induced 
scenario to address the underlying mechanism that dictated the development of humoral 
and cellular responses to different dosages of Der p 2 allergen used in this study. 
 
Our study showed that the D10 mice , which were primed by 10 μg of rDer p 2 protein, 
responded with elevated IgE titers, low IgG1 production, and increased Th2 cytokines IL-
4, IL-9, IL-10 and IL-13 - cytokines related to the development of the etiology of asthma 
(Webb DC et al., 2000; Soussi-Gounni A et al., 2001; Walter DM et al., 2001). The 
importance of these cytokines as regulators of humoral response has been extensively 
discussed in regards to their function in T cell response particularly in the context of 
allergy (Gauchat JF et al., 1990; Maggi E et al., 1992; Petit-Frere C et al., 1993; Dugas B 
et al., 1993; Barner M et al., 1998; McKenzie GJ et al., 1999, Herrick CA et al., 2000).  
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IL-4 has been long regarded as the most dominant factor in determining the likelihood for 
Th2 polarization in cultured cells (Maggi E et al., 1992) and as an essential factor in IgE 
class switch (Gauchat JF et al., 1990). Nevertheless, evidence that IL-4 not being entirely 
responsible for the synthesis or maintenance of IgE (McKenzie GJ et al., 1999; Herrick 
CA et al., 2000) has been reported. Previous in vivo study has demonstrated that mice 
deficient in IL-9 had lower antigen-specific IgE production (McMillan SJ et al., 2002) 
and IL-9 could potentiate IgE production through priming murine B cells and normal 
human B cells in an IL-4 dependent pathway (Petit-Frere C et al., 1993; Dugas B et al., 
1993). However, the regulating role of IL-9 in IgE production in D10 immunized mice 
was ruled out as blocking systemic IL-9 in D10 immunized mice demonstrated no impact 
on the IgE production as compared to controls (data not shown). IL-10 is a major 
regulatory factor in inflammatory responses (Akdis CA et al., 1998). Although the 
addition of IL-10 to antigen-primed splenic cultures has shown its capability to enhance 
the effect on specific IgE formation (Ohmori H et al., 1995), its participation in murine 
B-cell IgE synthesis has remained ambiguous (Akdis CA et al., 1998; Mond JJ et al., 
1996; Ohmori H et al., 1995). 
 
Previous studies have suggested that the role of IL-4 in the regulation of IgE synthesis 
might not be as significant as IL-13 in cutaneous sensitization (McKenzie GJ et al., 1999; 
Herrick CA et al., 2000). This study has suggested that IL-13 is a critical factor in initial 
priming as well as in the effector phase to sustain in vivo IgE production. This notion is 
derived from the IL-13 neutralizing study which showed that blocking IL-13 alone is 
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 sufficient to reduce IgE production in D10 immunized mice, indicating the independent 
role of IL-13 in the regulation of IgE. It further supports the previous finding that 
suggested IL-4 not being entirely accountable for the synthesis or maintenance of IgE 
(Herrick CA et al., 2000; McKenzie GJ et al., 1999; McMillan SJ et al., 2002, McKenzie 
GJ et al., 1998, Fallon PG et al., 2001). 
 
This study has suggested that D50 immunization could trigger the development of 
antigen-specific Treg cells. This notion is supported by the in vitro cultures that showed 
suppression of Th2 cytokines production and moderately low production of IFN-γ, but 
most importantly, TGF-β1 secretion was augmented. Furthermore, antigen-specific Th2 
cells were suppressed in proliferation response and cytokines production upon co-culture 
with splenic CD4+CD25+ T cells from the D50 immunized mice but not others. The 
characteristics of these CD4+CD25+ T cells resembled the Treg cells that showed 
increased suppressive activity by inhibiting the proliferation and cytokine production of 
antigenically stimulated T cells (Read S et al., 2000; Takahashi T et al., 2000; Thornton 
AM et al., 1998). In addition, compelling evidence suggests that Treg cell populations 
could facilitate the suppression of allergic inflammation and AHR through increased 
TGF-β production (Jutel M et al., 2003; Taylor A et al., 2004). As the typical hallmarks 
of Th1 response, IFN-γ and IgG2a (Chu RS et al., 1997; Carson DA and Raz E, 1997), 
were also detected in the in vitro cultures and in vivo of D50 immunized mice, it has not 
been ruled out that a concurrent Th1 response might also be induced in these mice. 
However, considering that Treg cells have previously been reported to produce IFN-γ (de 
Moraes LV et al., 2003) and the accumulated, non-antigen specific IFN-γ production has 
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 also been observed in PBS group, it is conceivable that the development of Treg cells in 
D50 immunization is a key immune response.   
 
The results of this study proposed that, in this subcutaneous sensitized regime, IL-13 is 
required in the early priming stage for the induction of IgE synthesis, and the lack of 
early IL-13 production as a result of Treg development in D50 priming might account for 
the continual basal IgE production. This is supported by the in vitro splenocyte culture 
study that demonstrated D10 immunized mice produced high IL-13 levels, and the 
CD4+C25+ T cells of D50 immunized mice could significantly suppressed the 
production of Th2 cytokines, particularly IL-13, in the established Der p 2-specific Th2 
cells. It is speculated that D50 immunization could activate Treg cells that suppressed IL-
13-dependent IgE production and this strong suppressive effect was sustained even after 
aerosol challenge. This is supported by the CD4+ T cell cytokine gene profile of D50 
immunized mice that showed attenuated IL-13 gene expression and low basal IgE titer in 
vivo after aerosol challenge. The IL-13 neutralizing study has revealed the importance of 
IL-13 in regulating IgE synthesis and its role could not be replaced by IL-4. This 
observation agreed with previous findings in which IL-13-deficient mice showed an 
impaired ability to generate Th2 responses after epicutaneous exposure to OVA (Herrick 
CA et al., 2003). The essential role of IL-13 in the effector phase was illustrated in OVA-
transgenic mice that showed the association of IL-13 in antigen-specific IgE production 
and its requirement in the maintenance of Th2 activation after primary exposure (Herrick 
CA et al., 2000; McKenzie GJ et al., 1999; Fallon PG et al., 2001). Furthermore, a study 
conducted on PBMC of young children in response to dust mite allergen showed strong 
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 association between elevated IL-13 levels and IgE production in early childhood (Ly NP 
et al., 2005). Taken together, our data clearly indicated that IL-13 is an essential factor 
for the regulation of IgE synthesis and its deficiency might account for the persistent low 
basal level of IgE detected in the D50 immunized mice. 
 
This study has shown that D50 immunized mice could suppress IgE production but not 
IgG1 production upon boosting with 10 μg of rDer p 2 protein. The potential role of 
suppressor T cells in the regulation of T cell dependent humoral responses has been 
raised on the basis of the recent work that showed specific in vivo depletion of CD25+ 
cells could increase production of IgG1, IgG2a and IgE titer, and the CD4+CD25+ Treg 
suppression was mediated through dampening the T cell help for B cell activation 
(Eddahri F et al., 2006). However, there was also evidence of Treg directly suppressing B 
cell IgG response without suppressing Th cells (Lim HW et al., 2005). In another study, 
depletion of CD4+CD25+ Treg did not affect the acute humoral response to 
polysaccharides and proteins expressed by intact Streptococcus pneumoniae (Lee KS et 
al., 2005). No definitive explanation for these controversial observations to date but it is 
likely that the dosage and nature of antigen plus the route and mode of immunization 
could have profound influences on the Treg activity on the regulation of immune 
responses. 
 
Repeated administration of D50 of Der p 2 allergen has shown to induce the development 
of Treg cells. This immunization regime resembled an allergen-specific 
immunotherapeutic approach that provides an early modulation of the immune response, 
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 and suppressed IgE production and Th2 cytokines as seen in D10 immunized mice. 
Allergen-specific immunotherapeutic, which involves repeated administration of high 
doses of allergen extract, is a current treatment for allergy symptoms in severely affected 
individuals (Graft DF, 1987; Norman PS, 1988; Bousquet J et al., 1998). This treatment 
modifies the natural course of allergic disease and may effect a cure; however, although 
efficacy rates for bee venom allergy are high (Akdis CA, 1996), efficacy rates are lower 
for grass pollen and house dust mite allergy (Bousquet J et al., 1998; Abrahamson MJ et 
al., 1995; Greidener DK, 1996). Thus, critical evaluation on the factors that dictated the 
humoral and cellular responses might provide a rational allergen-specific immunotherapy 
strategy for the downregulation of Th2-type responses by immunomodulation in allergy 
individuals.  
 
This study had provided some useful data to suggest that high dose allergen is required to 
trigger Treg responses, however, the amount of allergen required in allergen 
immunotherapy in humans should not be extrapolated on the basis of the allergen dosage 
used in mice. Optimized doses for effective immunotherapy have not been properly 
defined for many of the common allergens to be used in humans. To date, standardized 
crude mite extracts are being used in the clinics and the standardization is based on the 
content of the major allergen. For instance, the Dermatophagoides pteronyssinus extract 
used in allergen immunotherapy is based on the 7-12ug/ml of Der p 1 major allergen per 
injection (Harold SN, 2007). Although high dose of Der p 1 could be more effective to 
induce Treg responses, however, the high allergenicity of unmodified Der p 1 in the 
crude extract could cause severe anaphylactic reactions. Thus, the use of genetically 
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 modified hypoallergenic allergen is a safer and more efficacious alternative than 
standardized crude extract.  Indeed clinical trials using hypoallergenic allergens for 
allergen specific immunotherapy have been reported in recent years (Niederberger V et 
al., 2004). The study revealed that subcutaneous injection with increasing doses of 
hypoallergenic derivatives of the major birch pollen allergen Bet v 1 could reduce the 
cutaneous sensitivity as well as improve the symptoms in actively treated patients. 
 
In conclusion, this study has developed an immunization regime for antigen-specific IgE 
production using a major human allergen Der p 2 in the absence of an adjuvant. This 
experimental model recapitulates the dosage-dependent effect of antigen in the regulation 
of antibody production. Subcutaneous priming with D10 dosage triggered Th2 type cells 
activation and induced production of IL-13-dependent IgE, while D50 immunization 
could trigger Treg cells development and hinder IL-13-dependent IgE production. This 
study has shown that besides the reciprocal polarization of Th1/Th2 cell subsets as 
previously reported in allergen dosage models, the involvement of Treg cell activity in 
D50 priming might explain the antigen dose-dependent regulation on IgE antibody 
production. D50 priming could generate Treg cell that has a potential role in the 
prevention and control of Th2-mediated responses, indicating the feasibility of repetitive 
administration with major allergens as a viable immunotherapeutic regime in the 
treatment of allergic disease. This study has also illustrated that IL-13 might have a 
critical role in the regulation of IgE production in the mice sensitized by subcutaneous 
route. Finally, the suppressive effects of Treg cells on Der p2-specific Th2 cell response 
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suggested that the fundamental role of Treg cells in maintaining the balance of the 





Microarray profiling of differentially expressed genes induced by immunization 




DNA microarrays are high-throughput technological platforms that take advantage of the 
vast amount of sequence information and allow scientists to perform gene expression 
profiling or genotyping studies on a "global" or "genome-wide" scale. This large-scale 
monitoring of gene expression in hosts and pathogens, either separately or interactively, 
has provided us with systemic views of the disease mechanisms. Ongoing developments 
in DNA sequencing and microarray technologies continue to bring in novel opportunities 
for better understanding of genome-environment interactions responsible for diseases, as 
well as for their diagnosis and treatment (Chen T, 2006).  
 
Gene expression profiling has been extensively applied to the field of allergy and clinical 
immunology in recent years. Research performed on both human and murine Th1 and 
Th2 type cells has revealed gene differential expression profiles and signature genes for 
cytokine and transcription factor genes, bringing remarkable insights into better 
understanding the Th1/Th2 paradigm (Rogge L et al., 2000; Chtanova T et al., 2001; 
Hamalainen H et al., 2001). DNA microarray analysis has been shown as an effective 
way to study the in vivo cytokine effects in allergic rhinitis patients (Benson M et al., 
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2002a; Fritz SB et al., 2003), as well as providing a constructive tool for the 
identification of expression patterns associated with nasal polyposis (Fritz SB et al., 
2003; Liu Z et al., 2004). It has also shed light on the understanding of some rare diseases 
such as mastocytosis and hyper-IgE syndrome (D’Ambrosio C et al., 2003; Chehimi J et 
al., 2001), as well as other immune-mediated diseases, such as SLE (Rus V et al., 2004) 
and rheumatoid arthritis (Olsen N et al., 2004). With the aid of microarray analysis, novel 
candidate genes with a role in bronchial asthma have been identified in both bronchial 
biopsy (Laprise C et al., 2004) and epithelial cell culture models (Yuyama N et al., 
2002), and the role of arginase in asthma pathogenesis has been better defined 
(Zimmermann N et al., 2003).  
 
So far, microarray studies conducted in the context of allergy have been confined to the 
identification of differentially expressed genes and pathways related to Th2 response or 
the pathogenesis of asthma. In the current study, microarray technology was employed to 
identify genes that are associated with the allergen dosage dependent-immune response. 
Previous studies have demonstrated that repeated immunization with high doses of 
antigen could attenuated IgE responses with elevated levels of IgG1/IgG2a production, 
while multiple low doses induced high IgE titre and decreased levels of IgG1/IgG2a 
production (Arps V et al., 1998; Kolbe L et al., 1991; Sakai K et al., 1999). This dosage 
dependent response has also been demonstrated in the rDer p 2 protein immunized mice 
as described in chapter 2. The gene profiling was performed on the lymph nodes cells of 
these animals by using Affymetrix system. The differential expressed genes were 
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categorized based on their molecular and biological functions, and the potential roles of 
these candidate genes in modulating the immune responses were discussed in this study.  
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3.2 Materials and Methods 
 
3.2.1 Mice and experimental protocol 
 
CBA/CaH mice (6-8 weeks old) mice were primed via subcutaneous route with D10 or 
D50 of rDer p 2 protein on days 0, 4 and 8 as described in chapter 2 section 2.2.3 and 
figure 2.1a. Immunized mice were sacrificed on day 10 and lymph nodes were collected 
for total RNA extraction. Control mice were injected with 100 μl of PBS. The gene 
profiling was performed on two experimental groups. For the real-time PCR analysis, 6 
groups of mice, each consisting of D10, D50 and PBS primed mice, were used. 
 
3.2.2 Total RNA extraction  
 
Total RNA was extracted from lymph nodes cells by using RNeasy Mini kit (Qiagen Inc) 
according to the manufacturer’s protocol. The quality of RNA was verified by the 
detection reading of O.D. 260/280 which fall within a range of 1.9 to 2.1. The integrity of 
all total RNA samples was examined by visual inspection of intact 28S and 18S 
ribosomal RNA bands on 1% agarose gel prior to further processing.  
 
3.2.3 Sample preparation for gene microarray studies 
 
All reagents used in the sample preparation for microarray studies were purchased from 
Affymetrix system unless stated otherwise. Sample preparation and processing 
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procedures were carried out as described in the Affymetrix Gene Chip Expression 
Analysis Manual (Affymetrix Inc., Santa Clara, CA). Ten microgram of total RNA 
(pooled from four mice per group, n = 4) was used for synthesis of cDNA. The 
preparation of double-stranded (ds) cRNA was performed using One Cycle cDNA 
synthesis kit. Briefly, ten µg of total RNA was added in a 0.2 ml PCR tube containing 2 
µl of the poly-A RNA controls and 2 µL of 50 µM T7-Oligo(dT) primer. RNase-free 
water was added to a final volume of 12 µl. The mix was gently flicked a few times to 
mix, and then centrifuged briefly (~5 sec) to collect the reaction at the bottom of the tube. 
The mix was incubated for 10 min at 70°C, cooled at 4°C for at least 2 min. In a separate 
tube, the First-Strand master mix was prepared by adding 4 µl of 5 X first strand reaction 
mix, 2 µl of DTT (0.1 M) and 1 µl of dNTPs (10 mM) for a single reaction. Seven 
microliter of the First-Strand master mix was added to each RNA/T7-Oligo(dT) primer 
mix for a final volume of 19 µl. The mix was centrifuged briefly (~5 sec) to collect the 
reaction at the bottom of the tube and immediately incubate for 2 min at 42°C. One 
microliter of the SuperScript II was added to the RNA sample for a final volume of 20 µl. 
The reaction was incubated for 1 hr at 42 °C and then cooled for at least 2 min at 4°C. In 
a separate tube, Second-Strand master mix was assembled by adding 91 µl of DEPC 
water, 30 µl of 5 X second strand reaction mix, 3 µl of dNTPs (10 mM), 1 µl of E. coli 
DNA ligase, 4µl of E. coli DNA polymerase I and 1 µl of RNase H. One hundred and 
thirty microliter of Second-Strand master mix was added to the first-strand synthesis 
sample. The reaction was incubated for 2 hrs at 16°C. Next, 2 µl of T4 DNA polymerase 
was added and incubated for 5 min at 16°C. After incubation with T4 DNA polymerase, 
10 µl of EDTA (0.5 M) was added to stop the reaction.  
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 The sample was cleaned up using GeneChip Sample Cleanup Module as recommended 
by the manufacturer. In vitro transcription and biotin-labeling were prepared by using 
RNA Transcript In Vitro Labeling Kit as recommended by the manufacturer. Briefly, 6 µl 
of the template cDNA was added to a mix containing 4 µl of 10X IVT labeling buffer, 12 
µl the IVT labeling NTP mix and 4 µl of IVT labeling enzyme mix, and topped up with 
DEPC water to a final volume of 40 µl. The reaction was immediately incubated for 16 
hrs at 37°C. The labeled cRNA was stored at -20°C until purifying step. Synthesized 
cRNA was cleaned up using IVT cRNA Cleanup Kit as recommended by the 
manufacturer. The purified cRNA was quantitated by measuring the OD at 260 nm and 
the yield was estimated by using the equation RNAm - (total RNAi) (y) where RNAm = 
amount of cRNA measured after IVT (µg), total RNAi = starting amount of total RNA 
(µg) and y = fraction of cDNA reaction used in IVT. Next, 20 µl of cRNA (1 µg/ml) was 
chemically fragmented by adding 8 µl of 5X fragmentation buffer (200 mM Tris, pH 8.1; 
500 mM KOAc; 150 mM MgOAc) and topped up with DEPC water to 40 µl. The 
incubation was at 94°C for 35 min. The fragmented cRNA was analyzed on the 1 % 
agarose gel.  
 
3.2.4 Eukaryotic Target Hybridization  
 
Microarray hybridization, washing and fluorescent staining were performed by using the 
hybridization oven and Affymetrix GeneChip fluidics station at The National University 
of Singapore, Biosensors Focused Interest Group (BFIG) Facility. All reagents used are 
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listed in Appendix 1. Fragmented cRNA was added to a hybridization cocktail containing 
5 µl of control oligonucleotide B2 (3 nM), 15 µl of 20X Eukaryotic hybridization 
controls (bioB, bioC, bioD and cre biotin synthesis pathway genes of E. coli), 3 µl of 
herring sperm DNA (10 mg/ml), 3 µl of acetylated BSA (50 mg/ml), 150 µl of 
hybridization buffer and 30 µl of DMSO. The reaction was topped up with 300 µl of 
DEPC water. Hybridization cocktail was heated at 99 °C for 5 min in a heat block and 
transferred to a 45°C heat block for 5 min. In each experiment, 3 Mouse Genome 430 2.0 
probe arrays (Affymetrix, Santa Clara, CA, USA) were equilibrated with 250 µl of 1X 
hybridization buffer and incubated at 45°C for 10 min with rotation in the hybridization 
oven. The 1X hybridization buffer solution was removed from each probe array and 
loaded with 200 µl of hybridization cocktails individually. The probes were incubated in 
the hybridization oven at 45°C for 16 hrs.  
 
3.2.5 Eukaryotic Arrays: Washing, Staining, and Scanning  
 
The probes were washed using Fluidics Station 450, and fluorescent staining was 
performed using streptavidin-Phycoerythrin (SAPE, Molecular Probes, Eugene, OR) and 
anti-streptavidin antibody (Vector Laboratories, CA). The Fluidics Station 450 was 
operated by using GCOS/Microarray Suite. SAPE staining solution was freshly prepared 
by adding 600 µl of 2X stain buffer, 48 µl of 50 mg/ml of BSA, 12 µl of SAPE and 540 
µl of DEPC water into a 1.5 ml microfuge tube, and stored in the dark at 4°C.  The 
solution was mixed well and divided into two aliquots of 600 µl. The antibody solution 
mix was prepared by adding 300 µl of 2X stain buffer, 24 µl of 50 mg/ml of BSA, 6 µl of 
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goat IgG stock (10 mg/ml), 3.6 µl of 0.5 mg/ml biotinylated antibody and 266.4 µl of 
DEPC water into a 1.5 ml tube.  The fluidics protocol used for this study was EukGE-
WS2v4 (Table 3.1) The programming of fluidics protocol and the usage of the fluid 
station 450 was performed as instructed by the Affymetrix user manual. At the end of the 
wash, each probe array was ensured that no bubble was trapped before proceed to 
scanning.   
 
3.2.6 Data acquisition, processing and analysis 
 
Microarrays were scanned using Gene-array scanner 5000 at the Research Instrument, 
Singapore. Statistical analysis was performed by Bioinformatics group at the Nanyang 
Polytechnic, Singapore. The GeneChip array analysis yielded hybridization intensity for 
each represented gene as the signal intensity. Normalization of the microarray data was 
performed by the mas5 module of the Affymetrics package. A difference between two 
samples was defined as significant if 2-fold difference in average signal intensity with a p 
value under 0.04 from the mas5 module. Any gene for which this P value was < 0.04 was 
considered to be differentially expressed. The change is expressed as a log2 ratio. 
Therefore, single log ratio of 1 equals a fold change of 2. Genes were selected based on 
the following criteria: (i) Changes in expression of at least 2 fold higher or lower among 
each group (ii) Signal >500 and (iii) Detection p < 0.04. Only genes that fulfilled the 
filtering criteria in both repeated experiment were considered significant and selected. 
The gene expression fold difference was expressed as average log2 ratio ± s.e.m. 
Functional classifications were performed using the Panther Classification System 
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(Applied Biosystem, www.pantherdb.org) and the NetAffx™ Analysis Center 
(Affymetrix, www.affymetix.com).  
 
3.2.7 Hierarchical clustering 
 
Hierarchical clustering was applied for one of the represented data set using the 'TIGR 
Multiexperimental Viewer ‘3.0.1’ software. Genes with 'Present' call (p < 0.04) and 
significantly changes in expression of at least 2 fold higher or lower comparing the 
normal were selected for clustering. 
 
3.2.8 Real-time quantitative reverse transcription PCR (RQ-PCR) 
  
Total RNA from individual mouse was reverse transcribed into cDNA as described in 
chapter 2 section 2.2.14. Quantitative Real-time™ PCR was carried out with the Light 
Cycler Instrument (Roche Molecular Biochemicals) using Fast start DNA Master SYBR 
Green I (Roche Diagnostics, Switzerland) in accordance to the manufacturers’ 
instructions. The PCR was set up using 2 µl SYBR Green master mix, 1 µl of each 
primers (10 pmol), 1 µl of cDNA and top up with ddH2O to a final reaction volume of 10 
μl. A negative control (water to replace template) was included in each run. The 
amplification program was: denaturation 10 min at 95˚C, quantitation 40 cycles of 5 sec 
at 95˚C, 5 sec at 56˚C and 12 sec at 72˚C, melting 15 sec at 56˚C, cooling 30 sec at 40˚C. 
The nucleotide sequences of the primers are listed in Table 3.2. Primer pairs were 
designed to generate intron-spanning products of 170 to 300bp. Primers were tested for 
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gene product amplification from pooled cDNA samples, and the product sequence was 
confirmed. The housekeeping gene used in this study was HPRT.  
 
3.2.9 Determination of amplification efficiency and Comparative Ct Method  
 
Quantitated, amplified target gene product was spiked with HPRT product, logarithmic 
diluted in ddH2O to a range of 104 to 109 copies per microliter. The RQ-PCR was 
performed on the diluted templates as described in chapter 3 section 3.2.8 and the 
standard curve was created. The efficiency is determined from the slope of the standard 
curve according to the following formula: Efficiency = [10(-1/slope)] – 1, where slope is the 
slope of the standard curve plot. For a typical reaction, slopes between -3.1 and -3.6 
giving reaction efficiencies between 90 and 110% are typically acceptable 
(http://www.uic.edu/depts/rrc/cgf/realtime/deltact.htmle)  
The comparative Ct method was used to estimate expression levels and was performed as 
described (Livak KJ and Schmittgen TD, 2001). This method involves comparing the Ct 
values of the samples of interest with a control or calibrator such as a non-treated sample 
(in this study will be PBS treated mice). Ct, cycle threshold, is denote as the cycle number 
in which amplification crosses the threshold set in the geometric portion of amplification 
curve. The Ct values of both the calibrator and the samples of interest are normalized to 
an appropriate endogenous housekeeping gene.  
The comparative Ct method is also known as the 2–[delta][delta]Ct method, where 
[delta][delta]Ct = [delta]Ct,sample - [delta]Ct,reference.  
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Here, [delta]CT,sample is the Ct value for any sample normalized to the endogenous 
housekeeping gene and [delta]Ct, reference is the Ct value for the calibrator also normalized 
to the endogenous housekeeping gene. For the [∆][∆]Ct calculation to be valid, the 
amplification efficiencies of the target and the endogenous reference must be 
approximately equal. In this study, the amplification efficiencies of the target genes and 
housekeeping gene were about -3.4.     
 
3.2.10 Statistical analysis 
 
The significance between experimental groups was calculated by the Mann-Whitney U 
test (SPSS). A value of p < 0.05 was considered significant. 
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Table 3.1 Fluidics protocol 
 
Post Hybridization (Wash #1) 10 cycles of 2 mixes/cycle with Wash 
Buffer A at 25°C 
Post Hybridization(Wash #2) 4 cycles of 15 mixes/cycle with Wash 
Buffer B at 50°C 
Stain  Stain the probe array for 10 min in SAPE 
solution at 25°C 
Post Stain Wash 10 cycles of 4 mixes/cycle with Wash 
Buffer A at 25°C 
2nd Stain  Stain the probe array for 10 min in 
antibody solution at 25°C 
3rd Stain  Stain the probe array for 10 min in SAPE 
solution at 25°C 
Final Wash 15 cycles of 4 mixes/cycle with Wash 
Buffer A at 30°C. The holding temperature 
is 25°C 
 
• Wash Buffer A = non-stringent wash buffer 
• Wash Buffer B = stringent wash buffer 
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Table 3.2: Primer sequences for differential expressed genes 
 
Gene Primer sequence 
Sense 5’ GTTGGATACAGGCCAGACTTTGTTG 3’ HPRT (300 bp) 
(Accession no. 
 NM_013556) Anti-sense 5’ GAGGGTAGGCTGGCCTATGGG 3’ 
Sense 5’ GAACTCCACCAACTCCACCAC 3’  MGAT5 (191 bp) 
(Accession no. 
AF474154) Anti-sense 5’ GTCCACTCCATAGTCTGCGT 3’ 
Sense 5’ CTGGCAATGACTCTGATGATGA 3’  Rad51-AP1 (216 bp) 
(Accession no. 
AK011379) Anti-sense 5’ CACAGATAAAGCCAGGGCAA 3’ 
Sense 5’ TGGCGAACTCATTGTCTTAGGATA 3’ Peli1 (169 bp) 
(Accession no. 
 AF302503) Anti-sense 5’ CTGGTCCTTGTTGCTTATTGCCTTG 3’ 
Sense 5’ CAAACGGTTCATCTGGGAGTAT 3’  Rerg (207 bp) 
(Accession no. 
NM_181988 ) Anti-sense 5’ CTTCAGCGGCAGCACTTCTTC 3’ 
Sense 5’ GTGGAGGAAGAACGACAAGAACAT 3’  TβRII (210 bp) 
(Accession no. 




3.3.1 Microarray analysis of differentially expressed genes in lymph node cells  
 
To identify the genes induced by differential dosage of Der p 2 allergen, gene profiling 
was performed on the lymph nodes cells of rDer p 2 immunized mice. The quality of 
RNA used for gene profiling was analyzed by gel electrophoresis. The quality of pooled 
total RNA was validated by two distinct bands of 28s rRNA and 18s rRNA (figure 3.1a). 
The purified biotin-labeled cRNA showed a size distribution of labeled transcripts (figure 
3.1b). The fragmented cRNA produced a distribution of RNA fragment sizes from 
approximately 35 to 300 bases (figure 3.1c).  
 
The process and generation of microarray data is illustrated in figure 3.2. The array data 
were analyzed and a minimum change of at least 2-fold was adopted to select the over- 
and under-expressed genes in the allergen primed groups in comparison to the PBS 
control group. Among the 172 genes regulated by the D10 group, 15 known genes and 37 
EST genes were up-regulated, while 70 known genes and 50 EST genes were down-
regulated (figure 3.3). In the D50 group, out of the 151 genes, 19 known genes and 23 
EST were up-regulated, while 47 known genes and 62 EST genes were down-regulated. 
Eighty-three genes were found equally expressed in both groups.  
 
The molecular and biological processes of the known, differentially expressed genes are 
illustrated in the pie chart with the representing percentage in each category (figure 3.4-
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3.5). A number of genes which act as enzymes, hydrolases, inhibitors, transcription 
factors, nucleic acid binding molecules and signaling molecules have been identified. 
Some act as receptors while others have roles in protein modification, membrane 
trafficking, immunity and defense, cell adhesion, metabolism, structure formation and 
apoptosis. Table 3.3-3.6 illustrated the average fold difference of known genes derived 
from two sets of independent experiments (expressed in log2 ratio of D10/PBS and 
D50/PBS). Table 3.7-3.10 illustrated the average fold difference of unknown genes 
derived from two sets of independent experiments. The molecular function, biological 
process and associated pathways of the known, differentially expressed genes were 
tabulated in Table 3.11-3.14. One representative set of the tree clusters for known genes 
and unknown genes are included in the Appendix 2-5 and 6-9 in respective. 
 
3.3.2 Quantitative Real-time PCR validation of differential gene expression  
 
To verify the findings inform the microarray, selected genes were further studied by 
using quantitative real-time PCR. Lymph nodes of the immunized mice were taken 2 
days after the third immunization and evaluated for the gene expression level of 
Mannoside acetylglucosaminyltransferase 5 (MGAT5), RAD51 associated protein 1 
(Rad51AP1), Pellino 1 (Peli1), RAS-like, estrogen-regulated, growth-inhibitor (Rerg) and 
Transforming growth factor, β receptor II (TβRII) (figure 3.6a-e). The RT-PCR result 
showed a significant increased of MGAT5 gene expression in D50 immunized mice as 
compared to the D10 group (D50 vs D10: 8.0 ± 4.9 vs 1.6 ± 0.4, n=6). However, the 
MGAT5 gene expression level of D10 mice was not in consensus to the array result 
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(Table 3.3) that showed a decreased as compared to PBS group. There is no specific 
explanation to this observation but could be due to the effect of animal variations in the 
study. D50 immunized mice exhibited decreased genes expression of Peli1 and 
Rad51AP1 as compared to D10 group (Peli1: 0.4 ± 1.0 vs 1.06 ± 0.2, n=6; Rad51AP1: 
0.8 ± 0.2 vs 2.6 ± 1.1, n=5), corresponding to the gene profiling result in Table 3.4. The 
increased expression levels of Rerg and TβRII genes were also observed in D50 mice as 
compared to D10 group (Rerg: 3.0 ± 1.17 vs 1.3 ± 0.2, n=7 and TβRII: 2.6 ± 0.7 vs 0.7 ± 
0.3, n=7), corresponding to the array data in Table 3.6.  
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Figure 3.1: Monitoring of target preparation by agarose gel analysis.  
The pooled total RNA (a), purified biotin-labelled cRNA (b) and fragmented cRNA (c) 
were analyzed by agarose gel electrophoresis.  
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Figure 3.2: Flow chart illustrating the processing and generation of microarray 
data. The raw Cel data which contains 45101 genes were normalized for hybridization 
intensity and the genes with “present” signals were evaluated by using mas5 module of 
the Affymetrics package. A total of 26756 genes with “present signal” were extracted 
using the Java software, and those with a significant 2-fold difference in average signal 
intensity were extracted using Microsoft excel software. The hierarchical & Kmeans 
clustering were generated by using Jexpress software and the clustered gene groups & 
images were derived by using 'TIGR Multiexperimental Viewer 3.0.1' software.  
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Figure 3.3: Subset of genes induced by immunization with D10 or D50 of rDer p 2 
protein. The genes were categorized into upregulated (Up), downregulated (Down) or 
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Figure 3.4: Pie chart on the molecular function annotation of the differentially 
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Table 3.3: List of genes downregulated in D10 group (70) 
 





 D10/PBS D50/PBS 
BC031806 Smr1 submaxillary gland androgen regulated 
protein 1 
-7.80 ± 0.23 1.02 ± 0.53 
AF276975 Swam2 single WAP motif protein 2 -7.47 ± 2.28 0.13 ± 2.60 
AB036743 Cst10 cystatin 10 (chondrocytes) -5.93 ± 1.68 1.90 ± 0.50 
BC024627 Dcpp demilune cell and parotid protein -5.55 ± 1.63 0.48 ± 2.04 
AK009032 Psp parotid secretory protein -5.22 ± 0.28 0.69 ± 0.60 
AF079834 Car6 carbonic anhydrase 6 -5.02 ± 0.16 1.37 ± 0.86 
AK029642 Amy1 amylase 1, salivary -4.98 ± 0.13 1.15 ± 0.83 
BC014718 Dnase1 Deoxyribonuclease I -4.47 ± 0.25 1.83 ± 0.86 
AB001489 Pigr polymeric immunoglobulin receptor -4.33 ± 0.85 -1.43 ± 1.28 
AK009449 Crisp1 cysteine-rich secretory protein 1 -4.28 ± 0.54 1.85 ± 0.42 
AB017907 Pip prolactin induced protein -4.07 ± 0.34 1.91 ± 0.45 
AF288379 Klra20 killer cell lectin-like receptor subfamily A, 
member 20 
-3.69 ± 0.26 -0.56 ± 1.42 
NM_029404 Phf14 PHD finger protein 14 -3.21 ± 2.75 -1.01 ± 2.91 
AF513619 Fancl Fanconi anemia, complementation group L -3.21 ± 0.26 -1.28 ± 0.39 
AF148857 Peg12 paternally expressed 12 -3.19 ± 0.30 -0.83 ± 0.39 
NM_201227  Dte/Dand
5 
DAN domain family, member 5 -3.07 ± 0.30 0.39 ± 0.37 
AK007857 Sdro orphan short chain dehydrogenase/reductase -3.05 ± 1.66 0.30 ± 0.39 
BC002039 Fxyd3 FXYD domain-containing ion transport 
regulator 3 
-2.97 ± 1.02 -0.58 ± 1.74 
NM_172829  St6gal2 Beta galactoside alpha 2,6 sialyltransferase 2 -2.94 ± 0.73 0.09 ± 0.30 
NM_010349  Grik2 glutamate receptor, ionotropic, kainate 2 
(beta 2) 
-2.73 ± 0.86 -0.04 ± 0.59 
AF109633 Etv1 ets variant gene 1 -2.65 ± 0.86 0.47 ± 1.43 
AK007634 Snapc5 small nuclear RNA activating complex, 
polypeptide 5 
-2.60 ± 0.15 -0.46 ± 0.20 
AK034795 Vat1 vesicle amine transport protein 1 homolog (T 
californica) 
-2.49 ± 0.56 0.61 ± 0.23 
AK008189 Gsta4 glutathione S-transferase, alpha 4 -2.44 ± 0.17 0.03 ± 0.05 
XM_355790 Sec 512 SEC15-like 2 (S. cerevisiae) -2.40 ± 2.53 1.41 ± 1.32 
AK014880 Armc3 armadillo repeat containing 3 -2.33 ± 0.09 -0.04 ± 0.61 
AJ005564 Sprr2f small proline-rich protein 2F -2.28 ± 0.88 0.14 ± 0.51 
AF144133 Nisch Nischarin -2.09 ± 2.08 0.91 ± 2.32 
AF249870 Perp PERP, TP53 apoptosis effector -2.09 ± 0.66 -0.10 ± 1.04 
AF260557 Tbx20 T-box 20 -2.07 ± 0.39 -0.02 ± 0.11 
AK028341 Ddx1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 
1 
-2.03 ± 0.74 -0.52 ± 0.65 
AK008118 Hrmt1l3 heterogeneous nuclear ribonucleoprotein 
methyltransferase-like 3 (S. cerevisiae) 
-2.00 ± 0.68 -0.35 ± 0.05 
BC012704 Car4 carbonic anhydrase 4 -1.97 ± 0.62 -0.63 ± 0.50 
AF163315 Cml2 camello-like 2 -1.82 ± 0.36 0.09 ± 0.31 
AK004278 Fnbp1 formin binding protein 1 -1.81 ± 0.66 -0.07 ± 0.55 
NM_009822 Cbfa2t1h CBFA2T1 identified gene homolog (human) -1.81 ± 0.19 0.09 ± 0.47 
AF458063 Il17d interleukin 17D -1.79 ± 1.34 0.03 ± 1.11 
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BC017147 Klc3 kinesin light chain 3 -1.77 ± 1.44 -0.16 ± 1.01 
AF231125 Pcdh8 protocadherin 8 -1.77 ± 1.41 1.55 ± 2.02 
L01991 Cntn3 contactin 3 -1.76 ± 0.96 -0.24 ± 0.65 
AJ278069 Clstn2 calsyntenin 2 -1.65 ± 0.81 0.40 ± 0.03 
AF257061 Mbp myelin basic protein -1.62 ± 0.78 1.28 ± 0.20 
AF040945 Mab21l1 mab-21-like 1 (C. elegans) -1.57 ± 0.09 -0.04 ± 0.22 
AK032871 Adk adenosine kinase -1.55 ± 0.85 0.32 ± 0.80 
AB057759 Mlph Melanophilin -1.54 ± 2.74 0.57 ± 1.97 
AY069926 Sox21 SRY-box containing gene 21 -1.54 ± 1.94 0.99 ± 1.01 
AK028364 Adamts4 a disintegrin-like and metalloprotease 
(reprolysin type) with thrombospondin type 
1 motif, 4 
-1.53 ± 0.54 -0.08 ± 0.37 
BC095996 Tbrg3 transforming growth factor beta regulated 
gene 3 
-1.53 ± 0.32 0.69 ± 0.71 
AJ242929 Matn3 matrilin 3 -1.43 ± 0.63 0.29 ± 0.59 
NM_198634  Tigd3 tigger transposable element derived 3 -1.42 ± 2.00 0.03 ± 2.40 
AF474154  Mgat5 mannoside acetylglucosaminyltransferase 5 -1.41 ± 2.20 0.97 ± 1.03 
AF190699 Ttyh1 tweety homolog 1 (Drosophila) -1.37 ± 0.60 0.38 ± 0.99 
AK018094 Frcl1 frc, fringe-like 1 (Drosophila) -1.30 ± 0.88 -0.04 ± 0.90 
NM_008781 Pax3 paired box gene 3 -1.25 ± 0.32 0.31 ± 0.07 
AK011188 Robo2 roundabout homolog 2 (Drosophila) -1.24 ± 0.08 -0.11 ± 0.18 
L10385 Tgm3 transglutaminase 3, E polypeptide -1.22 ± 0.30 0.26 ± 0.34 
NM_011506 Sucla2 Succinate-Coenzyme A ligase, ADP-
forming, beta subunit 
-1.22 ± 0.11 0.96 ± 0.31 
M83218 S100a8 S100 calcium binding protein A8 
(calgranulin A) 
-1.13 ± 0.63 0.37 ± 0.41 
NM_172688  Map3k7 Mitogen activated protein kinase kinase 
kinase 7 
-1.07 ± 0.76 0.58 ± 1.13 
BC005431 Anpep alanyl (membrane) aminopeptidase -1.05 ± 1.51 0.95 ± 1.42 
BC011472 Kdelr3 KDEL (Lys-Asp-Glu-Leu) endoplasmic 
reticulum protein retention receptor 3 
-1.03 ± 1.99 0.89 ± 1.63 
AF020196 Pbx1 pre B-cell leukemia transcription factor 1 -1.03 ± 0.93 0.31 ± 0.64 
D29668 Igk-V8 immunoglobulin kappa chain variable 8 (V8) -0.97 ± 0.61 0.72 ± 1.03 
AJ292467 Wdr9 WD repeat domain 9 -0.97 ± 0.46 0.33 ± 0.46 
NM_028880  Lrrtm1 Leucine rich repeat transmembrane neuronal 
1 
-0.97 ± 0.14 0.43 ± 0.15 
AF214016 Mocs1 molybdenum cofactor synthesis 1 -0.94 ± 0.64 0.43 ± 0.27 
AF114378 Ldb3 LIM domain binding 3 -0.83 ± 0.20 0.83 ± 0.06 
AF221525 Cyp2d22 cytochrome P450, family 2, subfamily d, 
polypeptide 22 
-0.82 ± 0.51 0.31 ± 0.47 
AB010151 Stxbp1 syntaxin binding protein 1 -0.80 ± 0.21 0.27 ± 0.19 
XM_356077  Nek1 NIMA (never in mitosis gene a)-related 
expressed kinase 1 
-0.36 ± 0.20 0.87 ± 0.16 
 
1. The GenBank accession number. 
2. Fold change is the average of two arrays expressed in log base 2 ± s.e.m. 
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Table 3.4: List of genes upregulated in D10 group (15) 
 





 D10/PBS D50/PBS 
AF028122 Klra12 killer cell lectin-like receptor subfamily A, 
member 12 4.03 ± 1.26 2.07 ± 2.09 
NM_170778  Dpyd dihydropyrimidine dehydrogenase 2.83 ± 1.59 -0.24 ± 0.73 
NM_010314 Gng1 guanine nucleotide binding protein (G 
protein), gamma 1 subunit 2.52 ± 0.28 0.27 ± 1.41 
NM_134014  Xpo1 Exportin 1, CRM1 homolog (yeast) 2.25 ± 0.11 0.74 ± 0.53 
AF003870 Galc galactosylceramidase 2.07 ± 0.47 0.93 ± 0.59 
AB036838 Ndst4 N-deacetylase/N-sulfotransferase (heparin 
glucosaminyl) 4 1.86 ± 1.72 -0.43 ± 2.53 
AF020738 Fgf12 fibroblast growth factor 12 1.84 ± 2.18 -0.43 ± 3.06 
AB026127 Cbx3 chromobox homolog 3 (Drosophila HP1 
gamma) 1.46 ± 0.70 -0.28 ± 0.85 
AY004873 Pramel3 preferentially expressed antigen in 
melanoma-like 3 1.39 ± 1.12 -0.43 ± 1.88 
AF483516 Snap25 synaptosomal-associated protein 25 1.23 ± 0.86 -0.13 ± 1.04 
AF272847 Sfpq splicing factor proline/glutamine rich 
(polypyrimidine tract binding protein 
associated) 
1.08 ± 0.86 -0.99 ± 1.71 
AF066075 Pth parathyroid hormone 1.04 ± 0.81 -0.36 ± 0.54 
AF319173 Psca prostate stem cell antigen 1.03 ± 0.24 -0.86 ± 0.21 
AK014491 Xrcc3 X-ray repair complementing defective repair 
in Chinese hamster cells 3 0.71 ± 0.41 -0.59 ± 0.40 
AB046693 Rab27a RAB27A, member RAS oncogene family 0.69 ± 0.43 -0.42 ± 0.47 
 
1. The GenBank accession number. 
2. Fold change is the average of two arrays expressed in log base 2 ± s.e.m. 
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Table 3.5: List of genes downregulated in D50 group (47)  
 





 D10/PBS D50/PBS 
NM_019550  Ptbp2 Polypyrimidine tract binding protein 2 -1.56 ± 1.29 -3.69 ± 0.27 
NM_009071 Rock1 Rho-associated coiled-coil forming kinase 1 -0.45 ± 0.33 -3.31 ± 0.09 
AF302503 Peli1 pellino 1 -0.59 ± 0.29 -3.18 ± 0.51 
NM_008307  Htf9c HpaII tiny fragments locus 9c 0.39 ± 0.05 -2.97 ± 0.67 
NM_019670  Diap3 Diaphanous homolog 3 (Drosophila) 1.74 ± 1.21 -2.76 ± 1.42 
AF162853 Nfat5 nuclear factor of activated T-cells 5 0.48 ± 0.75 -2.76 ± 0.49 
NM_183428  Epb4.1 erythrocyte protein band 4.1 -0.38 ± 0.05 -2.70 ± 0.07 
AF421878 Sox9 SRY-box containing gene 9 0.66 ± 0.63 -2.59 ± 2.09 
BC032880 Aldh1a7 aldehyde dehydrogenase family 1, subfamily 
A7 
-0.26 ± 1.28 -2.53 ± 2.48 
NM_016962  Spg4 Spastic paraplegia 4 homolog (human) -0.68 ± 0.23 -2.50 ± 0.12 
AF090376 Gabre gamma-aminobutyric acid (GABA-A) 
receptor, subunit epsilon 
0.43 ± 0.08 -2.50 ± 0.07 
AK004594 Usp16 ubiquitin specific protease 16 0.90 ± 0.25 -2.37 ± 0.56 
AK019553 Daf2 decay accelerating factor 2 0.13 ± 0.08 -2.36 ± 1.02 
AK013905 Wt1 Wilms tumor homolog 0.37 ± 0.18 -2.27 ± 0.29 
AF176530 Fbxo15 F-box only protein 15 -0.04 ± 0.17 -2.19 ± 0.01 
AK012463 Psmd7 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 7 
0.04 ± 0.49 -2.16 ± 1.32 
NM_177306  Rfxdc1 Regulatory factor X domain containing 1 1.07 ± 0.92 -2.16 ± 0.15 
NM_194062 Nalp9c NACHT, LRR and PYD containing protein 
9c 
0.63 ± 0.14 -2.08 ± 0.14 
AF099187 Pde3a Phosphodiesterase 3A, cGMP inhibited 1.52 ± 0.11 -2.03 ± 0.04 
NM_144822  Cbara1 Calcium binding atopy-related autoantigen 1 -0.05 ± 0.65 -1.89 ± 0.77 
NM_007904  Ednrb Endothelin receptor type B 0.26 ± 0.36 -1.88 ± 1.06 
XM_485570  Mll5 myeloid/lymphoid or mixed-lineage 
leukemia 5 
0.29 ± 0.20 -1.85 ± 1.17 
BC020177 Atp1a3 ATPase, Na+/K+ transporting, alpha 3 
polypeptide 
0.70 ± 0.56 -1.82 ± 1.70 
NM_011444 Sox5 SRY-box containing gene 5 0.05 ± 1.10 -1.76 ± 0.33 
AK014887 Pde1c Phosphodiesterase 1C -0.01 ± 0.59 -1.64 ± 0.90 
AF096867 Syn2 synapsin II 0.54 ± 0.96 -1.61 ± 0.71 
BC003475 Tubb2 tubulin, beta 2 0.46 ± 0.25 -1.60 ± 0.73 
AK035987 Egfl5 EGF-like-domain, multiple 5 0.65 ± 0.77 -1.58 ± 0.10 
AK010296 Zdhhc6 zinc finger, DHHC domain containing 6 0.10 ± 0.41 -1.47 ± 0.51 
AK080899 Trpm6 transient receptor potential cation channel, 
subfamily M, member 6 
0.26 ± 0.22 -1.46 ± 0.01 
AF365933  Zfp264 zinc finger protein 264 0.93 ± 0.44 -1.39 ± 0.99 
AB003503 Gspt2 G1 to phase transition 2 -0.34 ± 0.54 -1.39 ± 0.54 
AF085696 Kcnj15 potassium inwardly-rectifying channel, 
subfamily J, member 15 
0.17 ± 1.49 -1.32 ± 1.34 
BC061172 Tncc troponin C, cardiac/slow skeletal 0.42 ± 0.37 -1.28 ± 0.11 
AK052685 Ren1 renin 1 structural 0.36 ± 0.13 -1.18 ± 0.55 
NM_134048 Cbll1 Casitas B-lineage lymphoma-like 1 0.02 ± 0.05 -1.17 ± 0.10 
NM_008608  Mmp14 matrix metalloproteinase 14 (membrane- 0.39 ± 0.27 -1.15 ± 0.72 
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inserted) 
AB041810 Bxdc1 brix domain containing 1 0.00 ± 0.39 -1.15 ± 0.33 
AF027503 Baiap1 BAI1-associated protein 1 0.20 ± 0.35 -1.14 ± 0.13 
NM_015823  Acvrinp1 Activin receptor interacting protein 1 0.13 ± 0.05 -1.10 ± 0.15 
M87801 Hoxa2 homeo box A2 0.61 ± 1.30 -1.03 ± 1.79 
AF213388 Abcc2 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 2 
0.93 ± 1.78 -1.03 ± 1.77 
AK032106 Syt4 synaptotagmin 4 0.22 ± 0.40 -1.00 ± 0.31 
NM_009535  Yes Yamaguchi sarcoma viral (v-yes) oncogene 
homolog 
0.49 ± 0.18 -0.98 ± 0.28 
AK011379 Rad51ap1 RAD51 associated protein 1 0.30 ± 0.90 -0.93 ± 0.84 
BC013459 Bmp4 bone morphogenetic protein 4 0.30 ± 0.06 -0.78 ± 0.09 
AK004597 Icam1 intercellular adhesion molecule 0.45 ± 0.25 -0.66 ± 0.20 
NM_031394  Sytl2 Synaptotagmin-like 2 0.46 ± 0.14 -0.59 ± 0.10 
 
1. The GenBank accession number. 
2. Fold change is the average of two arrays expressed in log base 2 ± s.e.m. 
 122
Table 3.6: List of genes upregulated in D50 group (19) 
 





 D10/PBS D50/PBS 
NM_026201 Ccar1 Cell division cycle and apoptosis regulator 1 0.34 ± 0.48 3.00 ± 1.19 
AF406755 Tgfβr2 transforming growth factor, β receptor II 1.28 ± 0.88 2.58 ± 0.67 
BC026463 Rerg 
RAS-like, estrogen-regulated, growth-
inhibitor -0.78 ± 0.65 2.47 ± 1.19 
AK043718 Pnma2 paraneoplastic antigen MA2 -0.23 ± 0.99 2.06 ± 0.46 
AJ621426 Sprn shadow of prion protein 0.02 ± 0.87 1.89 ± 0.72 
AF325263 Sfxn4 sideroflexin 4 0.56 ± 2.72 1.85 ± 2.64 
NM_181728  Art3 ADP-ribosyltransferase 3 -1.28 ± 0.71 1.63 ± 0.67 
BC050965 Fzd3 frizzled homolog 3 (Drosophila) 0.11 ± 0.65 1.52 ± 0.88 
AK036010 Vldlr very low density lipoprotein receptor 0.21 ± 0.69 1.48 ± 0.79 
AK036112 Kcna4 
potassium voltage-gated channel, shaker-
related subfamily, member 4 -1.05 ± 1.86 1.45 ± 1.57 
NM_011122   Plod1 
Procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 1 -1.33 ± 0.19 1.37 ± 1.01 
AF073882 Mtmr7 myotubularin related protein 7 -0.57 ± 0.07 1.20 ± 0.83 
AB030729 Papolb poly (A) polymerase beta (testis specific) -0.72 ± 1.18 1.20 ± 0.27 
NM_019628 Prpmp5 proline-rich protein MP5 -0.89 ± 0.15 0.99 ± 0.15 
AF201285 Tgfβ1i4 
transforming growth factor β 1 induced 
transcript 4 -0.26 ± 0.47 0.95 ± 0.35 
AF051102 Ggh gamma-glutamyl hydrolase -0.85 ± 0.20 0.94 ± 0.41 
AB008160 Stat3 
signal transducer and activator of 
transcription 3 -0.89 ± 1.16 0.92 ± 0.60 
AB023631 Ces3 carboxylesterase 3 -0.39 ± 0.81 0.69 ± 0.74 
AF184981 Fmo2 flavin containing monooxygenase 2 -0.50 ± 0.29 0.60 ± 0.20 
 
 
1. The GenBank accession number. 
2. Fold change is the average of two arrays expressed in log base 2 ± s.e.m. 
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Table 3.7: List of unknown genes downregulated in D10 group (50) 
 





 D10/PBS D50/PBS 
AK008407 2310057J18Rik RIKEN cDNA 2310057J18 gene -4.39 ± 0.38 1.55 ± 0.92 
BG079055 EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone -3.65± 0.28 0.32 ± 0.27 
BM940493  EST NIH_BMAP_Ret4_S2 Mus musculus cDNA clone -3.48 ± 0.36 0.10 ± 0.85 
BB364961  EST 
16 days embryo head cDNA, RIKEN 
full-length enriched library, 
clone:C130025B04 product:unknown 
EST, full insert sequence 
-1.91 ± 0.60 1.64 ± 1.17 
BE981626  EST NIH_BMAP_Ret4_S2 Mus musculus cDNA clone -2.07 ± 0.96 1.36 ± 1.70 
AW491340  EST NIH_BMAP_M_S4 Mus musculus cDNA clone -3.61 ± 1.13 -0.20 ± 0.78 
AW558581  EST Mouse Newborn Ovary cDNA Library Mus musculus cDNA clone -2.76 ± 1.04 0.38 ± 0.18 
BG067121  EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone -1.78 ± 0.45 1.29 ± 1.22 
NM_183029  C330012H03Rik RIKEN cDNA C330012H03 gene -2.49 ± 0.43 0.43 ± 0.11 
AK010213  2310079D11Rik RIKEN cDNA 2310079D11 gene -3.12 ± 0.00 -0.21 ± 0.08 
AV306186  EST RIKEN full-length enriched, 8 days embryo Mus musculus cDNA clone  -1.63 ± 0.78 1.26 ± 0.23 
AW556170  EST NIA Mouse Newborn Ovary cDNA Library Mus musculus cDNA clone -3.46 ± 0.17 -0.62 ± 0.12 
AK015738  4930509K18Rik RIKEN cDNA 4930509K18 gene -2.75 ± 0.22 0.07 ± 0.76 
AK034181 D10Bwg1379e DNA segment, Chr 10, Brigham & Women's Genetics 1379 expressed -2.14 ± 1.26 0.59 ± 0.42 
AK012378 6330407J23Rik RIKEN cDNA 6330407J23 gene -1.37 ± 0.99 1.20 ± 0.84 
AK006268 1700023D19Rik RIKEN cDNA 1700023D19 gene -2.17 ± 0.05 0.35 ± 0.53 
BB035685  EST 
RIKEN full-length enriched, 13 days 
embryo forelimb Mus musculus cDNA 
clone  
-2.89 ± 0.24 -0.42 ± 1.00 
AK020539 9530003O04Rik RIKEN cDNA 9530003O04 gene -2.07 ± 0.74 0.36 ± 0.17 
AK033891 A230055J12Rik RIKEN cDNA A230055J12 gene -2.21± 0.25 0.23 ± 0.19 
AK046123 AV344025 expressed sequence AV344025 -2.19 ± 0.29 0.16 ± 0.27 
AK014370  3300002I10Rik RIKEN cDNA 3300002I10 gene -2.72 ± 0.12 -0.39 ± 0.74 
BB667258 4930563B10Rik RIKEN cDNA 4930563B10 gene -1.22 ± 0.11 0.96 ± 0.31 
AK035504 AU041483 expressed sequence AU041483 -1.61 ± 0.74 0.56 ± 0.34 
AK014695 4833414E09Rik RIKEN cDNA 4833414E09 gene -1.98 ± 0.42 0.20 ± 0.45 
AV229522  EST 
RIKEN full-length enriched, 0 day 
neonate skin Mus  musculus cDNA 
clone  
-1.36 ± 0.57 0.77 ± 0.19 
AI848860 1500002B03Rik RIKEN cDNA 1500002B03 gene -1.57 ± 0.31 0.51 ± 0.12 
AK054336 AI987712 expressed sequence AI987712 -2.85 ± 0.08 -0.79 ± 0.44 
AK032438 6430546I09 hypothetical protein 6430546I09 -1.20 ± 0.18 0.85 ± 1.21 
AK029473 E230016M11Rik RIKEN cDNA E230016M11 gene -1.48 ± 0.40 0.56 ± 0.37 
BB552737 EST 
RIKEN full-length enriched, 2 days 
pregnant adult female ovary Mus 
musculus cDNA clone 
-1.22 ± 1.16 0.78 ± 0.19 
 124
BG063476  EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone -1.69 ± 0.42 0.21 ± 0.02 
AV240479  EST 
RIKEN full-length enriched, 10 day 
neonate skin Mus musculus cDNA 
clone  
-2.24 ± 0.70 -0.40 ± 0.10 
BG082689  EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone -2.26 ± 0.90 -0.43 ± 0.63 
AK016643  4933403O03Rik RIKEN cDNA 4933403O03 gene -1.25 ± 0.30 0.57 ± 0.06 
AI415201 1500011B03Rik RIKEN cDNA 1500011B03 gene -1.83 ± 0.95 -0.01 ± 0.23 
BB383493  7530428D23Rik RIKEN cDNA 7530428D23 gene -2.04 ± 0.16 -0.23 ± 0.01 
BG066476  EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone -1.04 ± 0.04 0.76 ± 0.50 
XM_484214  2900024P20Rik RIKEN cDNA 2900024P20 gene -2.30 ± 0.98 -0.57 ± 0.27 
AK010727 2410077I05Rik RIKEN cDNA 2410077I05 gene -1.71 ± 0.83 -0.07 ± 0.35 
C76958  D7Ertd143e DNA segment, Chr 7, ERATO Doi 143, expressed -0.84 ± 0.51 0.71 ± 1.01 
AK011587 2610028F08Rik RIKEN cDNA 2610028F08 gene -2.12 ± 0.42 -0.58 ± 0.02 
AU067727  D5Buc30e DNA segment, Chr 5, Bucan 30 expressed -1.39 ± 0.64 0.14 ± 0.32 
BM238675  EST Mouse Hematopoietic Stem Cell (Lin-/c-Kit+/Sca-1+)cDNA Library  -0.78 ± 0.23 0.72 ± 0.25 
NM_173432  AW539964 Expressed sequence AW539964 -1.33 ± 0.80 0.10 ± 0.45 
AI451419  EST Soares_thymus_2NbMT Mus musculus cDNA clone  -1.31 ± 0.10 0.07 ± 0.23 
BB432990  EST 
RIKEN full-length enriched, adult male 
hippocampus Mus musculus cDNA 
clone  
-1.25 ± 1.72 0.00 ± 1.62 
BB025438  EST 
RIKEN full-length enriched, adult male 
pituitary gland Mus musculus cDNA 
clone  
-0.89 ± 1.18 0.36 ± 1.34 
BB087975  EST 
12 days embryo embryonic body 
between diaphragm region and neck 
cDNA, RIKEN full-length enriched 
library, clone:9430013J05 
product:unknown EST, full insert 
sequence 
-1.26 ± 0.43 -0.07 ± 0.37 
AW121529  EST NIH_BMAP_M_S3.2 Mus musculus cDNA clone -0.58 ± 0.20 0.57 ± 0.26 
AI194387 C330002I19Rik RIKEN cDNA C330002I19 gene -1.14 ± 0.16 -0.02 ± 0.16 
AK008407 2310057J18Rik RIKEN cDNA 2310057J18 gene -4.39 ± 0.38 1.55 ± 0.92 
BG079055 EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone -3.65 ± 0.28 0.32 ± 0.27 
BM940493  EST NIH_BMAP_Ret4_S2 Mus musculus cDNA clone -3.48 ± 0.36 0.10 ± 0.85 
BB364961  EST 
16 days embryo head cDNA, RIKEN 
full-length enriched library, 
clone:C130025B04 product:unknown 
EST, full insert sequence 
-1.91 ± 0.60 1.64 ± 1.17 
BE981626  EST NIH_BMAP_Ret4_S2 Mus musculus cDNA clone -2.07 ± 0.96 1.36 ± 1.70 
AW491340  EST NIH_BMAP_M_S4 Mus musculus cDNA clone -3.61 ± 1.13 -0.20 ± 0.78 
AW558581  EST Mouse Newborn Ovary cDNA Library Mus musculus cDNA clone -2.76 ± 1.04 0.38 ± 0.18 
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BG067121  EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone -1.78 ± 0.45 1.29 ± 1.22 
NM_183029  C330012H03Rik RIKEN cDNA C330012H03 gene -2.49 ± 0.43 0.43 ± 0.11 
AK010213  2310079D11Rik RIKEN cDNA 2310079D11 gene -3.12 ± 0.00 -0.21 ± 0.08 
AV306186  EST RIKEN full-length enriched, 8 days embryo Mus musculus cDNA clone  -1.63 ± 0.78 1.26 ± 0.23 
AW556170  EST NIA Mouse Newborn Ovary cDNA Library Mus musculus cDNA clone -3.46 ± 0.17 -0.62 ± 0.12 
AK015738  4930509K18Rik RIKEN cDNA 4930509K18 gene -2.75 ± 0.22 0.07 ± 0.76 
AK034181 D10Bwg1379e DNA segment, Chr 10, Brigham & Women's Genetics 1379 expressed -2.14 ± 1.26 0.59 ± 0.42 
AK012378 6330407J23Rik RIKEN cDNA 6330407J23 gene -1.37 ± 0.99 1.20 ± 0.84 
AK006268 1700023D19Rik RIKEN cDNA 1700023D19 gene -2.17 ± 0.05 0.35 ± 0.53 
BB035685  EST 
RIKEN full-length enriched, 13 days 
embryo forelimb Mus musculus cDNA 
clone  
-2.89 ± 0.24 -0.42 ± 1.00 
AK020539 9530003O04Rik RIKEN cDNA 9530003O04 gene -2.07 ± 0.74 0.36 ± 0.17 
AK033891 A230055J12Rik RIKEN cDNA A230055J12 gene -2.21 ± 0.25 0.23 ± 0.19 
AK046123 AV344025 expressed sequence AV344025 -2.19 ± 0.29 0.16 ± 0.27 
AK014370  3300002I10Rik RIKEN cDNA 3300002I10 gene -2.72 ± 0.12 -0.39 ± 0.74 
BB667258 4930563B10Rik RIKEN cDNA 4930563B10 gene -1.22 ± 0.11 0.96 ± 0.31 
AK035504 AU041483 expressed sequence AU041483 -1.61 ± 0.74 0.56 ± 0.34 
AK014695 4833414E09Rik RIKEN cDNA 4833414E09 gene -1.98 ± 0.42 0.20 ± 0.45 
AV229522  EST 
RIKEN full-length enriched, 0 day 
neonate skin Mus  musculus cDNA 
clone  
-1.36 ± 0.57 0.77 ± 0.19 
AI848860 1500002B03Rik RIKEN cDNA 1500002B03 gene -1.57 ± 0.31 0.51 ± 0.12 
AK054336 AI987712 expressed sequence AI987712 -2.85 ± 0.08 -0.79 ± 0.44 
AK032438 6430546I09 hypothetical protein 6430546I09 -1.20 ± 0.18 0.85 ± 1.21 
AK029473 E230016M11Rik RIKEN cDNA E230016M11 gene -1.48 ± 0.40 0.56 ± 0.37 
BB552737 EST 
RIKEN full-length enriched, 2 days 
pregnant adult female ovary Mus 
musculus cDNA clone 
-1.22 ± 1.16 0.78 ± 0.19 
BG063476  EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone -1.69 ± 0.42 0.21 ± 0.02 
AV240479  EST 
RIKEN full-length enriched, 10 day 
neonate skin Mus musculus cDNA 
clone  
-2.24 ± 0.70 -0.40 ± 0.10 
BG082689  EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone -2.26 ± 0.90 -0.43 ± 0.63 
AK016643  4933403O03Rik RIKEN cDNA 4933403O03 gene -1.25 ± 0.30 0.57 ± 0.06 
AI415201 1500011B03Rik RIKEN cDNA 1500011B03 gene -1.83 ± 0.95 -0.01 ± 0.23 
BB383493  7530428D23Rik RIKEN cDNA 7530428D23 gene -2.04 ± 0.16 -0.23 ± 0.01 
BG066476  EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone -1.04 ± 0.04 0.76 ± 0.50 
XM_484214  2900024P20Rik RIKEN cDNA 2900024P20 gene -2.30 ± 0.98 -0.57 ± 0.27 
AK010727 2410077I05Rik RIKEN cDNA 2410077I05 gene -1.71 ± 0.83 -0.07 ± 0.35 
C76958  D7Ertd143e DNA segment, Chr 7, ERATO Doi 143, expressed -0.84 ± 0.51 0.71 ± 1.01 
AK011587 2610028F08Rik RIKEN cDNA 2610028F08 gene -2.12 ± 0.42 -0.58 ± 0.02 
AU067727  D5Buc30e DNA segment, Chr 5, Bucan 30 expressed -1.39 ± 0.64 0.14 ± 0.32 
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BM238675  EST Mouse Hematopoietic Stem Cell (Lin-/c-Kit+/Sca-1+)cDNA Library  -0.78 ± 0.23 0.72 ± 0.25 
NM_173432  AW539964 Expressed sequence AW539964 -1.33 ± 0.80 0.10 ± 0.45 
AI451419  EST Soares_thymus_2NbMT Mus musculus cDNA clone  -1.31 ± 0.10 0.07 ± 0.23 
BB432990  EST 
RIKEN full-length enriched, adult male 
hippocampus Mus musculus cDNA 
clone  
-1.25 ± 1.72 0.00 ± 1.62 
BB025438  EST 
RIKEN full-length enriched, adult male 
pituitary gland Mus musculus cDNA 
clone  
-0.89 ± 1.18 0.36 ± 1.34 
BB087975  EST 
12 days embryo embryonic body 
between diaphragm region and neck 
cDNA, RIKEN full-length enriched 
library, clone:9430013J05 
product:unknown EST, full insert 
sequence 
-1.26 ± 0.43 -0.07 ± 0.37 
AW121529  EST NIH_BMAP_M_S3.2 Mus musculus cDNA clone -0.58 ± 0.20 0.57 ± 0.26 
 
1. The GenBank accession number. 
2. Fold change is the average of two arrays expressed in log base 2 ± s.e.m. 
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Table 3.8: List of unknown genes upregulated in D10 group (37) 
 
Fold change 2 Accession 
No. 1 Symbol name 
Description 
 D10/PBS D50/PBS 
AK037152 A030001H23Rik RIKEN cDNA A030001H23 gene 2.26 ± 0.42 -1.48 ± 0.73 
AK015891  4930524O08Rik RIKEN cDNA 4930524O08 gene 3.62 ± 0.40 0.13 ± 0.13 
AK014727  4833419G08Rik RIKEN cDNA 4833419G08 gene 2.53 ± 0.64 -0.40 ± 1.39 
AK018926 1700094C09Rik RIKEN cDNA 1700094C09 gene 2.03 ± 0.35 -0.90 ± 0.17 
AK007164  1700110M21Rik RIKEN cDNA 1700110M21 gene 2.99 ± 0.35 0.16 ± 0.81 
AF463524 2610510D13Rik RIKEN cDNA 2610510D13 gene 3.81 ± 0.13 0.99 ± 0.65 
AK021311 D530037P16Rik RIKEN cDNA D530037P16 gene 3.53 ± 1.63 0.75 ± 1.66 
BG074689  EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone H3138B02  2.86 ± 0.73 0.13 ± 1.53 
AK018558  9030618K22Rik RIKEN cDNA 9030618K22 gene 2.11 ± 0.48 -0.61 ± 0.43 
AK012462 C330014O21Rik RIKEN cDNA C330014O21 gene 1.94 ± 0.96 -0.60 ± 1.00 
BE957357 EST NIH_BMAP_MSC_S1 Mus musculus cDNA clone UI-M-BG2-bce-h-03-0-UI 2.43 ± 0.16 0.12 ± 0.57 
BG079266  EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone H3037G07  1.15 ± 1.25 -1.10 ± 1.59 
AK016521  4932412D23Rik RIKEN cDNA 4932412D23 gene 1.52 ± 0.60 -0.72 ± 0.93 
AK004797 1200015N20Rik RIKEN cDNA 1200015N20 gene 0.08 ± 1.10 -2.14 ± 0.43 
XM_125968  1700034F02Rik RIKEN cDNA 1700034F02 gene 2.85 ± 2.08 0.72 ± 1.99 
BQ175572  EST NIH_BMAP_DJ2 Mus musculus cDNA clone 0.94 ± 0.26 -0.99 ± 0.47 
C79309  EST Mouse 3.5-dpc blastocyst cDNA Mus musculus cDNA clone J0064C11 1.98 ± 1.51 0.11 ± 1.31 
BG070345  EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone H3086D01  1.41 ± 1.03 -0.43 ± 1.71 
AK079326 9630025B04Rik RIKEN cDNA 9630025B04 gene 0.89 ± 0.48 -0.89 ± 0.13 
BB525091 D430002O22Rik RIKEN cDNA D930044O18 gene 1.30 ± 1.14 -0.44 ± 0.52 
NM_029640  1810044A24Rik RIKEN cDNA 1810044A24 gene 1.18 ± 0.57 -0.56 ± 0.16 
XM_112125  Gene model 47, (NCBI) 
Mus musculus similar to Putative 
Methyltransferase-related  2.53 ± 1.44 0.80 ± 0.87 
XM_483888 LOC432450 Hypothetical gene supported by AK029229 1.36 ± 3.56 -0.30 ± 3.11 
XM_354606 Gene model 877, (NCBI) 
Mus musculus similar to hypothetical 
protein FLJ14166 1.01 ± 1.21 -0.64 ± 1.57 
AK011897 2610206C17Rik RIKEN cDNA 2610206C17 gene 0.66 ± 0.20 -0.98 ± 0.34 
BB150699  EST 
RIKEN full-length enriched, 6 days 
neonate skin Mus musculus cDNA 
clone A030008F02  
2.25 ± 0.95 0.67 ± 1.51 
AK003475 1110005L13Rik RIKEN cDNA 1110005L13 gene 1.85 ± 1.90 0.28 ± 2.45 
BB210907  EST 
RIKEN full-length enriched, 0 day 
neonate thymus Mus musculus cDNA 
clone A430101J08  
1.03 ± 1.00 -0.52 ± 1.15 
AK015639  4930487N04Rik RIKEN cDNA 4930487N04 gene 0.55 ± 0.72 -0.98 ± 1.02 
BE957323 EST NIH_BMAP_MSC_S1 Mus musculus cDNA clone UI-M-BG2-bce-h-03-0-UI 1.11 ± 0.51 -0.41 ± 0.71 
BG071600  EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone   H3101A04 1.73 ± 1.15 0.23 ± 1.53 
AK012462 C330014O21Rik RIKEN cDNA C330014O21 gene 0.55 ± 0.41 -0.94 ± 0.05 
AK016653  4933404K13Rik RIKEN cDNA 4933404K13 gene 0.98 ± 1.44 -0.41 ± 1.45 
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AK002675 0610025O11Rik RIKEN cDNA 0610025O11 gene 1.24 ± 0.80 -0.08 ± 0.69 
AK006027 4930509O20Rik RIKEN cDNA 4930509O20 gene 2.19 ± 2.13 0.87 ± 2.17 
AW552105  EST 
NIA Mouse Newborn Ovary cDNA 
Library Mus musculus Cdna clone 
L0208D03 
2.77 ± 0.85 1.54 ± 0.94 
BB041915 EST 
RIKEN full-length enriched, 13 days 
embryo male testis Musmusculus 
cDNA clone 6030458L20  
1.08 ± 0.30 -0.13 ± 0.29 
 
1. The GenBank accession number. 
2. Fold change is the average of two arrays expressed in log base 2 ± s.e.m. 
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Table 3.9: List of unknown genes downregulated in D50 group (62)   
 
Fold change 2 Accession 
No. 1 Symbol name 
Description 
 D10/PBS D50/PBS 
XM_355193 LOC381251 similar to Nur77 downstream protein 1 0.43 ± 0.00 -3.53 ± 0.69 
NM_028330 2810051F02Rik RIKEN cDNA 2810051F02 gene 0.63 ± 0.62 -3.09 ± 0.20 
BB085975 A830082N09Rik RIKEN cDNA A830082N09 gene 1.48 ± 0.75 -1.88 ± 0.61 
AK014995 4933437F24Rik RIKEN cDNA 4933437F24 gene 0.17 ± 0.33 -3.39 ± 1.32 
AK083486 D2Ertd173e DNA segment, Chr 2, ERATO Doi 173, expressed 0.46 ± 0.06 -2.39 ± 1.01 
AI429145 1700009N14Rik RIKEN cDNA 1700009N14 gene 0.40 ± 1.47 -2.45 ± 0.22 
AK017960 5830431M20Rik RIKEN cDNA 5830431M20 gene 1.13 ± 0.68 -1.72 ± 0.28 
AA589418 EST Stratagene mouse skin (#937313) Mus musculus cDNA clone -0.18 ± 1.44 -2.85 ± 0.87 
NM_172767 Loh11cr2a 
loss of heterozygosity, 11, 
chromosomal region 2, gene A 
homolog (human) 
-0.23 ± 0.08 -2.78 ± 0.23 
XM_143339  Similar to hypothetical protein FLJ33620 0.12 ± 0.06 -2.38 ± 1.12 
BB114080 EST 
RIKEN full-length enriched, adult 
male urinary bladder Mus musculus 
cDNA clone 
0.93 ± 0.08 -1.55 ± 0.98 
BM239546 EST 
NIA Mouse Hematopoietic Stem Cell 
(Lin-/c-Kit+/Sca-1+) cDNA Library 
(Long) 
0.27 ± 0.63 -2.21 ± 0.28 
BG069580 EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone 1.19 ± 0.40 -1.20 ± 1.71 
AK077016 4932411A10 hypothetical protein 4932411A10 -0.52 ± 0.81 -2.91 ± 0.08 
AK018247 6330571C24Rik RIKEN cDNA 6330571C24 gene -0.53 ± 0.13 -3.21 ± 0.89 
AI504701 9130020L07Rik RIKEN cDNA 9130020L07 gene 0.82 ± 0.01 -1.52 ± 0.68 
AK004797 1200015N20Rik RIKEN cDNA 1200015N20 gene 0.08 ± 1.10 -2.14 ±  0.43 
BG075036 EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone 0.57 ± 0.79 -1.64 ± 1.95 
AK006848 4933416O17Rik RIKEN cDNA 4933416O17 gene 0.80 ± 0.51 -1.38 ± 1.63 
BB091346 EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone -0.25 ± 0.89 -2.39 ± 1.71 
BM240141 EST 
NIA Mouse Hematopoietic Stem Cell 
(Lin-/c-Kit+/Sca-1+) cDNA Library 
(Long) 
0.37 ± 0.56 -1.75 ± 1.01 
C80900 EST 
NIA Mouse Hematopoietic Stem Cell 
(Lin-/c-Kit+/Sca-1+) cDNA Library 
(Long) 
-0.29 ± 0.04 -2.36 ± 0.52 
AK016186 4930560O18Rik RIKEN cDNA 4930560O18 gene 0.61 ± 0.23 -1.45 ± 0.41 
XM_145503 LOC243905 Hypothetical LOC243905 0.19 ± 0.43 -1.85 ± 0.57 
AU045440 EST Mouse 3.5-dpc blastocyst cDNA Mus musculus cDNA clone 0.24 ± 0.34 -1.79 ± 0.14 
BE197105 A430093A21Rik RIKEN cDNA A430093A21 gene 0.34 ± 1.21 -1.65 ± 2.10 
NM_177368 8430438D04Rik RIKEN cDNA 8430438D04 gene 0.86 ± 1.15 -1.11 ± 1.72 
AC079938 9030607J07Rik RIKEN cDNA 9030607J07 gene 0.19 ± 0.16 -1.75 ± 0.32 
AK034150 B230343J05Rik RIKEN cDNA B230343J05 gene 0.27 ± 0.05 -1.62 ± 0.40 
XM_483987 LOC432536 similar to hypothetical protein DKFZp564N2472 0.57 ± 0.30 -1.32 ± 1.11 
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AK076770 4930443F05Rik RIKEN cDNA 4930443F05 gene -0.68 ± 0.23 -2.50 ± 0.12 
BG063769 EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone 0.58 ± 1.90 -1.24 ± 1.20 
AK015886 4930524J08Rik RIKEN cDNA 4930524J08 gene 1.17 ± 0.36 -0.62 ± 0.96 
AB016273 1700026P10Rik RIKEN cDNA 1700026P10 gene 0.47 ± 0.15 -1.31 ± 0.07 
AK007269 1700124K17Rik RIKEN cDNA 1700124K17 gene 1.22 ± 0.23 -0.55 ± 0.30 
AK021247 C430039J16Rik RIKEN cDNA C430039J16 gene 1.01 ± 0.59 -0.65 ± 1.15 
NM_001009
980 2410193C02Rik RIKEN cDNA 2410193C02 gene -0.02 ± 0.41 -1.64 ± 0.47 
XM_484154 4930512B01Rik RIKEN cDNA 4930512B01 gene 1.85 ± 1.90 0.28 ± 2.45 
AU022054 EST Mouse unfertilized egg cDNA Mus musculus cDNA clone -0.30 ± 0.86 -1.83 ± 1.14 
AK021083 C030015A19Rik RIKEN cDNA C030015A19 gene -1.09 ± 1.13 -2.61 ± 0.82 
XM_484525 BC031575 CDNA sequence BC031575 0.16 ± 0.79 -1.36 ± 0.80 
XM_484154 4930512B01Rik RIKEN cDNA 4930512B01 gene 0.04 ± 1.26 -1.41 ± 1.29 
BB525754 EST 
RIKEN full-length enriched, 15 days 
embryo head Mus musculus cDNA 
clone 
0.67 ± 1.69 -0.77 ± 1.36 
AK018072 6130400H19Rik RIKEN cDNA 6130400H19 gene 1.27 ± 0.68 -0.16 ± 0.80 
AK039627 BC023106 cDNA sequence BC023106 -1.49 ± 0.31 -2.90 ± 0.17 
AK002265 0610030G03Rik RIKEN cDNA 0610030G03 gene 0.06 ± 0.65 -1.34 ± 0.87 
BC060982 U46068 cDNA sequence U46068 0.50 ± 0.26 -0.85 ± 0.21 
AI428512 G630054C21Rik RIKEN cDNA G630054C21 gene 1.24 ± 0.80 -0.08 ± 0.69 
AK018999 1700129O19Rik RIKEN cDNA 1700129O19 gene 0.38 ± 0.37 -0.92 ± 0.13 
NM_175205 4632419I22Rik RIKEN cDNA 4632419I22 gene 0.67 ± 0.50 -0.61 ± 0.68 
AK020543 9530004M16Rik RIKEN cDNA 9530004M16 gene 0.48 ± 0.33 -0.78 ± 0.39 
AV277898 EST 
RIKEN full-length enriched, adult 
male testis (DH5a) Mus musculus 
cDNA clone 
0.35 ± 0.56 -0.91 ± 0.65 
BB473987 EST 
RIKEN full-length enriched, 13 days 
embryo heart Mus musculus cDNA 
clone 
0.52 ± 0.11 -0.72 ± 0.03 
AK003346 1110003E08Rik RIKEN cDNA 1110003E08 gene 0.96 ± 1.34 -0.27 ± 1.39 
BC026389 EST Mus musculus, clone IMAGE:4190185, mRNA, partial cds 0.53 ± 1.68 -0.69 ± 1.47 
XM_354606 Gm877 gene model 877, (NCBI) 0.02 ± 0.05 -1.17 ± 0.10 
AK019903 5330422M15Rik RIKEN cDNA 5330422M15 gene 0.47 ± 0.21 -0.71 ± 0.28 
BC010246 2810431N21Rik RIKEN cDNA 2810431N21 gene 0.3 ± 0.24 -0.94 ± 0.32 
AK011513 2610022C02Rik RIKEN cDNA 2610022C02 gene -0.26 ± 0.27 -1.43 ± 0.44 
AK020466 9430052A13Rik RIKEN cDNA 9430052A13 gene 0.41 ± 0.33 -0.75 ± 0.33 
XM_358416 Gm1567 gene model 1567, (NCBI) -0.45 ± 0.12 -1.49 ±  0.08 
AV092359 EST Mus musculus tongue C57BL/6J adult Mus musculus cDNA clone 0.35 ± 0.33 -0.68 ± 0.30 
 
1. The GenBank accession number. 
2. Fold change is the average of two arrays expressed in log base 2 ± s.e.m. 
 131
 132
Table 3.10: List of unknown genes upregulated in D50 group (23) 
 
Fold change 2 Accession 
No. 1 Symbol name 
Description 
 D10/PBS  D50/PBS 
NM_026407 2610033C09Rik RIKEN cDNA 2610033C09 gene -1.54 ± 2.25 3.98 ± 1.51 
NM_172540 4732479N06Rik RIKEN cDNA 4732479N06 gene 3.49 ± 0.26 7.69 ± 1.03 
AK032648 9630011N22Rik RIKEN cDNA 9630011N22 gene -1.28 ± 1.13 2.64 ± 0.30 
AK006804 1700055O19Rik RIKEN cDNA 1700055O19 gene -1.15 ± 1.08 1.83 ± 0.17 
R74675 D7Bwg0826e DNA segment, Chr 7, Brigham & Women's Genetics 0826 expressed -0.59 ± 1.27 2.20 ± 1.68 
BB797794 EST 
RIKEN full-length enriched, 1 month 
neonate cerebellum Mus musculus 
cDNA clone G630008D15 
-0.43 ± 2.70 2.18 ± 1.75 
AK009298 2310011G06Rik RIKEN cDNA 2310011G06 gene -0.46 ± 0.18 1.96 ± 0.53 
AK014037  3110009O07Rik RIKEN cDNA 3110009O07 gene -0.45 ± 0.71 1.90 ± 0.28 
AK029949 4933409K07Rik RIKEN cDNA 4933409K07 gene -0.58 ± 0.41 1.64 ± 0.35 
AK007203  1700113P08Rik RIKEN cDNA 1700113P08 gene -0.24 ± 0.58 1.96 ± 0.18 
AK084765 D330040H18Rik RIKEN cDNA D330040H18 gene -0.48 ± 1.60 1.58 ± 0.70 
AK038386 A230001M10Rik RIKEN cDNA A230001M10 gene -0.89 ± 0.14 1.15 ± 0.86 
AV269323  EST 
Adult male testis cDNA, RIKEN full-
length enriched library, 
clone:4930542D16 
product:unclassifiable, full insert 
sequence 
-0.77 ± 1.20 1.20 ± 0.56 
AV382158  EST 
Adult male diencephalon cDNA, 
RIKEN full-length enriched library, 
clone:9330104A10 product:unknown 
EST, full insert sequence 
-0.95 ± 0.44 0.96 ± 0.75 
BG073657  EST NIA Mouse 15K cDNA Clone Set Mus musculus cDNA clone H3126E09  -0.10 ± 3.62 1.71 ± 3.38 
AK045392 EST cDNA sequence BC019943 -0.65 ± 0.85 1.14 ± 0.44 
BB267006  EST 
10 days neonate cortex cDNA, RIKEN 
full-length enriched library, 
clone:A830028E23 product:unknown 
EST, full insert sequence 
0.01 ± 1.86 1.64 ± 2.28 
AK043509 B230216G23Rik RIKEN cDNA B230216G23 gene 1.74 ± 0.01 3.31 ± 0.23 
AK017939 5830418G11Rik RIKEN cDNA 5830418G11 gene -0.76 ± 0.26 0.75 ± 0.15 
XM_126551  9930033H14Rik RIKEN cDNA 9930033H14 gene -0.49 ± 0.38 1.00 ± 0.46 
BB271008 A830052D11Rik RIKEN cDNA A830052D11 gene -0.72 ± 0.29 0.74 ± 0.18 
AK045684 B230303O12Rik RIKEN cDNA B230303O12 gene -0.88 ± 0.08 0.38 ± 0.20 
AK033975 9330161F08Rik RIKEN cDNA 9330161F08 gene -0.65 ± 1.04 0.48 ± 1.04 
 
1. The GenBank accession number. 
2. Fold change is the average of two arrays expressed in log base 2 ± s.e.m. 
 
 
Table 3.11: Classification of genes downregulated in D10 group. 
Classification/ 
Accession no.  
Gene 
symbol Gene description  Molecular function Biological function Pathway  
Enzymes and inhibitors 
AK009449 Crisp1 cysteine-rich secretory protein 1 Hydrolase;Protease 
Spermatogenesis and 
motility;Fertilization   
AK028341 Ddx1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 RNA helicase;Hydrolase 
Nucleoside, nucleotide and nucleic 
acid metabolism;Protein 
biosynthesis;Translational 
regulation;Developmental processes   
AK004278 Fnbp1 formin binding protein 1 Transferase activity Biological process unclassified   
AK008189 Gsta4 glutathione S-transferase, alpha 4 Other transferase Detoxification   
BC014718 Dnase1 deoxyribonuclease I 
Endodeoxyribonuclease;Non-
motor actin binding 
protein;Hydrolase 
DNA degradation;Apoptotic processes 
  
AF148857 Peg12 paternally expressed 12 Kinase inhibitor 
Protein phosphorylation; 






a disintegrin-like and 
metalloprotease (reprolysin 
type) with thrombospondin 
type 1 motif, 4 
Signaling molecule; 
Metalloprotease Proteolysis;Cell communication 
  
BC005431 Anpep alanyl (membrane) aminopeptidase Metalloprotease Proteolysis   
AB036743 Cst10 cystatin 10 (chondrocytes) Cysteine protease inhibitor Proteolysis   
Protein modification 




methyltransferase-like 3 (S. 
cerevisiae) 
Methyltransferase Protein methylation   
AF474154 Mgat5 mannoside acetylglucosaminyltransferase Glycosyltransferase Protein modification   
133 
5 
NM_172829  St6gal2 beta galactoside alpha 2,6 sialyltransferase 2 Glycosyltransferase 
Other polysaccharide 
metabolism;Protein modification   
L10385 Tgm3 transglutaminase 3, E polypeptide 
Acyltransferase;Calmodulin 
related protein;Annexin Protein modification   
AF513619 Fancl Fanconi anemia, complementation group L 
Ubiquitin-protein ligase 
activity; protein binding, ligase 
activity 
DNA repair; ubiquitin cycle; 
gametogenesis;regulation of cell 
proliferation 
  




protein retention receptor 3 
Other receptor;Membrane 
traffic regulatory protein Constitutive exocytosis   
XM_355790  Sec15l2 SEC15-like 2 (S. cerevisiae) Membrane traffic protein Exocytosis;Transport   
AB010151 Stxbp1 syntaxin binding protein 1 Membrane traffic regulatory protein 
Regulated exocytosis; Transport; 
Neurotransmitter release   
Immunity and defense 





B-cell- and antibody-mediated 
immunity   
AF458063 Il17d interleukin 17D Interleukin 
Cytokine and chemokine mediated 
signaling pathway; Ligand-mediated 
signaling 
  





Receptor mediated endocytosis; B-
cell- and antibody-mediated immunity   
AF276975 Swam2 single WAP motif protein 2 Molecular function unclassified Defense response to bacteria   









AF288379 Klra20 killer cell lectin-like receptor subfamily A, member 20 
Receptor;Other defense and 
immunity protein 
Cell adhesion-mediated signaling; Cell 
adhesion; Natural killer cell mediated 
immunity 
  
M83218 S100a8 S100 calcium binding protein Calmodulin related protein Macrophage-mediated immunity;Cell   
134 
A8 (calgranulin A) motility; chemotaxis 
Transcription regulation and DNA binding 
AK032132 Cbfa2t1h CBFA2T1 identified gene homolog (human) Other transcription factor 
mRNA transcription 
regulation;Oncogene   
AF109633 Etv1 ets variant gene 1 Other transcription factor;Nucleic acid binding 
mRNA transcription regulation; 
MAPKKK cascade; Embryogenesis; 
Neurogenesis; Muscle development 
  
BC002039 Fxyd3 FXYD domain-containing ion transport regulator 3 
Ion channel;Select regulatory 
molecule Signal transduction;Ion transport   
AK012493 Pax3 paired box gene 3 Homeobox transcription factor;Nucleic acid binding 
mRNA transcription 
regulation;Developmental processes   
NM_029404 Phf14 PHD finger protein 14 DNA binding Regulation of transcription, DNA-dependent   
AK007634 Snapc5 small nuclear RNA activating complex, polypeptide 5 Transcription factor;Nuclease mRNA transcription;Other metabolism   
AY069926 Sox21 SRY-box containing gene 21 HMG box transcription factor;Nucleic acid binding 
mRNA transcription 
regulation;Neurogenesis   
AF260557 Tbx20 T-box 20 Other transcription factor;Nucleic acid binding 
mRNA transcription 
regulation;Developmental processes   
NM_198634  Tigd3 tigger transposable element derived 3 Nucleic acid binding Biological process unclassified   
AJ292467 Wdr9 WD repeat domain 9 Protein binding; transcription regulator activity 
Signal transduction; regulation of 
transcription from Pol II promoter   
NM_201227  Dte DAN domain family, member 5 Signaling molecule Developmental processes 
Wnt signaling 
pathway 
AF020196 Pbx1 pre B-cell leukemia transcription factor 1 Homeobox transcription factor Hematopoiesis;Oncogene   
AF144133 Nisch nischarin Receptor activity; integrin binding 
Rac protein signal transduction; actin 
cytoskeleton organization and 





















AK032871 Adk adenosine kinase Nucleotide kinase Nucleoside, nucleotide and nucleic acid metabolism   
AK029642 Amy1 amylase 1, salivary Amylase Carbohydrate metabolism   
BC012704 Car4 carbonic anhydrase 4 Dehydratase Other carbon metabolism   
AF079834 Car6 carbonic anhydrase 6 Dehydratase Other carbon metabolism   
NM_011506  Sucla2 
succinate-Coenzyme A 
ligase, ADP-forming, beta 
subunit 
Synthetase Carbohydrate metabolism;Coenzyme and prosthetic group metabolism   
AK034795 Vat1 
vesicle amine transport 
protein 1 homolog (T 
californica) 
Other oxidoreductase Fatty acid metabolism   
AK007857 Sdro 
orphan short chain 
dehydrogenase/reductase 
(Interim) 
Dehydrogenase Steroid metabolism   
Cell adhesion molecule  
AJ278069 Clstn2 calsyntenin 2 
Cell adhesion molecule; 
Calmodulin related 
protein;Annexin 
Cell adhesion-mediated signaling;Cell 
adhesion   
L01991 Cntn3 contactin 3 CAM family adhesion molecule Cell adhesion;Neurogenesis   
NM_028880  Lrrtm1 leucine rich repeat transmembrane neuronal 1 Other cell adhesion molecule Cell adhesion;Other neuronal activity   




Structural   
AJ005564 Sprr2f small proline-rich protein 2F Structural molecule activity Biological process unclassified   
AJ242929 Matn3 matrilin 3 Extracellular matrix structural protein Skeletal development   
AF257061 Mbp myelin basic protein Myelin protein Cell structure   
Miscellanous 
NM_010349  Grik2 glutamate receptor, Glutamate receptor;Ion channel Cell surface receptor mediated signal Huntington disease; 136 










AF114378 Ldb3 LIM domain binding 3 Non-motor actin binding protein Muscle contraction; Cell motility   
AF040945 Mab21l1 mab-21-like 1 (C. elegans) Molecular function unclassified Neurogenesis   
AB057759 Mlph melanophilin 
Actin binding; protein binding; 
myosin binding; Rab interactor 
activity 
Intracellular protein transporter; 
melanocyte differentiation    
AF214016 Mocs1 molybdenum cofactor synthesis 1 Molecular function unclassified 
Mo-molybdopterin cofactor 
biosynthesis    
AF249870 Perp PERP, TP53 apoptosis effector 
Other miscellaneous function 
protein Apoptosis 
p53 pathway; p53 
apoptosis effector 
related to PMP-22 
AF221525 Cyp2d22 cytochrome P450, family 2, subfamily d, polypeptide 22 Oxygenase Electron transport   
AK009032 Psp parotid secretory protein Lipid binding Biological process unclassified   
BC031806 Smr1 submaxillary gland androgen regulated protein 1 Peptide hormone Biological process unclassified   
Unclassified 
BC024627 Dcpp demilune cell and parotid protein Molecular function unclassified Biological process unclassified   
AB017907 Pip prolactin induced protein Molecular function unclassified Biological process unclassified   
AK042509 Tbrg3 transforming growth factor beta regulated gene 3 Molecular function unclassified Biological process unclassified   
AF190699 Ttyh1 tweety homolog 1 (Drosophila) Molecular function unclassified Biological process unclassified   
AK014880 Armc3 armadillo repeat containing 3 Molecular function unclassified Biological process unclassified   
AK018094 Frcl1 frc, fringe-like 1 (Drosophila) Molecular function unclassified Biological process unclassified   
137 




Accession no.  
Gene 
symbol Gene description  Molecular function Biological function Pathway  
Hydrolases and enzymes   
AF003870 Galc galactosylceramidase Galactosidase Carbohydrate metabolism; Lipid metabolism   
AK014491 Xrcc3 
X-ray repair complementing 
defective repair in Chinese 
hamster cells 3 
DNA strand-pairing protein; 
Hydrolase DNA recombination; Stress response   
NM_170778  Dpyd dihydropyrimidine dehydrogenase Dehydrogenase Pyrimidine metabolism   




(polypyrimidine tract binding 
protein associated) 
Other transcription factor; 
Other RNA-binding protein; 
Ribonucleoprotein 
mRNA splicing; Hematopoiesis   
AF020738 Fgf12 fibroblast growth factor 12 Growth factor 
Cell surface receptor mediated signal 
transduction; MAPKKK cascade; 
Ligand-mediated signaling; 
Neurogenesis; Mesoderm development 
FGF signaling 
pathway 
AF319173 Psca prostate stem cell antigen Molecular function unclassified Signal transduction; Oncogenesis   
AB046693 Rab27a RAB27A, member RAS oncogene family Small GTPase 
Intracellular signaling cascade; General 







AF483516 Snap25 synaptosomal-associated protein 25 SNARE protein 








group III receptor 
pathway 138
NM_134014  Xpo1 exportin 1, CRM1 homolog (yeast) 
protein transporter activity; 
Other miscellaneous function 
protein 
Biological process unclassified   





Other transferase; Cysteine 
protease 
Signal transduction; Immunity and 
defense; Developmental processes; 
Other polysaccharide metabolism; 
Protein modification; 
  
AF028122 Klra12 killer cell lectin-like receptor subfamily A, member 12 
Other receptor; Other defense 
and immunity protein 
Cell adhesion-mediated signaling; Cell 




AB026127 Cbx3 chromobox homolog 3 (Drosophila HP1 gamma) 
Chromatin/chromatin-binding 
protein Chromatin packaging and remodeling   
AY004873 Pramel3 preferentially expressed antigen in melanoma-like 3 hormone activity  Biological process unclassified   
AF066075 Pth parathyroid hormone Peptide hormone Skeletal development   
Unclassified 
AK020863 Gng1 
guanine nucleotide binding 
protein (G protein), gamma 1 
subunit 
Molecular function 










symbol Gene description  Molecular function Biological function Pathway  
Hydrolases and other enzymes  
BC020177 Atp1a3 ATPase, Na+/K+ transporting, alpha 3 polypeptide 
Ion channel; Cation 
transporter; Other hydrolase 
Cation transport; Calcium ion 
homeostasis   
NM_019670  Diap3 diaphanous homolog 3 (Drosophila) 
Endoribonuclease; Non-motor 
actin binding protein;Esterase Biological process unclassified 
Cytoskeletal 
regulation by Rho 
GTPase-Mammalian 
diaphanous 
AB003503 Gspt2 G1 to phase transition 2 Translation release factor; G-protein;Hydrolase 
Protein biosynthesis; Translational 
regulation; Cell cycle control;Cell 
proliferation and differentiation 
  
AK014887 Pde1c phosphodiesterase 1C Phosphodiesterase Metabolism of cyclic nucleotides; Signal transduction   
AF099187 Pde3a phosphodiesterase 3A, cGMP inhibited Phosphodiesterase 
Metabolism of cyclic nucleotides; 
Signal transduction   
NM_016962  Spg4 spastic paraplegia 4 homolog (human) Other hydrolase Intracellular protein traffic   
AK004594 Usp16 ubiquitin specific protease 16 Hydrolase;Protease Protein modification; Proteolysis   
AK052685 Ren1 renin 1 structural Aspartic protease Proteolysis   
NM_008608  Mmp14 matrix metalloproteinase 14 (membrane-inserted) 
Metalloprotease; Other 





BC032880 Aldh1a7 aldehyde dehydrogenase family 1, subfamily A7 Dehydrogenase Biological process unclassified   
Transcription factor and nucleic acid binding molecules 
M87801 Hoxa2 homeo box A2 Homeobox transcription factor; Nucleic acid binding 
mRNA transcription regulation; 
Developmental processes   
AF162853 Nfat5 nuclear factor of activated T-cells 5 Other transcription factor Biological process unclassified   
 
NM_177306  Rfxdc1 regulatory factor X domain containing 1 Other transcription factor mRNA transcription regulation   140
NM_011444 Sox5 SRY-box containing gene 5 HMG box transcription factor; Nucleic acid binding 
mRNA transcription regulation; 
Developmental processes   
AK013905 Wt1 Wilms tumor homolog KRAB box transcription factor; Nucleic acid binding 
mRNA transcription regulation; Cell 
cycle control; Cell proliferation and 
differentiation; Tumor suppressor 
  
AF365933  Zfp264 zinc finger protein 264 KRAB box transcription factor; Nucleic acid binding mRNA transcription regulation   
NM_008307  Htf9c HpaII tiny fragments locus 9c RNA methyltransferase; RNA methyltransferase 
Nucleoside, nucleotide and nucleic acid 
metabolism   
XM_485570  Mll5 myeloid/lymphoid or mixed-lineage leukemia 5 Nuclease 
Nucleoside, nucleotide and nucleic acid 
metabolism; Other metabolism   
NM_019550  Ptbp2 polypyrimidine tract binding protein 2 mRNA splicing factor mRNA splicing   
Membrane trafficking proteins  
AF096867 Syn2 synapsin II Membrane traffic regulatory protein Neuronal activities   
AK032106 Syt4 synaptotagmin 4 Membrane traffic regulatory protein Exocytosis; Transport   
NM_031394  Sytl2 synaptotagmin-like 2 Membrane traffic regulatory protein Exocytosis   
Signaling molecules and receptors  
AF027503 Baiap1 BAI1-associated protein 1 Kinase Other intracellular signaling cascade; Protein targeting   
BC013459 Bmp4 bone morphogenetic protein 4 TGF-beta superfamily member 
Receptor protein serine/threonine 
kinase signaling pathway; Ligand-




NM_007904  Ednrb endothelin receptor type B G-protein coupled receptor G-protein mediated signaling; Regulation of vasoconstriction, dilation 
Endothelin signaling 
pathway-endothelin 
receptor A, B 
AK035987 Egfl5 EGF-like-domain, multiple 5 Extracellular matrix linker protein 
Cell adhesion-mediated signaling; 







(GABA-A) receptor, subunit 
epsilon 
GABA receptor;Ion channel 
Ligand-mediated signaling; Anion 




AK004597 Icam1 intercellular adhesion molecule 
Receptor;CAM family 
adhesion molecule 
Cell adhesion-mediated signaling; Cell 
adhesion; B-cell- and antibody-
mediated immunity 
  
AF302503 Peli1 pellino 1 Kinase modulator Signal transduction   
NM_009071 Rock1 Rho-associated coiled-coil forming kinase 1 
Non-receptor serine/threonine 
protein kinase 
Protein phosphorylation; Other 
intracellular signaling cascade; Cell 
adhesion; Cell motility 
Cytoskeletal 










NM_009535  Yes Yamaguchi sarcoma viral (v-yes) oncogene homolog 
Non-receptor tyrosine protein 
kinase 
Carbohydrate transport; Protein 
phosphorylation; Intracellular signaling 
cascade; Transport; Immunity and 
defense; Oogenesis; Embryogenesis; 
Neurogenesis; Mesoderm development; 
Cell cycle control; Cell proliferation 
and differentiation; Oncogene 








family C (CFTR/MRP), 
member 2 
ATP-binding cassette (ABC) 
transporter 
Small molecule transport; Extracellular 
transport and import; Detoxification   
NM_015823  Acvrinp1 activin receptor interacting protein 1 Other cell junction protein Protein targeting and localization   
NM_144822  Cbara1 calcium binding atopy-related autoantigen 1 
Calmodulin related 
protein;Annexin Muscle development    
AK019553 Daf2 decay accelerating factor 2 Complement component Immunity and defense   
AF085696 Kcnj15 
potassium inwardly-
rectifying channel, subfamily 
J, member 15 
Voltage-gated potassium 
channel Cation transport   
AK012463 Psmd7 proteasome (prosome, macropain) 26S subunit, non-
Other miscellaneous function 
protein 
Proteolysis; Developmental processes; 
Cell cycle control; Cell proliferation 
Cell cycle-
Proteasome; 142 
ATPase, 7 and differentiation Ubiquitin proteasome 
pathway 
AK080899 Trpm6 
transient receptor potential 
cation channel, subfamily M, 
member 6 
Receptor; Other ion channel Biological process unclassified   
BC003475 Tubb2 tubulin, beta 2 Tubulin 
Intracellular protein traffic; 
Chromosome segregation; Cell 
structure; Cell motility 
Cytoskeletal 




AK011379 Rad51ap1 RAD51 associated protein 1 Molecular function unclassified DNA recombination; Other metabolism   
NM_134048 Cbll1 Casitas B-lineage lymphoma-like 1 
Ubiquitin-protein ligase 
activity protein binding  
Negative regulation of cell adhesion; 
positive regulation of cell migration and 
endocytosis  
  
AF176530 Fbxo15 F-box protein 15 Protein binding   




NM_194062 Nalp9c NACHT, LRR and PYD containing protein 9c 
Molecular function 
unclassified Apoptosis    
Unclassified  
AB041810 Bxdc1 brix domain containing 1 Molecular function unclassified Biological process unclassified   
AK010296 Zdhhc6 zinc finger, DHHC domain containing 6 
Molecular function 











symbol Gene description  Molecular function Biological function Pathway  
Enzymes  
AB023631 Ces3 carboxylesterase 3 catalytic activity, carboxylesterase, esterase Detoxification   
AF184981 Fmo2 flavin containing monooxygenase 2 Oxygenase 
Electron transport; Other 
metabolism   
AF051102 Ggh gamma-glutamyl hydrolase Cysteine protease Proteolysis   
AF073882 Mtmr7 myotubularin related protein 7 Protein phosphatase Other protein metabolism   
NM_011122   Plod1 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 Oxygenase 
Protein metabolism and 
modification; Other metabolism   
NM_181728 Art3 ADP-ribosyltransferase 3 Glycosyltransferase Protein ADP-ribosylation   
Signaling molecule  
BC050965 Fzd3 frizzled homolog 3 (Drosophila) G-protein coupled receptor 
G-protein mediated signaling; Other 





Cadherin and Wnt 
signaling pathway 
AB008160 Stat3 signal transducer and activator of transcription 3 
Other transcription factor; Nucleic 
acid binding 
mRNA transcription regulation; 
JAK-STAT cascade; Stress 
response; Inhibition of apoptosis; 













AF201285 Tgfb1i4 transforming growth factor beta 1 induced transcript 4 Other transcription factor mRNA transcription regulation   
AF406755 Tgfbr2 transforming growth factor, beta receptor II 
TGF-beta 
receptor;Serine/threonine protein 
Protein phosphorylation; Cytokine 




kinase receptor;Protein kinase pathway; Receptor protein 
serine/threonine kinase signaling 
pathway 







subfamily, member 4 
Voltage-gated potassium channel Cation transport   
AB030729 Papolb poly (A) polymerase beta (testis specific) mRNA polyadenylation factor mRNA polyadenylation   
AK043718 Pnma2 paraneoplastic antigen MA2 Other defense and immunity protein Oncogene   
AF325263 Sfxn4 sideroflexin 4 Cation transporter;Other transfer/carrier protein Cation transport   
AK036010 Vldlr very low density lipoprotein receptor Other receptor Oogenesis   
NM_026201 Ccar1 cell division cycle and apoptosis regulator 1 Molecular function unclassified Positive regulation of apoptosis   
Unclassified  
AJ621426 Sprn shadow of prion protein (Interim) Molecular function unclassified Biological process unclassified   



























































































































Figure 3.6: Verification of microarray results by real-time quantitative RT-PCR. 
Mice were immunized with D10 or D50 of rDer p 2 protein, or PBS alone on days 0, 4 
and 8. On day 10, lymph nodes were isolated and total RNA extracted converted to 
cDNA for quantitative real-time PCR analysis. (n = 6 groups of mice, each group consist 
of D10, D50 and PBS). 
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3.4 Discussion  
 
Microarray experiments in allergy research have the potential to identify new transcripts 
and/or novel pathways for further study in established experimental methods and may 
assist in the discovery of new disease mechanisms, biomarkers and perhaps therapeutic 
targets for allergic diseases. In the present study, microarray technology was employed to 
identify genes that were differentially expressed in mice primed with different doses of 
rDer p 2 protein.  
 
Differential gene expression of the protein primed mice was based on the reproducibility 
of two independent arrays. The use of pooled designs is often discouraged because of its 
inability to identify and appropriately transform or remove aberrant subjects and the 
difficulty to estimate within population variation. However, study using "virtual" pooling 
of data from real experiments and computer simulations has revealed pooling samples 
appropriately is statistically valid and efficient for microarray experiments (Peng X et al., 
2003). Furthermore, the inference for most genes is not adversely affected by pooling and 
it has been recommended that pooling be done when fewer than three arrays are used in 
each condition (Kendziorski C et al., 2005). 
 
The differentially expressed candidate genes were categorized according to those 
possessing enzymatic activity, involved in immune and defense mechanisms and those 
having a regulatory role in transcription and cell signaling. An interesting observation 
from the array and real-time PCR studies is the differential expression of MGAT5. 
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MGAT5 is an enzyme that modifies the N-glycans on the T cell receptor (TCR) 
(Demetriou M et al., 2001). It regulates TCR association with a multivalent galectin-
glycoprotein lattice that restricts ligand-induced TCR recruitment to the immune synapse. 
MGAT5 gene was downregulated in D10 immunization. It is possible that the Th2 
response seen in the D10 mice was a consequence of reduced MGAT5 gene expression 
lowering the T cell activation threshold. Previous studies have shown that a deficiency in 
MGAT5 lowers the T cell activation thresholds by increasing the number of TCRs 
recruited to the antigen-presenting surface, leading to T cell activation in the absence of 
CD28 co-signaling (Morgan R et al., 2004). Furthermore, MGAT5 -/- deficient mice 
administered with protein-reactive hapten oxazolone developed type IV DTH reaction 
that persisted for a longer time as compared to wild type MGAT5 +/+ mice. The in vitro 
study also demonstrated that resting Th2 cells could induce significantly less MGAT5 
mRNA compared to Th1 cells upon re-stimulation via the TCR.  
 
The elevated MGAT5 gene expression in D50 mice might signify this gene’s role in 
suppression of the Th2 response and induction of a regulatory response involving TGF-
β1. The increased expression of both TβRII and TGF-β1 induced transcript 4 (Tgfβ1i4) 
as shown in the array data of the D50 mice was correlated with the increased TGF-β1 
production in both splenic and lymph nodes cell cultures of D50 mice (figure 2.3e-f), 
suggesting that immunization with 50 μg/ml of Der p 2 protein resulted in the activation 
of TGF-β1 signaling pathway. TGF-β1 is well known for its immune-suppressive, anti-
inflammatory and anti-proliferative properties (Wahl SM et al., 1987; Adams DH et al., 
1991; Randolph GJ et al., 2002). These effects of TGF-β1 are mediated through the TβRI 
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and TβRII that have serine/threonine kinase domains (Wahl SM et al., 1987; Adams DH 
et al., 1991; Randolph GJ et al., 2002).  Evidence shows that TGF-β1 is profoundly 
inhibitory for the differentiation and expansion of both Th1 and Th2 cells in mice, if 
present during primary stimulation (Ludviksson BR et al., 2000). Furthermore, the 
immunoprecipitation study showed that the binding of TGF-β1 to TβRII was reduced in 
MGAT5 deficient mice as compared to wild type mice (Partridge EA et al., 2004). 
Previous studies have shown that TGF-β signaling could stimulate the expression of 
MGAT5 in mesenchymal cells (Miyoshi E et al., 1995) and TGF-β1 could increase the 
surface expression of MGAT5-modified N-glycans (Partridge EA et al., 2004). Taken 
together, one can propose that the upregulated MGAT5 expression following D50 
immunization might lead to an increased T cell activation threshold and established the 
regulatory or tolerance response via TGF-β1 signaling.  
 
Besides the TβRII and Tgfβ1i4, a number of genes related to TGF-β were observed in the 
current study. The notion on TGF-β1 signaling pathway being induced in D50 
immunized mice was further supported by the decreased expression of Rad51AP1, 
activin receptor interacting protein 1 (Acvrinp1) and bone morphogenetic protein 4 
(BMP4) genes. TGF-β1 signaling pathway has prominent effects on a number of DNA 
monitoring and repair systems that act as caretakers of the genome (Kinzler KW et al., 
1997). Rad50 is responsible for ATP-binding and joining of the non-complementary ends 
in antibody class switching recombination mechanism (Hopfner KP et al., 2002). TGF-β1 
has been reported to reduce the expression of Rad51 and decrease Rad51-mediated DNA 
repair efficiency to promote DNA instability (Kanamoto T et al., 2002). Further studies 
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are required to address whether there is any effect on the TGF-β1 regulatory response of 
Rad51AP1 gene expression in the D50 mice. Activin is a multifunctional growth and 
differentiation factor that belongs to the TGF-β superfamily (Vale W et al., 1986). Its 
associated protein, Acvrinp1, is responsible for its association with activin receptors and 
Smad3 specifically to form a quaternary complex during signaling (Shoji H et al., 2000). 
In view of Smad3 being one of the signaling molecules triggered downstream in the 
TGF-β signaling pathway, the decreased expression of Acvrinp1 in D50 immunized mice 
might indicate the reduction in competition for TGF-β1 signaling pathway or has some 
interference in the physiological regulation of signal transduction. BMP4 is a member of 
the TGF-β superfamily that involves in patterning and cellular fate determination during 
the development of many tissues, and has been shown to increase the proliferation of 
human hematopoietic progenitors (Yamaguchi A et al., 2000). Considering that TGF-β1 
could act as a negative regulator of murine hematopoietic progenitor cell proliferation 
(Goey H et al, 1989), the activation of TGF-β1 signaling pathway in D50 immunized 
mice might account for the decreased gene expression level of BMP4. 
 
Data derived from the in vitro cultures of D50 immunized mice showed that there was an 
increased in IL-10 production by the Der p 2-stimulated lymph nodes cells (figure 2.3e). 
Such observation could be correlated with the elevated expression of stat3 in the array 
data as stat3 is strongly implicated as a key mediator of IL-10 responses (Weber-Nordt 
RM et al, 1996). Stat3 is recruited directly to the IL-10/IL-10R complex via either of two 
tyrosine residues in the IL-10R1 cytoplasmic domain that becomes phosphorylated in 
response to IL-10. Overexpression of a dominant negative stat3 mutant or an inducible 
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active form of stat3 have demonstrated that stat3 activation is both necessary and 
sufficient to inhibit macrophage proliferation by an IL-10 pathway at least in part via 
enhancement of expression of the cell cycle inhibitors p19INK4D and p21CIP1(O’Farrell 
AM et al., 2000). Studies exploring the role of Treg cells in allergic disease have 
primarily focused on inducible Tr1 or Th3 cells, distinctively characterized by their 
ability to secrete TGF-β1 and IL-10 respectively. IL-10 and TGF-β1 have been suggested 
to exert synergistic, suppressive effects on T cell proliferation and immunostimulatory 
cytokine secretion (Kitani A et al., 2003; van Oosterhout and Bloksma 2005). It has been 
reported that IL-10 might sensitize activated T cells to suppress the action of TGF-β1 by 
enhancing TβRII expression on the activated cells since TGF-β1 has been shown to 
induce the expression of immunosuppressive IL-10 by T cells (Cottrez F and Groux H, 
2001; Kitani A et al., 2003). Thus, it is the level of activation rather than solely the 
expression of IL-10 or TGF-β1 that defines the Treg subset involved.  
 
Increased expression of Rerg, a member of the Ras superfamily that possesses intrinsic 
ability to bind and hydrolyze GTP, is observed in D50 mice. A previous study has shown 
that overexpression of Rerg protein in MCF-7 breast carcinoma cells could result in a 
significant inhibition of both anchorage-dependent and anchorage independent growth in 
vitro (Finlin BS et al., 2001), suggesting that its inhibitory action on the cell proliferation 




A decreased nuclear factor of activated T-cells 5 (NFAT5) gene expression in D50 
immunized mice might signify its involvement in Treg cells development and Th2 
response. NFAT5 transcription factor is necessary for optimal T cell development in vivo 
and allows for optimal cell growth ex-vivo under conditions associated with osmotic 
stress (Miyakawa H et al., 1999). Transgenic mice expressing the dominant inhibitory 
form of NFAT5 have demonstrated a significant reduction in the number of mature 
peripheral T cells, suggesting a possible involvement in the impairment or suppression of 
cell growth or development in D50 immunized mice (Trama J et al., 2002). A recent 
study on transgenic mice expressing a dominant negative NFAT mutant showed that the 
inhibition of NFAT in T cells resulted in a reduction of antigen-specific Th2 antibody 
response and IL-4 production by CD4+T cells (Diehl S et al., 2004). Since the activation 
of NFAT in CD4+ T cells is essential in the development of a Th2 immune response in 
vivo, the reduced NFAT5 gene expression might account for the suppressed Th2 response 
in D50 immunized mice. 
 
Underexpressed Peli1 and intercellular adhesion molecule 1 (ICAM-1) in D50 
immunized mice might suggest their significance in the development of a Th2 type 
response. Interfering RNA (siRNA) and cellular overexpression studies demonstrated that 
Peli1 is specifically required for NFκB activation and IL-8 gene expression in response to 
IL-1 mediated signaling (Jiang Z et al., 2003). Interestingly, the OVA-induced airway 
hypersensitivity response in IL-1 alpha/beta-deficient mice was significantly reduced 
from the levels seen in wild-type mice, signifying that IL-1 is required for Th2 cell 
activation during the induction of local inflammation in delayed-type hypersensitivity 
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responses (Nakae S et al., 2003; Nambu A et al, 2006). A previous study has illustrated 
that B cell-B cell interaction through ICAM-1 and one of its counter receptors, LFA-1, 
regulates IgE synthesis by modulating C epsilon germ-line transcription (Katada Y et al., 
1996). Enhanced soluble serum ICAM-1 is a marker of the activity of asthmatic patients 
(Ando M et al., 2001) and ICAM-1-deficient mice had shown a reduction of immediate-
type hypersensitivity response and decreased serum IgE production (Shimada Y et al., 
2003)..  
 
RAB27A, member RAS oncogene family (RAB27a) and synaptosomal-associated 
protein 25 (SNAP25), which were both upregulated in the D10 immunized mice, have 
been reported to be associated with and essential for the docking step of regulated 
exocytosis (Tsuboi T and Fukuda M, 2005). RAB27a is required for the secretion of lytic 
granules in cytotoxic T lymphocytes (Tolmachova T et al., 2004) and SNAP25 is a pre-
synaptic target for the depressant action of reactive oxygen species on transmitter release 
(Giniatullin AR et al., 2006). Recently, a group of researchers reported that RAB27b, 
which is highly homologous to RAB27a, was upregulated in the microarray analysis of 
PBMC–derived T cell responses to house dust mite (Bosco A et al., 2006). In their 
observation, a synaptotagmin-like 3 protein, which binds to RAB27A and has a role in 
exocytosis and protein transport, was also upregulated, indicating that the genes involved 
in exocytosis might play some roles in Th2 responses or atopy.    
 
A number of genes involved in innate immunity and host defense have been shown to be 
downregulated in D10 mice. Single WAP motif protein 2 (SWAM2) has been identified 
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as a whey acidic protein (WAP) motif protein with antibacterial activity (Hagiwara K et 
al., 2003). The expression of cysteine-rich secretory protein 1 (CRISP1) in the salivary 
gland (lacriminal gland) suggested that it may have a function in nonspecific host defense 
(Haendler B et al., 1999). Interestingly, CRISP is evolutionarily related to venom 
allergen 5 from vespid wasps and venom allergen 3 from fire ants, in which both are 
potent allergens that mediate allergic reactions to stings insects of the Hymenoptera 
family (Lu G et al., 1993). Other genes possibly involved in innate immunity but 
appeared underexpressed in D10 immunized mice include the proteins derived from 
secretory gland eg. submaxillary gland androgen regulated protein 1 (Smr1), demilune 
cell and parotid protein (Dcpp), prolactin induced protein (PIP), parotid secretory protein 
(PSP). PSP appears as a normal product of the lacrimal glands where, as in saliva, it may 
function as a nonimmune antimicrobial agent in the protection of tissue surfaces exposed 
to the external environment (Robinson CP et al., 1997). Further study is required to 
elucidate the relationship of these genes with the immune responses of D10 mice.  
  
From the array data, several genes are found involved in the Wingless (Wnt) signaling 
pathway. They are namely frizzled homolog 3 (Drosophila)(Fzd3), DAN domain family, 
member 5 (Dte), protocadherin 8 (Pcdh8), paternally expressed 12 (Peg12) or Frat3 and  
signaling molecule mitogen activated protein kinase kinase kinase 7 (Map3k7) or TGF-β-
activating kinase 1 (TAK1). The Wnt-signaling pathway has been implicated in a variety 
of processes in neurodevelopment and the frizzled proteins have been identified as 
receptors for Wnt ligands. Human Fdz3 protein is one of the major components of the 
Wnt signaling pathway (Katsu T et al., 2003) and is highly expressed in the bone marrow 
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progenitor B cells (Dosen G et al., 2006). Dte is a member of DAN domain family that 
modulates the action of TGF-β family members during development (Pearce JJ et al., 
1999). Peg12/Frat3 is expressed primarily in embryonic stages and might be a positive 
regulator of the Wnt signaling pathway (Kobayashi S et al., 2002). It is unclear how these 
genes are associated with the immune responses of the Der p 2 immunized mice, but they 
might be have role in Wnt signaling pathway in lymphopoiesis (Qiang YW and Rudikoff 
S et al., 2004; Timm A and Grosschedl R, 2005; Dosen G et al., 2006). The proliferation 
and/or survival of these B and T cells are found associated with activation of the 
'canonical' Wnt/β-catenin pathway. Furthermore, the first characterized interaction 
between Wnt and TGF-β pathways was demonstrated in the construction of a complex 
between lymphoid enhancer binding factor/T-cell-specific factor (LEF-1/TCF) and β-
catenin along with Smad4 on the Xenopus homeobox gene promoter (Labbe E et al., 
2000). This study has revealed that TGF-β and Wnt signaling pathways can 
independently or cooperatively regulate the LEF1/TCF target genes, suggesting the 
cooperation between these pathways may be important for the specification of cell fates 
during development (Letamendia A et al., 2001).  
 
Interestingly, Map3k7/TAK1, a gene that has roles in Wnt signaling pathway and Treg 
cells development, was found decreased in gene expression in the D10 group. Recent 
study has shown that TAK1 is a member of Mapkkk family that acts as a positive 
mediator of TGF-β signal transduction (Liu HH et al., 2006). Using T cell-specific 
TAK1-deficient mice, TAK1 has shown to play indispensable roles in T cell development 
and the maintenance of tolerance (Sato S et al., 2005). Although the development of Treg 
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cells is proposed in D50 immunized mice (as described in chapter 2), the array data 
showed no significant increase in the expression level of TAK1 in D50 as compared to 
PBS group (Table 3.3). It is suggested that a constitutive expression level of TAK1 is 
sufficient in the homeostasis maintenance of immune system, that is the generation of 
central Treg cells, and the deficit of Treg cells development in D10 immunized mice may 
be apparent only in the situation with reduced TAK1. However, further investigation is 
required to clarify this proposition.  
 
This differential gene expression profiling of mice immunized with different dosages of 
rDer p 2 has suggested several genes that might dictate the immune responses. A 
summary on the relationship of differential expressed genes and pathways is depicted in 
figure 3.7. The identification of genes associated with the dosage-dependent response is 
important to advance exploration towards the treatment for allergic diseases especially 
that the effect of D50 immunization resembled the high dose peripheral tolerance in 
allergen-specific immunotherapy. Further investigations are to be conducted on the innate 
immunity genes that are found downregulated in the D10 immunized mice. The 
differentially expressed genes that are associated with TGF-β and Wnt signaling 
pathways might open up new avenue and provide new targets for allergy therapy. Lastly, 
more clarifications are required to conclude the importance and functional aspects of the 
dosage-dependent genes induced in these mice, which may provide a new opening for 
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The incidence of asthma, hay fever and other IgE mediated diseases has been steadily 
increasing over the past few years, despite the introduction of increasingly potent and 
effective drugs (Johansson SG et al., 2001). Thus, more effective therapies are necessary 
to modulate immune responses that could mitigate or prevent allergic illness 
(Hamelmann E et al., 2003; Creticos PS et al., 2004). Genetic immunization is a very 
promising therapeutic approach to allergy treatment. It has been shown to be effective in 
directing immune response towards a favorable Th1 phenotypic expression (Kwon SS et 
al., 2001; Hsu CH et al., 1996; Peng HJ et al., 2002) and has been reported to be 
successful preventive and therapeutic approaches in animal model of Type I allergies 
(Hsu CH et al., 1996; Lee DJ et al., 1997; Peng HJ et al., 2002; Wolfowicz CB et al., 
2003; Li GP et al., 2005; Hartl A et al., 1999, 2004; Toda M et al., 2002). These studies 
have demonstrated that injection of plasmid DNA-encoding clinically relevant allergens 
can induce immune responses with a Th1 bias and promote the formation of IFN-γ-
producing CD4+ T cells. These IFN-γ-secreting Th1 cells can stimulate B cells to 
synthesize IgG2a antibodies and inhibit IgE production, thereby representing an indirect 
indicator for the induction and action of Th1 cells.  
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Although a robust immune response can be readily illustrated in small animals, multiple 
immunizations of high dosages are often required to achieve modest responses in 
primates. Human trials failed to generate high levels of humoral and cellular immunity as 
observed in animal models, suggesting that the immunogenicity of DNA vaccine needs to 
be improved in humans (Wang RB et al., 1998; Widera G et al., 2000). The reasons for 
the lack of efficacy in larger animals might be due to an inefficient uptake of DNA by 
cells in situ or a level of protein expression insufficient to elicit strong immune responses 
(Bachy M et al., 2001; Widera G et al., 2000). To circumvent this problem, a strategy 
involving in vivo delivery of an electric field is sought to elevate gene expression and 
immune responses. This technology has significantly increased the potency of DNA 
vaccines in mice, guinea pigs, and rabbits and, thus, may prove useful at enhancing the 
effectiveness of DNA vaccines in larger animals, such as nonhuman primates and 
humans (Widera G et al., 2000).   
 
The effectiveness of DNA vaccination is dependent on the interaction between T-
lymphocytes and APCs. DC is a potent and unique APC that has been shown to play a 
critical role in inducing protective immune responses of DNA vaccines (Porgador A et 
al., 1998; Akbari O et al., 1999; Coombes BK et al., 2001). The importance of DCs is 
underscored by the fact that DNA transfected DCs could lead to general activation of 
DCs in the draining lymph nodes, which provide optimal conditions for effective T cell 
activation and memory. Conversely, the pathogenic role of DCs in allergic disease has 
also been documented (Charbonnier AS et al., 2003; Van Rijt LS et al., 2005). In vitro-
generated DCs from patients sensitized to the Der p 1 antigen when adoptively 
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transferred to human PBMC-reconstituted SCID mice were capable of inducing a marked 
increase in the production of specific IgE upon allergen challenge (Charbonnier AS et al., 
2003). In another study, in vivo depletion of lung DCs during allergen challenge could 
abrogate typical features of asthma, and the Th2 cytokine secretion were restored upon 
adoptive transfer of CD11c DCs (Van Rijt LS et al., 2005).  
 
Current approaches to optimizing the efficacy of DNA vaccines include incorporation of 
immunostimulatory sequences (ISS) in the plasmid backbone (Kojima Y et al., 2002; 
Zhang A et al., 2005), utilizing appropriate delivery mechanisms (Widera G et al., 2000; 
Otten G et al., 2004), incorporating localization/secretory signals (Baldwin SL et al., 
1999; Drew DR et al., 2000; Jiang C et al., 2002) and augmenting responses with 
adjuvants such as cytokines (Barouch DH et al., 2004). Increased gene expression has 
been reported to be essential for improving the efficacy of DNA vaccines (Baldwin SL et 
al., 1999; Drew DR et al., 2000; Jiang C et al., 2002). The importance of signal sequence 
in the induction of protective immunity was illustrated when DNA plasmids without 
leader sequence were less immunogenic than their full-length counterparts. In addition, it 
has been proposed that poor antigen secretion may hold up the release of antigen from 
transfected cells and result in reduced circulating antigen available to achieve an optimal 
immune response (Drew DR et al., 2000; Jiang C et al., 2002).   
 
Antigen presentation by MHC II molecules and activation of CD4+ helper T cells are 
important for the generation of immunological memory (Janssen EM et al., 2003; 
Shedlock DJ et al., 2003). This is particularly applicable to DNA vaccines, which elicit a 
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much lower innate immune response (Barouch DH et al., 2000). The access to MHC II 
pathways is conventionally mediated by endocytosis or phagocytosis of exogenous 
antigens but the DNA-encoded, endogenously synthesized antigens do not gain efficient 
access of these pathways and are limited in the activation of CD4+ T cells (Yewdell JW 
et al., 1990; Zhong G et al., 1996). In order to overcome the problem of endogenous 
antigen access to MHC II compartment, several studies have incorporated the lysosomal-
associated membrane proteins (LAMPs) in the DNA systems (Kim TW et al., 2003; 
Maecker HT et al., 1998; Lu Y et al., 2003). LAMPs are major lysosomal membrane 
glycoproteins that contain a cytoplasmic tail targeting sequence that directs trafficking of 
molecule thorough endosome/lysosome pathway. These studies have demonstrated to 
enhance intracellular antigen processing (Kim TW et al., 2003), and enhanced and 
elicited long-lasting immune responses to the antigens (Maecker HT et al., 1998; Lu Y et 
al., 2003) 
 
The development of a commercially viable prophylactic DNA vaccine for human use 
requires extensive information on the factors that affect immunogenicity of DNA 
vaccines, so that strong and favorable immune responses can be mounted. In the present 
study, electroporation technology was engaged to investigate the effect of different mice 
genetic backgrounds in Der p 2 gene immunization. Mice were immunized with DNA 
construct containing Der p 2 gene with signal peptide sequence (pCI-52) and the immune 
responses were evaluated. Although efficacy studies of DNA vaccines for allergic 
diseases have been previously reported, the immunological impact and potential risks of 
incorporating signal sequences in DNA vaccine constructs for allergic diseases have not 
been fully addressed to date. To address this issue, mice were immunized with DNA 
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constructs containing Der p 2 without signal peptide sequence (pCI-2), Der p 2 with 
signal peptide sequence (pCI-52) or pCI-52 plus a LAMP-1 protein (pCI-52LA). The 
immunized mice were evaluated for their humoral and cellular responses. In addition, 
DCs adoptive transfer experiments were performed to further characterize the quality of 









Female BALB/cJ, CBA/CaH, C57BL/6J, and AKR/J mice (6 to 8 weeks old) were 
purchased from the Sembawang Laboratory, Singapore. Mice were housed and treated as 
described in chapter 2 section 2.2.2. Five to 6 weeks old guinea pigs were purchased from 
the Sembawang Laboratory, Singapore, and housed under conventional conditions in the 
Animal Holding units at The National University of Singapore. All animal experiments 
were performed according to the guidance approved by Institutional Guidelines for 
Animal Care and Handling (IACUC).  
 
4.2.2 Molecular cloning vector and host strain 
 
The mammalian expression vector pCI (Appendix 10) was acquired from Promega 
(Madison, WI, USA). The Escherichia coli strain DH5α (Invitrogen) was engaged in the 
propagation of recombinant plasmid.  
 
4.2.3 DNA immunization and in vivo electroporation 
 
DNA immunization was performed by intramuscular injection with 50 μg (in 50 μl of 
PBS) of plasmid DNA into the quadriceps of the mouse, followed by in vivo 
electroporation as previously described (Wolfowicz CB et al., 2003). Briefly, the 
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quadriceps of the anesthetized mice was shaved and DNA was injected using a 1 ml 
syringe and a 27G needle in the anterior tibialis, followed by immediate electroporation 
with an ECM 830 apparatus (BTX, Genetronics, San Diego, CA). Electroporation was 
performed with a 0.5 cm 2-needle array inserted 2 mm deep in parallel to the muscle 
fibers that delivered four pulses of 20 ms, 80V each, with a 200 ms interval. 
Experimental mice were given pCI plasmid that contains the Der p 2 gene as described 
below. Control mice were given 50 μg of pCI vector.  
 
4.2.4 PCR amplification 
 
PCR amplification was performed with 0.5 µl of Taq polymerase (5U/µl), 5 µl of 10X 
Thermophilic buffer, 1.5 µl of MgCl2 (55 mM), 1 µl of sense and anti-sense primer (10 
pmol), and 1 µl of dNTPs (10 mM), 1 µl of template and top up with ddH2O to a volume 
of 50 μl. Each sample was incubated in a DNA thermal cycler (Perkin Elmer Gene Amp 
PCR system 9700, PE applied Biosystems, Foster City, CA USA) for a total of 30 cycles. 
Each cycle consisted of 30 sec at 94˚C, 30 sec at 55˚C, and 1 min at 72˚C. A starting 
incubation of 5 min at 94˚C and a final extension of 10 minutes at 72˚C were included in 
each program. A negative control (no template added) was included in the amplification. 
All primers list in this study were purchased from Research Biolabs (Singapore). All 
DNA constructs have Kozak consensus sequence GCCACC preceding the ATG start 
codon and a TGA stop codon at the 3' end. All enzymes were purchased from Promega 
unless stated otherwise.  
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4.2.5 pCI-52 construct  
 
The full length of Der p 2 gene previously cloned into plasmid pCI vector was used as 
template for PCR amplification in this study. The mature coding region of Der p 2 was 
cloned into the pCI vector containing Der p 5 leader sequence (LS) and designated as 
pCI-52 construct (figure 4.1a). The construction of pCI-52 was carried out by insertion of 
the PCR amplified fragment of Der p 2 gene (Accession number AF276239), using 
oligonucleotide primers 5′-TTCCGGAGATCAAGTCGATGTCAAAG-3′ and 5′-
CGCTTAAGAATTAGCGCCTAAAATCG-3′, and cloned in-frame with the pCI 
plasmid that contained Der p 5 leader sequence (pCI-5), as previously described 
(Wolfowicz CB et al., 2003). Briefly, two PCR reactions were set up as described in 
section 4.2.4 and the pooled amplified Der p 2 product was cleaned up by using GFX 
PCR DNA purification Kit (GE Healthcare, Upsala, Sweden) according to the 
manufacturer’s instructions. The product was eluted in 30 µl of ddH2O. The purified 
sample was then added with 2 µl of BspE I (New England Biolab, London, England), 5 
µl of 10X NEBuffer 3 (New England Biolab) and topped up with ddH2O to a final 
volume of 50 µl. After 3 hrs of incubation, 2 µl of NotI enzyme (10 U/µl) and 5 µl of 
Buffer D were added and topped up with ddH2O to a final volume of 100 µl. The reaction 
was incubated at 37ºC for 3 hrs. Five micrograms of the pCI-5 DNA was restricted with 
BspE I and Not I at 37ºC for 3 hrs as mentioned above. Both were analyzed on the 1 % 
agarose gel and gel-purified using Gel Band Purification Kit (GE Healthcare). The 
restricted products were eluted in 30 µl of ddH2O. The ligation reaction was set up by 
adding 15 µl of the Der p 2 gene product to a 1.5 ml tube containing 1 µl of T4 DNA 
ligase (Promega), 2 µl of 10X ligase buffer, 1 µl of the linearized vector pCI-5 and 2 µl 
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of ddH2O. The reaction was incubated at 16ºC for 18 hrs. Next, the Der p 2 gene 
construct was transformed into E. coli DH5α by using CaCl2 and heat shock protocol 
(Sambrook J et al., 1989). Transformed cells were plated onto Luria-Broth (LB) agar 
plate (1% Tryptone (Difco, Becton Dickinson, Missouri, USA), 1% NaCl (Merck), 0.5% 
Yeast extract (Difco), 15% Bacto-agar (Difco), pH 7.5) containing 50 µg/ml ampicillin 
(Sigma). Positive clones were verified by restriction digest with BspE I and NotI 
enzymes, and DNA sequencing. Large scale cell culture was performed by overnight 
incubation in 2L of LB medium containing 2 ml of ampicillin (50 µg/ml), shaking at 250 
rpm and 37oC. Large scale plasmid DNA extraction was carried out by using the 
endotoxin free Nucleobond plasmid Giga kit (Clontech Laboratories, Palo Alto, CA, 
USA) according to the manufacturer’s instructions. DNA was suspended in sterile PBS 
and stored at –20°C.  
 
4.2.6 pCI-52LA construct  
  
A LAMP-1 targeting region was incorporated into the pCI-52 construct and designated as 
pCI-52LA construct (figure 4.1b).The pCI-52LA construct was generated by cloning a 
region of the LAMP-1 (1305-1412 nucleotides, accession number AY069968) and the 
mature region of the Der p 2 gene into pCI-5. The LAMP-1 targeting sequence was 
amplified as described in section 4.2.4 by using sense primer 5′-
CATAAAATCCGCGATTTGATCCCCATTG-3′ and anti-sense 5′-
CTATCTAGACTAGATGGTCTGATAGCCGGCGTG-3′. The mature Der p 2 coding 
sequence was amplified using sense primer 5′-GTTTCCGGAGATCAAGTCGATGTC-3′ 
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and anti-sense primer 5′-GGAAGCGGCCGCTAGATGGTCTGATAG-3′. Both 
amplified products were cleaned up by using GFX PCR DNA purification Kit and eluted 
in 30 µl of ddH2O. The LAMP-1 fragment was fused in-frame to the 5’ end of Der p 2 by 
PCR amplification. One microliter of each purified product was used as template. The 
primers used in this amplication were the sense primer of LAMP-1 and the anti-sense 
primer of Der p 2. The amplified product was cleaned up, enzyme restricted, gel purified 
and subsequently cloned in the pCI-5 construct as described in section 4.2.5.  
 
4.2.7 pCI-2 construct   
 
The mature coding region of Der p 2 gene was cloned into pCI vector and designated as 
pCI-2 construct (figure 4.1c). The mature Der p 2 coding region without a signal peptide 
was amplified as described in section 2.2.4 by using primers 5’-
AGCCTCGAGCCACCATGGATCAAGTCGAT-3’ and 5’-
CGCTTAAGAATTAGCGCCTAAAATCG-3’. The amplified product was cleaned up, 
enzyme restricted and gel purified as described in section 4.2.5. Five micrograms of the 
pCI vector was restricted with BspE I and Not I and gel purified as described above. The 
amplified product was cloned subsequently into the linearized pCI vector.  
 
4.2.8 Sequencing sample preparation and analysis 
 
The reading frame of the recombinant constructs were confirmed with DNA sequencing 
by using ABI-prism Big Dye termination reaction mix (PE applied biosystems) and 
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Perkin Elmer Automatic DNA sequencer. The PCR mixture was set up by adding 200 ng 
of template to 8 μl of Big Dye termination reaction mix and 1 μl of sense or anti-sense 
primer (10 pmol), and top up with ddH2O to 20 μl. The amplification condition was 25 
cycles of 95°C for 30 sec, 50°C for 15 sec and 60°C for 4 min. The reaction products was 
precipitated by adding 2 μl of 3 M NaOAc and 50 μl of 100% ethanol, and incubated at -
20˚C for 30 mins. The precipitant was centrifuged at 14,000 rpm for 20 min and washed 
with 250μl of 70% ethanol. Precipitant was left for air dry and added with 12 μl of Hi-
formamide (PE applied biosystems). The sequence was analyzed on an ABI PRISM™ 
377 DNA Sequencer with 5% polyacrylamide at 30 W constant power for 10 hrs. DNA 
sequence data was analyzed by using Bioinformatics Centre (BIC) programme at 
http://www.bic.nus.edu .sg/Resources.     
 
4.2.9 Immunization regimen 
 
To study the effect of different genetic background on Der p 2 gene immunization, 
BALB/cJ (H2 haplotype d), CBA/CaH (H2 haplotype k), C57BL/6J (H2 haplotype b), 
and AKR/J mice (H2 haplotype k) were immunized as described in section 4.2.3  on days 
0 and 14 with pCI-52 construct (figure 4.2a). Mice were bled weekly and sera were 
analyzed for Der p 2 specific antibodies by ELISA as described in chapter 2 section 2.2.4. 
CBA/CaH mice were sacrificed on day 21 and the spleens were harvested for short-term 
cultures. CD4+ T cells were enriched and re-stimulated with 10 µg of rDer p 2 protein as 
described below. Culture supernatants were collected at 48 hr, 72 hr and 96 hr. The 
immune responses of mice immunized with rDer p 2 protein without adjuvant were 
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studied by immunizing CBA/CaH mice with 10 µg of rDer p 2 protein on days 0, 4, and 8 
(figure 4.2b). This group of mice was used as a control for the protein immunization 
regimen. Sera were analyzed for Der p 2 specific antibodies by ELISA as described in 
chapter 2 section 2.2.4. For T cell study, immunized mice were sacrificed on day 10 for 
splenocyte cultures as described in chapter 2 section 2.2.5. The supernatants were 
collected at 72 hr and 96 hr, and T cell cytokine profiling was performed by ELISA as 
described in chapter 2 section 2.2.11.   
 
To study the effect of different Der p 2 gene constructs on CBA/CaH mice, mice were 
immunized with pCI, pCI-2, pCI-52 or pCI-52LA on days 0 and 14. Immunized mice 
were then subcutaneous injected with 10 μg of rDer p 2 for three times (figure 4.2c). 
Immunized mice were bled and sera collected were analyzed for Der p 2 specific 
antibodies by ELISA as described in chapter 2 section 2.2.4. For T cells study, the protein 
immunized mice were sacrificed on day 21. The spleens were collected for short-term 
cultures and dead cells were removed as described in chapter 2 sections 2.2.5, 2.2.6 and 
2.2.7. The cytokine profile of short-term culture T cells was performed on the 
supernatants collected at 72 hr and 96 hr by ELISA as described in chapter 2 section 
2.2.11.   
 
For DC transfer studies, mice were immunized with the respective DNA constructs at 
days 0 and 14. DNA immunized mice were sacrificed at day 21 and the DCs from the 
lymph nodes of DNA primed mice were used in the adoptive transfer experiments. The 
enriched DCs were injected intravenously into naive mice which were then subsequently 
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challenged with subcutaneous injections of rDer p 2 as shown in figure 4.2d. Sera 
collected were analyzed for Der p 2 specific antibodies by ELISA as described in chapter 
2 section 2.2.4. 
 
4.2.10 CD4 + T cells cytokine profiling  
 
The CD4+ T cells were enriched and the purity was determined as described in chapter 2 
section 2.2.12. The enriched CD4+ T cells showed at least 95% purity. To determine the 
cytokine production of CD4+ T cells, 50 µl of T cells (2X106 cells/ml) and 50 μl of APCs 
(6 X106 cells/ml) were added to 96-well U bottomed plate, followed by 100 µl of rDer p 2 
protein (20 μg/ml). The supernatants were harvested from the stimulated cells and 
assayed for the presence of IFN-γ and IL-4 by ELISA as described in chapter 2 section 
2.2.11.  
 
4.2.11 Isolation of dendritic cells 
 
Lymph nodes were collected from superficial cervical, axillary, brachial, sciatic and 
inguinal regions of the mice and digested in the PBS containing 100 U/ml of collagenase 
(Boehringer Mannheim, Mannheim, Germany) at 37°C for 30 min. Cells were collected 
and washed with 10 mls of 1X HBSS. The pellet was suspended in the PBS containing 5 
mls of EDTA (0.1 M) for 5 min at room temperature to disrupt DC-T cell complexes. 
Low-density cells were enriched by Optiprep media (AXIS-SHIELD PoC AS, Oslo, 
Norway) centrifugation as recommended by the manufacturer. The cells were blocked 
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with PBS containing 5% fetal calf serum and anti-mouse FcR (CD16/CD32) 
(PharMingen) for 20 min at 4°C. Next, the cells were washed with staining buffer, 
incubated for another 20 min at 4°C with anti-CD11c microbeads (Miltenyi Biotec). 
Subsequently, CD11c+ cells were sorted out using cell sorted AutoMACs and the 
program “positive selection 2”.  To determine the purity, a portion of the cells were 
stained with CD11c-PE (S-HCL-3)(Pharmingen). The purified DCs of approximately 
80% in purity were adoptively transferred to naïve mice via intravenous administration, 
at 1×105 DCs/mouse. 
 
4.2.12 Detection of circulating Der p 2 protein in sera 
 
Costar ELISA plates were coated with monoclonal anti-Der p 2 antibody (mAbC4) (Tsai 
JJ et al., 2000) diluted in coating buffer to a concentration of 2 μg/ml and incubated at 
4°C overnight.  After washing the plate with PBST, 100 µl of blocking buffer was added 
and incubated at room temperature for 2 hrs. The plate was washed again. Fifty 
microliters of the serially diluted rDer p 2 protein (standards) or diluted sera samples of 
immunized mice were added to the wells and incubated at 4°C overnight. The plate was 
washed and the biotinylated guinea pig anti-Der p 2 IgG was used at 250 ng/ml as the 
detection antibody. The plate was washed and ExtraAvidine Alkaline Phosphates 
(1:2000; Sigma) was added and incubated for 1 hr. Finally, the plates were washed and 
developed with 50 µl of Sigma Fast pNitrophenyl phosphatase substrate (Sigma) and 
optical density was measured at 405 nm on a microplate reader. The detection limit of 
this assay was 0.1 ELISA unit. The antiserum against Der p 2 was generated by 
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intradermal immunization of guinea pig with 50 μg of rDer p 2 in complete Freund’s 
adjuvant on day 0, and boosted with 50 μg of rDer p 2 in incomplete Freund’s adjuvant 
on days 10 and 20. The guinea pig IgG was purified by protein G Sepharose 4 fast flow 
(Amersham Biosciences AB, Uppsala, Sweden). The labeling of guinea pig IgG with 
biotin was performed using biotin hydroxysuccinimide ester (Sigma) according to the 
manufacturer’s instructions. 
 
4.2.13 Statistical analysis 
 
The significance between experimental groups was calculated by the Mann-Whitney U 




4.3.1 Differential immune responses were induced in mice with different genetic 
background  
 
To test whether the immune responses to Der p 2 gene bore strain specificity, 
immunizations were performed on mice strains BALB/cJ, C57BL/6J, AKR/J, and 
CBA/CaH on days 0 and 14. Der p 2-specific IgG1 antibody responses were detected in 
all mice strains starting from day 14 (figure 4.3a). CBA/CaH mice responded with high 
IgG1 production, which peaked at day 28 with 230,000 ± 78,000 ELISA units and 
sustained at 145,000 ± 52,000 ELISA units on day 35. Likewise, the IgG1 level in 
C57BL/6J mice peaked at day 28 with ~137,000 ± 56,000 ELISA units and dropped 
slightly to 118,000 ± 44,000 ELISA units on day 35. AKR/J and BALB/cJ mice 
responded consistently with IgG1 profiles of about 30,000 ELISA units on day 21 to day 
35.  
 
CBA/CaH mice responded with higher IgG2a levels of 14,000 ± 3,400 ELISA units on 
day 28 and enhanced to 19,000 ± 5,300 ELISA units on day 35 (figure 4.3b). The IgG2a 
response was similar in BALB/cJ and AKR/J mice, in which both showed slightly lower 
levels (~14,000 ELISA units), as compared to CBA/CaH mice  on day 35. There was a 
remarkably low production of IgG2a in C57BL/6J mice, with about 20-fold less than the 
rest. This might be due to the genetic deficit in producing IgG2a, and IgG2c should have 
been used as the readout for humoral response. While some detectable levels of IgE were 
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observed in CBA/CaH mice (0.25 ± 0.05 ELISA unit), the IgE titer was below detection 
limit in other groups (data not shown). These results indicated that genetic background 
has a certain impact on the magnitude of antibody production in response to the 
immunization with Der p 2 gene. CBA mouse strain was the best responder for Der p2 as 
shown by the production of the highest levels of IgG1 and IgG2a as compared to other 
strains, thus CBA strain was selected for the subsequent experiments. 
 
4.3.2 Th1 type cytokine responses were induced in DNA immunization  
 
To determine whether the Th1- or Th2-dominant cytokines are involved in genetic 
vaccination, CBA/CaH mice were immunized with pCI-52 and the CD4+ T cell cytokine 
profiles were compared to those from groups immunized with pCI vector or epicutaneous 
sensitized with 50 μg of rDer p 2 allergen. A model of Th2 response was established 
using the epicutaneous sensitization protocol as previously described in chapter 2 section 
2.2.3. The pCI-52 vaccinated group responded with high levels of IFN-γ (~ 6000 ELISA 
units) as compared to the control pCI (3000 ELISA units) (figure 4.4a). Hardly any IFN-γ 
levels were detected in the rDer p 2 sensitized group. The IL-4 secreted by the pCI-52 
group was reduced by 3-fold as compared to the rDer p 2 sensitized mice (figure 4.4b). 
Mice immunized with pCI-52 showed increased IFN-γ production and the magnitude of 
IL-4 was lower, as compared to other groups. The pCI group also elicited a high IFN-
γ/IL-4 ratio, an indication of Th1 response, because the CpG motif itself has an adjuvant 
effect that drives Th1 reaction. Overall, a Th1-skewed response was elicited in the pCI-
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52 group, as compared to the rDer p 2 sensitized mice, which showed a strong Th2 
response.  
 
4.3.3 Der p 2 specific IgE and Th2 responses in mice immunized with rDer p 2 
protein without adjuvant 
 
The naïve mice receiving three subcutaneous injections of 10 μg of rDer p 2 protein at 
days 0, 4 and 8 showed detectable and significant Der p 2 specific IgE at day 14 (0.76 ± 
0.19 ELISA units) and the IgE titers increased up to 3.66 ± 1.06 ELISA units at day 28 
(figure 4.5a). High levels of Der p 2 specific IgG1 (ranging from 1,700 - 3,000 ELISA 
units) were induced with the similar kinetics in these mice (figure 4.5b). There was no 
significant level of specific IgG2a detected in these mice (data not shown). Splenocytes 
from the protein immunized mice stimulated with rDer p 2 produced significantly higher 
levels of IL-4 and lower levels of IFN-γ as compared to PBS group (p < 0.05, figure 4.5c-
d), indicating that a typical Th2-skewed phenotype was induced in these mice. This well 
established immunization protocol is a potent strategy to induce antigen specific Th2 
responses without using any conventional adjuvant and is exploited in this study as a Th2 
challenge to mice immunized with the various DNA constructs.  
 
4.3.4 Der p 2 specific antibody responses in DNA immunized mice. 
 
The immunogenicity of the various DNA constructs expressing different forms of Der p 2 
antigen was compared in mice immunized with construct pCI-2, pCI-52 and pCI-52LA, 
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respectively.  Mice immunized with construct pCI-52 produced statistically significant 
and higher levels of IgG1 subclass as compared to other groups (p < 0.05, figure 4.6a). 
The IgG1 titer in these mice reached 23,600 ± 7,300 ELISA units on day 28, boosted at 
least 5-fold at day 49, and subsequently maintained at an average of 80,000 ELISA units. 
In contrast, the IgG1 production for the pCI-52LA construct was at relatively low levels 
of 1200 ELISA units until day 42, and rose to an average level of 20,000 ELISA units 
after protein challenge. The IgG1 production for pCI-2 immunized mice was consistently 
maintained at a range of 500-3,000 ELISA units. Mice immunized with the pCI vector 
DNA did not produce any Der p 2 specific antibodies and showed a background reading 
of about 20 ELISA units up to day 42. However, the three subcutaneous injections of 
rDer p 2 protein into the vector immunized control mice induced significant levels of 
specific IgG1 (about 300 ELISA units) from day 49 onwards, the kinetics of IgG1 
production correlated well with the kinetics of the specific IgE production in these mice 
as shown in figure 4.6a & 4.6c.  
 
For the specific IgG2a production, the initial profiles were almost similar in all DNA 
immunized mice, ranging from 1,000-2,000 ELISA units (figure 4.6b). Upon rDer p 2 
protein challenge, mice primed with pCI-2 or pCI-52 showed an approximate 10-fold 
increase in IgG2a titer (about 24,000 ELISA units) at day 56. The pCI-2 immunized mice 
subsequently displayed an average IgG2a titer of 15,000 ELISA units. Mice primed with 
pCI-52LA were found to generate predominantly higher titers of IgG2a than the rest (p < 
0.05), with an approximate 15-fold increase at day 56, and subsequently maintained at an 
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average of 80,000 ELISA units. Mice immunized with the pCI vector responded with an 
average background level of approximately 50 ELISA units after the protein challenge.  
 
Prior to the subcutaneous protein challenge, there were some detectable levels of Der p 2 
specific IgE titres in pCI-52 immunized mice (0.25 ± 0.05 ELISA units), and the specific 
IgE levels in pCI-2 and pCI-52LA immunized mice were below the detection limit of 0.2 
ELISA units in our IgE ELISA assays (figure 4.6c). After the protein challenge, mice that 
were immunized with construct pCI-2 had a slight elevation in specific IgE levels (0.32 ± 
0.15 ELISA units) while the control mice immunized with pCI vector DNA displayed 
IgE titers of about 1.5 ELISA units. The kinetics and profiles of the specific IgE and 
IgG1 production induced by 3 subcutaneous injections of rDer p 2 protein in the pCI 
vector control mice were very similar, but with reduced levels of antibodies, as compared 
to that of protein immunized control mice (figures 4.5a-b). The reduced levels of IgE and 
IgG1 seen in these pCI vector control mice were probably due to the Th1 adjuvant effects 
of the CpG motif present in the pCI vector backbone DNA.  It is well established that 
specific IgE levels are generally much lower than that of total IgE and the low but 
significant levels of specific IgE detectable by ELISA usually represent a reliable and 
meaningful indicator for Th2 responses. Nevertheless, T cells studies were then carried 
out to further characterize the phenotypes of the immune responses in these mice.  
 
4.3.5 T cell responses of DNA immunized mice 
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This study has shown that the pCI-52 construct could induce remarkably high levels of 
specific IgG1, moderate levels of IgG2a, accompanied by some detectable levels of 
specific IgE, suggesting that the immune responses primed by construct pCI-52 could be 
of a mixed Th1/Th2 phenotype. This had prompted us to perform further studies to 
characterize the T-helper type response by examining the T cell cytokine profiles. 
Splenocytes from the immunized and control mice were stimulated with rDer p 2 for 10 
days and then the enriched Der p 2 specific T cells were re-stimulated with rDer p 2 
protein. Culture supernatants were collected at 72 hr and 96 hr for IL-4 and IFN-γ 
analysis by ELISA. As shown in figure 4.7a, upon secondary stimulation with rDer p 2, 
IFN-γ in the culture supernatants of cells from pCI-52 primed mice was only detectable at 
96 hr time point (1.5 ± 0.3 ng/ml). Cells from pCI-52LA primed mice showed about 3-
fold increase in IFN-γ production (4.9 ± 0.4 ng/ml) as compared to that of pCI-52 and 
pCI primed mice (p <0.05) while cells from mice primed by pCI-2 construct produced an 
intermediate levels of IFN-γ (2.8 ± 1.3 ng/ml).  Low levels of IL-4 (approximately 20 
pg/ml, figure 4.7b) were detected in cell cultures of pCI-52, pCI and PBS primed mice. 
Induction of this basal level of IL-4 production was non-antigen specific and the cell type 
responsible for the IL-4 production was unclear. The IL-4 levels were much lower than 
that produced by the typical Th2-skewed cells (100-150 pg/ml; figure 4.5c). 
Nevertheless, this basal IL-4 production was greatly attenuated in cells cultures of the 
pCI-52LA and pCI-2 primed mice (p < 0.05).  
 
4.3.6 Adoptive transfer of DCs from pCI-52 vaccinated mice primed for IgE 
production  
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 The T cell cytokine data implied that the pCI-52 construct could induce immune 
responses of a mixed Th1/Th2 phenotype, but there was some ambiguity in the data 
obtained. This had prompted us to further address the question by carrying out the DCs 
transfer experiments. DCs from the various groups of DNA immunized mice were 
adoptively transferred to the naïve mice, which were subsequently challenged with three 
subcutaneous injections of rDer p 2 protein. Recipients of DCs from pCI-52 immunized 
mice showed a significant increase in Der p 2 specific IgE production, which peaked at 
10.3 ± 3.7 ELISA units  on day 35 (p < 0.05, figure 4.8a), with a corresponding increase 
in Der p 2 specific  IgG1 production (2,380 ± 1,030 ELISA units, figure 4.8b). IgE titers 
were maintained at an average of about 7 ± 2 ELISA units (p < 0.05) up to day 49. The 
induction profiles and kinetics of Der p 2 specific  IgE and IgG1 production were similar 
to the humoral responses of mice that only received three subcutaneous injections of rDer 
p 2 protein described earlier (as shown in figure 4.5a-b). However, a higher magnitude of 
IgE production was observed in mice receiving DCs from pCI-52-primed mice after the 
Th2 protein challenge as compared to the solely protein immunized control mice. The 
data suggested that there was some degree of augmentation of IgE production in mice 
primed by DCs from pCI-52-immunized mice.  
 
In contrast, such significant priming for specific IgE production was not observed in 
other groups of mice receiving DCs from pCI-52LA and pCI-2 immunized mice upon 
similar rDer p 2 protein challenge. It is also worth noting that mice receiving DCs of pCI 
immunized mice elicited relatively low levels of specific IgE (1.1-1.8 ELISA units) and 
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specific IgG1 (approximately 500 ELISA units). The magnitude of the Th2-skewed 
humoral responses in these mice was significantly lower than that seen in mice receiving 
the pCI-52-primed DCs and the control mice immunized with rDer p 2 protein only 
(figure 4.5a and 4.5b). This observation can probably be explained by the non-antigen 
specific suppressive effects on Th2 responses that were conferred by the CpG motifs of 
the pCI vector backbone DNA. Only low and insignificant levels of IgG2a were induced 
in all groups of mice (data not shown). 
 
4.3.7 Circulating Der p 2 protein detected in mice primed with pCI-52 
 
The results from the DCs adoptive transfer experiments strongly suggested that construct 
pCI-52 could prime a potent Th2-skewed response and induced strong specific IgE 
production. It is postulated that DCs in these mice could be sensitized by the significant 
levels of secretory Der p 2 produced endogeneously. To confirm this notion, detection of 
Der p 2 in mouse serum after DNA immunization was performed using Der p 2 sandwich 
ELISA.  As shown in figure 4.9, a significantly high level of circulating Der p 2 protein 
(700 ± 150 pg/ml, p < 0.001) was detected in the sera of mice immunized with construct 































Figure 4.1: Schematic diagram of the linear DNA constructs 
The mature coding region of Der p 2 was cloned into the pCI vector containing Der p 5 
leader sequence (LS) and designated as pCI-52 construct (a). A LAMP-1 targeting region 
was incorporated into the pCI-52 construct and designated as pCI-52LA construct (b). 
The mature coding region of Der p 2 gene was cloned into the pCI vector and designated 













































Figure 4.2: Schematic diagram on the experimental regimens. 
BALB/cJ, CBA/CaH, AKR/J and C57BL/6J mice were immunized via intramuscular 
route with pCI-52 construct on days 0 and 14. CBA/CaH mice were sacrificed on day 21 
for splenocyte cultures (a). CBA/CaH mice were subcutaneously primed with 10 µg of 
rDer p 2 on days 0, 4 and 8. Immunized mice were sacrificed on day 10 for splenocyte 
cultures (b). CBA/CaH mice were immunized via intramuscular route with DNA 
constructs (pCI, pCI-2, pCI-52 or pCI-52LA) on days 0 and 14. On days 35, 39 and 43, 
mice were challenged by subcutaneous injection with 10 μg of rDer p 2. Mice were also 
bled on day 17 for the quantitation of circulating Der p 2 protein by ELISA. Immunized 
mice were sacrificed on day 21 for the splenocyte cultures and the isolation of DCs from 
lymph nodes (c). Naïve CBA/CaH mice were adoptively transferred with enriched DCs 
from the respective DNA primed mice by the intravenous route and subsequently 
challenged with rDer p 2 on days 13, 17 and 21 (d). All mice were bled weekly and sera 
were collected for Der p 2-specific immunoglobulin analysis by ELISA. 
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Figure 4.3: Kinetics of Der p 2-specific antibodies in BALB/cJ, C57BL/6J, AKR/J 
and CBA/CaH mice immunized with pCI-52 DNA construct. Immunization was 
performed on days 0 and 14 with 50 μg of pCI-52 DNA construct followed by in vivo 
electroporation. Sera were collected and assayed for IgG1 (a) and IgG2a (b) by ELISA. 























































Figure 4.4: Cytokine production of CD4+ T cells stimulated with rDer p 2 protein.  
Mice were immunized with pCI or pCI-52, or epicutaneously sensitized with 50 μg of 
yeast recombinant Der p 2 protein (Sen Dp2). Mice were sacrificed for splenocyte 
cultures with rDer p 2 protein for 10 days. CD4+ T cells were isolated and re-stimulated 
with rDer p 2 protein. Culture supernatants were collected at 48 hr, 72 hr and 96 hr for 
IFN-γ (a) and IL-4 (b) cytokine analysis. Data illustrated the representation of two 


































































Figure 4.5: Specific immunoglobulin responses and splenic cytokine profile of mice 
immunized with rDer p 2 protein. Mice were administered with 10 μg of rDer p 2 
protein on days 0, 4, and 8 via subcutaneous route and monitored for Der p 2 specific IgE 
(a) and IgG1 (b) production. To assay for splenocytes cytokine profile, mice were 
similarly immunized and spleens were harvested on day 10. Splenocytes were cultured 
with 10 μg/ml of rDer p 2 and supernatants were collected at 72 hr and 96 hr for IL-4 (c) 
and IFN-γ (d) assays. Results shown are mean ± s.e.m., n = 4-5 per group. *compared 
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Figure 4.6: Specific immunoglobulin responses of mice immunized with DNA 
constructs and challenged with rDer p 2 protein. Mice were immunized with 50 μg of 
pCI-52, pCI-2, pCI-52LA or pCI vector on days 0 and 14, and challenged with 10 μg of 
rDer p 2 protein on days 35, 39 and 43. Mice were bled and sera were monitored for Der 
p 2 specific IgG1 (a), IgG2a (b) and IgE (c) production. Results shown are mean ± s.e.m., 
n = 5 per group. *compared with pCI, pCI-2 or pCI-52LA, # compared with pCI, pCI-2 

































































Figure 4.7: Splenocytes cytokine production of DNA immunized mice.  
Mice were immunized with DNA plasmids or PBS on days 0 and 14. Spleens were 
harvested on day 21 and splenocytes were cultured with 10 μg/ml of rDer p 2. Der p 2-
specific cells were harvested on day 10 and re-stimulated with rDer p 2 protein. Culture 
supernatants were collected at 72 hr and 96 hr, and assayed for IFN- γ (a) and IL-4 (b) 
production. Results shown are mean ± s.e.m., n = 4-5 per group. * compared with pCI, 
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Figure 4.8: Humoral responses of mice adoptively transferred with DNA primed 
DCs. Mice were immunized with DNA constructs on day 0 and 14. DCs isolated from 
the lymph nodes of DNA primed mice were adoptively transferred into the recipient mice 
at 1X105 DCs /mouse. Recipient mice were challenged with 10 μg of rDer p 2  protein on 
days 13, 17 and 21. Mice were bled and sera were analyzed for Der p 2 specific IgE (a) 
and IgG1 (b) production. Results shown are mean ± s.e.m., n = 5-8 per group. * 















































Figure 4.9: Quantitation of circulating Der p 2 protein in immunized mice.  
Mice were immunized with 50 μg of pCI-52, pCI-2, pCI-52LA or pCI vector on days 0 
and 14. Sera were collected on day 0 and 17 for the detection of rDer p 2 protein by 
sandwich ELISA. Results shown are mean ± s.e.m., n = 7-11 per group. * compared with 




The induction of an immune response to a protein expressed in vivo, directly from an 
administered DNA vaccine, represents an attractive approach for the prophylaxis of 
allergic disease. In this study, electroporation technology was employed to investigate the 
genetic immunization with plasmid DNA encoding for the Der p 2 allergen. In vivo 
electroporation is a simple, inexpensive method with low intrinsic toxicity (Tsong TY et 
l., 1991). It has shown to aid in efficient gene transfer into muscle with high levels of 
protein expression (Aihara H and Miyazaki J, 1988). Mathiesen (1999) pointed out that 
both muscle damage at the site of electroporation and the subsequent regeneration were 
not involved in enhanced transfection efficiency. These reports all verified that this 
strategy could overcome the barrier of DNA cellular uptake that hindered the efficacy of 
the DNA vaccine. 
 
This study has evaluated the effects of DNA immunization with the Der p 2 gene alone, 
Der p 2 gene fused with Der p 5-derived signal peptide sequence, and Der p 2 gene fused 
with the signal peptide plus the LAMP-1 targeting sequences on the basis of both 
humoral and cellular responses. The signal peptide sequence of the Der p 2 gene was 
replaced with that of the Der p 5, as it has been previously shown that the Der p 5 gene 
vaccination led to induction of high levels of antigen specific Th1 skewed protective 
immunity (Hsu CH et al., 1996). Furthermore, incorporation of the Der p 5 signal peptide 
sequence in the Der p 1 gene immunization resulted in an enhanced in vivo expression of 
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Der p 1 protein in transfected muscle cells (Wolfowicz CB et al., 2003), thus making it 
an ideal candidate signal peptide sequence for this study. 
 
While immune responsiveness in protein-based immunization (i.e., the generation of 
antibody, CTL, and helper T cells) has been proven to depend upon differences in the H2 
haplotypes of the MHC (McDevitt HO et al., 1972; Heber-Katz E et al., 1983), this study 
has shown that MHC haplotypes have only partial influence on the immunogenicity to 
the Der p 2 gene. Although CBA/CaH and AKR/J mice bear similar haplotypes H-2k, 
these two groups of mice responded with variable levels of Der p 2-specific antibody 
production. CBA/CaH mice induced larger amounts of IgG1 as compared to AKR/J, but 
both elicited similar amounts of IgG2a. C57BL/6J mice (H-2b haplotype) produced huge 
amounts of IgG1 with low levels of IgG2a, while BALB/cJ (H-2d haplotype) appeared to 
have similar antibody profiles as AKR/J mice. These data indicate that these mice have 
no clear lineage of strain-dependent antibody responses.  
 
Considering that mice could elicit diverse immune responses to various antigens and their 
susceptibility to some pathogens are known to be controlled by H-2 and non-H-2 genes 
(Shreffler DC et al., 1975), their immune responsiveness to Der p 2 gene has to be further 
validated with other genetic factors instead of relying on the MHC haplotype alone. Tools 
that can be used to identify the genetic factors that contribute to the atopy-related 
phenotypes include gene-targeted mice, genetic and physical mapping. Differential 
immune reactions among various mouse strains are primarily attributable to differences 
in MHC genes. However, several observations suggest the involvement of other 
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genetically linked loci to atopy-related phenotypes (Heinzmann A and Daser A, 2002), 
such as the Tcrvb8, IL-4 and interferon-γ genes (Venugopal G et al., 1995), the IL-5R 
chain (Daser A et al ., 2000), IL-4R allotypes (Schulte T et al., 1997), the differential 
regulation of antigen presentation in high and low IgE responder mice (Rizzo LV et al., 
1991) and the deficiency of critical constituents that contribute to natural airway 
hyporesponsive mice (Drazen JM et al., 1996), had been reported. 
 
The administration of pCI-52 into CBA/CaH mice elicited a mixed Th1 and Th2 immune 
responses with detectable IgE in some mice, or at least a Th1 response with a large 
amount of IgG1. This is in contrast to previous DNA vaccination studies, which induced 
mainly a Th1 response with a high IgG2a response, low amounts of IgG1, and no 
detectable IgE (Hsu CH et al., 1996; Peng HJ et al., 2002). However, some studies have 
found that IgE can also be detected after genetic immunization. The administration of a 
plasmid encoding bovine beta-lactoglbulin (BLG) could elicit BLG-specific IgE in some 
mice (Adel-Patient K et al., 2002), which was correlated to the quantity of IgG1. Chatel 
et al., (2003) have also demonstrated that immunization with peanut allergen pAra h 4 
resulted in a Th2 biased with high levels of IgG1 and even presence of IgE. The CD4+ T 
cell cytokine profiling of pCI-52 immunized mice showed that Th1 response was 
induced. This is evident by the large amounts of IFN-γ production and suppression of a 
level of IL-4 as compared to the epicutanous sensitized model. The epicutanous 
sensitized murine model has been reported to elicit large amounts of IgG1 and IgE, with a 
strong Th2 cytokine profile (Huang CH et al., 2003). DNA plasmid basically contains 
non-coding DNA sequences (CpG motifs) that can activate cellular components of innate 
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and adaptive immunity and that play an important role in anti-allergy immune responses 
(Sato Y et al., 1996). The anti-allergy properties of CpG motifs are attributed to IFN-αβγ 
and IL-12-induced Th1 immune responses. Polarized Th1 cells further produced IFN-γ, 
which in turn inhibits IL-4 production and down-regulates IgE synthesis, blocking the 
release of inflammatory mediators (Thalhamer J et al., 2001). Thus, the Th2 response in 
pCI-52 immunized mice might be suppressed by the CpG motif in the plasmid backbone, 
which accounts for the low, yet detectable, levels of IgE in some mice.  
 
The possibility that in vivo electroporation dictated the Th2 response in pCI-52 
immunized mice was ruled out, as previous studies have shown that electric pulses have 
no influence in the IgG1/IgG2a ratio and could not affect the cytokine environment of the 
APCs involved in the response (Bachy M et al., 2001; Widera G et al., 2000). It has been 
argued that IgG1 has been referred to as a Th2 antibody. However, there have been 
studies that indicated IL-12-dependent IgG1 production has non-anaphylatic potential, as 
compared to those induced by IL-4 (Faquim-Mauro EL et al., 1999, 2000). As there was 
a low level of IL-4 in the pCI-52 immunized mice, it is uncertain if the IgG1 anti-Der p 2 
induced in this experiment was IL-4 or IL-12 driven, and needs further clarification.   
 
It is well established that the backbone sequences of plasmid DNA vectors containing 
ISS or CpG motifs that enhance Th1-skewed responses (Zelenay S et al., 2003). Previous 
studies demonstrated that allergen gene vaccination by the intramuscular route induced 
Th1-skewed responses and inhibited IgE production (Kwon SS et al., 2001; Hsu CH et 
al., 1996; Wolfowicz CB et al., 2003). This study has revealed that mice immunized 
 193
intramuscularly with the pCI-52 construct exhibited a mixture of Th1 and Th2 responses, 
an unexpected observation. Priming of Th2 responses in pCI-52 primed mice was first 
indicated by production of low but detectable levels of Der p 2 specific IgE and 
significant levels of specific IgG1. It was further confirmed by DC adoptive transfer 
experiments and the detection of circulating Der p 2 protein in the mouse sera. It is 
proposed that the Der p 5 derived signal peptide  facilitated a high level expression of Der 
p 2 in vivo, resulting in leakage or secretion of Der p 2 into systemic circulation, creating 
a microenvironment with high level of circulatory Der p 2 protein. The APCs such as 
DCs could then be exogenously primed and conferred Th2 sensitizing effects mimicking 
an exposure to aeroallergen. Such APCs could be endowed with the Th2 triggering 
capability but their effects could be partly suppressed by the CpG mediated-Th1 response 
resulting in a mixed Th1/Th2 phenotype in the pCI-52 immunized mice. It has been ruled 
out the possibility of interfering effects of T cells and B cells in this study, as adoptively 
transferred T cells or B cells failed to induce any significant IgE production upon Th2-
skewed protein challenge (data not shown), indicating that the IgE response was induced 
by the transferred DCs only. It has been reported that antigen-pulsed DCs could 
exacerbate asthmatic features (Lambrecht BN et al., 2000; Sung S et al., 2001; Graffi SJ 
et al., 2002) and play an important role in the pathogenesis of allergic disease (Jiang C et 
al., 2002; Barouch DH et al., 2004). The administration of OVA-pulsed myeloid DCs to 
the airways of naive animals induced sensitization to OVA, leading to a vigorous Th2 
response after re-challenge of the airways with OVA aerosol (Lambrecht BN et al., 2000; 
Sung S et al., 2001; Graffi SJ et al., 2002). Furthermore, vaccination with OVA-pulsed 
bone marrow DCs or Langerhan cells did not reduce allergen-specific Th2 responses in a 
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murine model of severe atopic asthma (Trujillo-Vargas CM et al., 2005). Taken together, 
these data clearly indicated that the use of a strong signal peptide in DNA construct is 
highly unfavorable for allergen DNA vaccine design as this priming could potentially 
lead to undesirable Th2 sensitization. 
 
This study has demonstrated that DNA vaccines that encode the Der p 2 allergen gene 
fused with a N-terminal signal peptide and a C-terminal LAMP-1 targeting sequence 
could enhance a strong antigen-specific Th1 response. The LAMP-1 is a type I 
transmembrane protein localized predominantly to lysosomes (Chen JW et al., 1985, 
1988). It has been well established that the LAMP-1 targeting sequence could direct the 
targeting of the endogenously synthesized protein antigen to an endosomal/lysosomal 
vesicular pathway in the transfected APCs and enhanced the delivery of the antigen to the 
MHC II compartment of APCs such as DCs (Wu TC et al., 1995). In this study, contrary 
to pCI-52 and when compared to pCI-2 and pCI vector control, pCI-52LA DNA priming 
displayed the highest IFN-γ and IgG2a production upon receiving a protein challenge.  
This strong Th1 response has also been reported in the efficacy study of DNA vaccines 
containing LAMP (Kim TW et al., 2003; Marques ET Jr et al., 2003; de Arruda LB et al., 
2004). Using LAMP for targeting human papillomavirus E7 to the subcellular 
compartments has led to enhanced vaccine potency by stimulating E7-specific CD4+ Th1 
cell response (Kim TW et al., 2003). The incorporation of the lysosome-targeting signal 
in HIV gag DNA vaccines has been shown to promote long-term CD4+ and CD8+ T 
cells memory response and strong antigen-specific Th1 response, as compared to 
constructs lacking LAMP (Marques ET Jr et al., 2003; de Arruda LB et al., 2004). In this 
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study, pCI-52LA construct was capable of cellular retention of Der p 2 expressed in vivo, 
and triggered a strong Th1-skewed response. Although the pCI-2 construct lacking 
secretory signal peptide might also result in cellular retention of Der p 2, a lower 
magnitude of Th1 response was induced. Specific targeting of the expressed Der p 2 to 
the lysosomal compartment conferred by the pCI-52LA construct greatly enhanced the 
magnitude of Th1 responses after the protein boost. Furthermore, this data revealed that 
the pCI-2 construct immunization may not induce fully protective immunity in view of 
the fact that some IgE was produced and the magnitude of Th1 responses was relatively 
lower than that induced by pCI-52LA construct upon the protein challenge.  This is 
probably due to the specific MHC II targeted compartment of transfected APCs that 
enhanced the CD4+ mediated response, whereas cytoplasmic protein that lacks targeted 
signaling will be processed and present to MHC I and, thus, less effective in eliciting 
MHC II responses (de Arruda LB et al., 2004).  
 
This study demonstrated that the use of a strong signal peptide could lead to an enhanced 
level of circulating allergen that primed Th2-skewed responses, and such risk could be 
eliminated by the incorporation of the intracellular targeting sequences to direct the 
allergen into the lysosomal compartment to induce strong Th1 responses without the 
concurrent induction of Th2 responses. It is worth noting that the priming of the masked 
Th2 responses by pCI-52 was not clearcut in the primary responses seen in mice, rather 
the DC adoptive transfer experiments clearly revealed that such DNA vaccination 
approaches could sensitize mice to produce specific IgE upon subsequent encounters with 
allergen. Previous proof of concept studies showed that DNA construct encoding the full 
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length Der p 5 gene could induce strong and protective Th1-skewed responses, which 
could inhibit IgE production and Th2-mediated physiopathologies (Hsu CH et al., 1996).  
However, the potential risk of such construct concurrently priming for low levels of Th2-
skewed responses, which could be easily masked by the much stronger Th1-skewed 
responses, has not been fully addressed using the DCs adoptive transfer approach 
describes in the current study.  The findings derived from the current study caution 
against the use of signal peptide sequences in the design of DNA constructs for 
vaccinations against allergic diseases. In addition, this study has shown that the 
incorporation of an intracellular targeting signal sequences in DNA vaccine construct 
could promote a safer and more efficacious responses against allergic reactions. 
Furthermore, the use of a DNA-prime and protein boost strategy could potentially 
enhance Th1 responses, representing a useful strategy to augment the efficacy of DNA 








It is well documented that the antigens of house dust mites such as Dermatophagoides 
pteronyssinus represent a major cause of type 1 allergies worldwide (Arlian LG et al., 
2001). To date, allergen-specific immunotherapy is the only treatment able to cure 
allergic diseases (Akdis M et al., 2005). Allergen–specific immunotherapy is 
conventionally performed using allergic proteins; recently preclinical studies 
demonstrated that allergen gene-immunization could induce allergen-specific protective 
immunity against allergic reactions. A major area that deserves more research is the 
elucidation of the underlying mechanisms for the efficacy of such treatment. To better 
understand the cellular and molecular mechanisms of allergen-specific immunotherapy, 
the immunological responses and the mechanisms of mice immunized with Der p 2 
protein or Der p 2 gene were evaluated.   
 
The first part of the study has demonstrated the immune responses of murine model in 
which an indoor aeroallergen is capable of triggering antigen specific, dosage-dependent 
immune response in an adjuvant-free approach. Mice primed with D10 of rDer p 2 
protein reacted with elevated IgE titer, low IgG1 production and also displayed increased 
Th2 cytokine production. On the other hand, a suppressed Th2 response, along with low 
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basal level of IgE titer and high IgG1 production were detected in the D50 immunized 
mice. It is proposed that D50 immunization induced the development of Treg cells, as 
evident by the increased production of TGF-β1 and IL-10 as compared to D10 
immunized mice and PBS control mice. Furthermore, the in vitro culture of antigen-
specific Th2 cells showed suppressive effect in proliferation responses and cytokine 
production upon co-culture with splenic CD4+CD25+ T cells from the D50 immunized 
mice. This study has also suggested that IL-13 is a critical factor for IgE synthesis in the 
protein immunized mice primed by subcutaneous route. Its deficit in the early and 
effector stages of D50 immunized mice, possibly as a result of Treg cells development, 
has account for the failure to induce and sustain the in vivo production of IgE production 
as compared with the D10 immunized mice. A significantly suppressed production of IL-
13 was seen in the Der p 2-specific Th2 cells induced by CD4+CD25+ T cells of D50 
immunized mice but not other groups. Furthermore, the IL-13 gene expression was 
attenuated in the D50 immunized mice as compared to others after aerosol challenge. The 
abrogation of serum IL-13 in D10 immunized mice by neutralizing study has shown a 
significant decrease in IgE production, regardless of the presence of IL-4, as compared to 
the control. Altogether, these studies have suggested that D50 priming induced the 
development of Treg cells and hindered the IL-13-dependent IgE synthesis.  
 
To elucidate the molecular mechanisms involved in the antigen dosage effects on the 
differential immune responses, DNA microarray approach was adopted to identify the 
differentially expressed genes and delineate the molecular events that dictate the dosage 
dependent-immune responses. The induction of Treg cells in D50 immunized mice was 
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further supported by differential gene expression of MGAT5, TGF-β related genes and 
genes that are associated with TGF-β pathway. An upregulated expression of MGAT5 
gene in the D50 immunized mice might signify an increase in T cell activation threshold 
and establish the regulatory or tolerance response via TGF-β signaling pathway, while a 
decrease of MGAT5 gene expression in D10 immunized mice might involve in lowering 
of T cell activation threshold and preferentially drive Th2 type responses. TβRII gene 
was up-regulated in D50 mice. TβRII is an essential receptor in the mediation of TGF-β 
signaling pathway, thus an upregulation of this receptor might indicate a turn-on of the 
TGF-β signaling pathway. Correspondingly, the increased expression of Tgfβ1i4 might 
be induced as a result of TGF-β1 production.  TGF-β1 has shown to decrease the Rad51 
expression and reduce Rad51-mediated DNA repair efficiency to promote DNA 
instability (Kanamoto T et al., 2002), however, it is unclear about the association of 
Rad51AP1 with TGF-β regulatory response in D50 immunized mice. The activin 
signaling pathway involved the interaction of ARIPI with activin receptors and Smad3 to 
form a quaternary complex (Shoji H et al., 2000). Thus, the reduced ARIP gene 
expression might indicate a reduction in competition for TGF-β signaling pathway or an 
interference with the physiological regulation of signal transduction. BMP4 has a positive 
role in the proliferation of hematopoietic progenitor cells while TGF-β plays a negative 
regulatory function, thus the suppressed BMP4 gene expression in D50 immunized mice 
might be due to the increased production of TGF-β production. The increased expression 
of Rerg gene might imply its inhibitory action on the cell proliferation response and that 
correspond with the  TGF-β induced regulatory response in D50 immunization.  
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The decreased in expression of NFAT5, Peli1 and ICAM-1 genes in D50 immunized 
mice corresponded with the suppressed Th2 response and the low basal IgE titer. NFAT 
transcription factor is necessary in the activation of CD4+ T cells and essential in 
development of a Th2 immune response in vivo, thus the reduced NFAT5 gene 
expression might account for the suppressed Th2 response in D50 immunized mice. Peli1 
gene is reported to be involved in the IL-1 mediated signaling that drives Th2 activation 
(Jiang Z et al, 2003; Nakae S et al., 2003; Nambu A et al, 2006). ICAM has been shown 
involved in the regulation of IgE synthesis by modulating C epsilon germ-line 
transcription (Katada Y et al., 1996) and its deficiency has shown a reduction of 
immediate-type hypersensitivity response and decrease in serum IgE production 
(Shimada Y et al., 2003). Taken together, these observations suggested that D50 priming 
could induce the development of Treg cells and impair Th2 response. 
 
RAB27a and SNAP25, which were both upregulated in the D10 immunized mice, have 
been reported to be essential in the docking step of regulated exocytosis (Tsuboi T and 
Fukuda M, 2005). RAB27a is required for the secretion of lytic granules in cytotoxic T 
lymphocytes (Tolmachova T et al., 2004) and SNAP25 is a pre-synaptic target for the 
depressant action of reactive oxygen species on transmitter release (Giniatullin AR et al., 
2006). The correlation of the exocytotic genes in Th2 responses or atopy has been 
previous reported and recapitulated in this study.     
 
Intriguingly, several genes that are associated with innate immunity and host defense 
have been downregulated in D10 immunized mice. These include SWAM2 that has 
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antibacterial activity (Hagiwara K et al., 2003), and CRISP1 that plays a role in 
nonspecific host defense (Haendler B et al., 1999). Proteins derive from secretory gland 
that may function as nonimmune antimicrobial agents include Smr1, Dcpp, PIP and PSP.  
 
The array data have also identified several genes that are involved in the Wnt signaling 
pathway. They include Fzd3, Dte, Pcdh8, Peg12/Frat3 and Map3k7/TAK1. The 
association of these genes with the immune responses of the Der p 2 immunized mice 
remains unclear, but there is possible association of these genes with the role of Wnt 
signaling pathway in the proliferation and/or survival of B and T cells (Qiang YW and 
Rudikoff S et al., 2004; Timm A and Grosschedl R, 2005; Dosen G et al., 2006). The 
connection of Wnt and TGF-β signaling pathways emerged at LEF1/TCF target genes, 
suggesting that the cooperation between these pathways may be important for the 
specification of cell fates during development (Letamendia A et al., 2001). Indeed, 
Map3k7/TAK1, one of the genes found decreased in gene expression level in the array 
data of D10 mice, has been reported to be associated in both Wnt signaling pathway and 
impaired development of Treg cells. 
 
As an alternative to the administration of protein allergens, vaccination with allergen-
gene has been proposed as a strategy for SIT.  In second part of the study, I aimed to gain 
deeper understanding of the mechanisms underlying genetic vaccination in mice. Mice 
were immunized with plasmid encoding different forms of Der p 2 protein, followed by 
in vivo electroporation. Firstly, the influence of genetic background on Der p 2 gene 
immunization was examined in BALB/cJ (H2 haplotype d), CBA/CaH (H2 haplotype k), 
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C57BL/6J (H2 haplotype b) and AKR/J (H2 haplotype k) mice by immunization with 
DNA construct containing Der p 2 gene with signal peptide sequence (pCI-52). The 
antibody profiles indicated that differential immune responses were induced in mice with 
different genetic background. These mice showed no clear lineage of strain-dependent 
antibody responses and their immune responsiveness to Der p 2 gene has to be further 
validated with other genetic factors instead of relying on the MHC haplotype alone. The 
CD4+ T cell cytokine profiling of pCI-52 immunized mice showed high levels of IFN-γ 
production and but suppressed IL-4 production. These results also indicated that 
administration of pCI-52 into CBA/CaH mice elicited a mixed Th1 and Th2 phenotype 
with detectable IgE in some mice.  
 
Next, the immunological impact and potential risks of incorporating signal peptide 
sequences in DNA constructs were evaluated by studying the effects of DNA 
immunization with the pCI-2, pCI-52 and pCI-52LA constructs. CBA/CaH mice 
immunized with pCI-52LA showed strong and clear-cut Th1-type response, as evident by 
high IFN-γ production and elevated levels of Der p 2-specific IgG2a production whereas 
construct pCI-2 induced only moderate levels of Th1 response. The mixed Th1 and Th2 
phenotype was further validated in mice immunized with construct pCI-52 as they 
produced substantial circulating Der p 2 protein. Mice adoptively transferred with DCs 
primed by pCI-52 construct, but not by the pCI-2 or pCI-52LA constructs, were 
sensitized to produce high levels of Der p 2-specific IgE. Increased expression of 
secretory form of antigens encoded by DNA vaccines has been regarded as an important 
factor in eliciting a strong immune response, however, this study has highlighted the 
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potential risk of incorporating a strong signal peptide sequence that facilitated a high 
level expression of Der p 2 in vivo, resulting in leakage or secretion of Der p 2 into 
systemic circulation that provoked a masked Th2 response, resulting in pre-sensitization 
of DNA vaccinated mice. The additional inclusion of lysosomal-targeting sequences to 
such construct, however, could improve the safety and efficacy of DNA vaccination 
against allergy.  
 
In summary, the results from the first part of the study have shed light on the mechanistic 
action of protein immunization using Der p 2 allergen in mice and contributed valuable 
information for the development of a better efficacy vaccine. The Der p 2 gene 
vaccination study has revealed its potential in suppressing Th2 response and provides a 
better understanding on the potential risk in the induction of masked Th2 response. The 
information generated in both protein and gene vaccinations has revealed that these 
approaches hold promise to become effective therapeutic strategies in suppressing the 






There are several aspects in this study that require further investigation: 
 
1. This study has shown that priming with 50 μg of Der p 2 allergen could induce the 
development of Treg cells. Further phenotypic and functional characterizations of these 
antigen-specific CD4+CD25+ T cells are essential as this information will provide 
important knowledge in peripheral tolerance and modulation of the immune responses in 
allergy individuals.  
 
2. The induction of Treg cells and a deficiency in IL-13 production has been proposed to 
be responsible for the low basal IgE antibody responses in D50 immunized mice. 
Additional study is required to verify whether there is a direct involvement of TGF-β 
regulatory activity in the IL-13 production and/or in the selective manipulation of 
antibody responses. This information will be useful for future development of therapeutic 
strategy.  
 
3. Functional studies are required to determine the importance of the various novel Th2-
associated genes in allergic responses and also the regulatory genes that are possibly 
deficit in allergy phenotype. For instance, the protein expression profiles of the candidate 
genes in the allergen-stimulated PBMC of normal or allergic individuals can be evaluated 
by western blot, fluorescence activated cell sorting (FACS), and immunohistochemical 
methods. The functional characterization of the novel candidate genes can also be 
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assessed by using transgenic mice, knockout mice or functional assays with the use of 
blocking or neutralizing antibodies in wildtype mice. The functional characterization of 
the novel candidate genes will provide useful information for further development   of 
these candidate genes as potential biomarkers for atopy related disease or as potential 
targets for the intervention of allergic disease development. 
 
4. Der p 2 gene vaccinations in different mice strains has been shown variable humoral 
responses and H2 haplotype is not the key factor that influences these responses. Further 
studies are required to elucidate the genetic factors that affect the quality of the antibody 
responses. This will provide valuable information on the choice of animal strain to be 
used in the future allergen gene vaccination.   
 
5. The Der p 2 construct that contains LAMP targeting sequence has been shown to 
induce a strong favorable Th1 response. However, due to time constraint, the mechanistic 
actions that dictate the immune responses have not been evaluated. Further study should 
be conducted to address whether the antigen-specific antibodies and CD8+ T cells 
induced in this immunization confer any protective roles. This will provide valuable 
information for better development of the gene vaccination.         
 
6. This study has evaluated the immune responses induced by the Der p 2 construct that 
contains LAMP targeting sequence in CBA/CaH mice. However, the efficacy study of 
this construct in the protection against allergic response has not been evaluated. This is 
due to the fact that this mouse strain is least susceptible to development of AHR (Brewer 
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JP et al., 1999).  Other mice strains that are better models for AHR measurement should 
be used to assess the effectiveness of this construct for the protection against allergic 
disease.   
 
7. Improvement on DNA vaccines for allergy treatment can be achieved by modifying the 
gene constructs. These include adapting the sequence of allergen gene to mammalian 
codon usage, DNA coding for hypoallergenic allergen derivatives i.e. fragments, mutants 
and minigenes, generating several different allergen-epitope fusion molecules, using 
allergen-cytokine fusion molecules and co-application of cytokine genes to balance up 
the Th1/Th2 ratio. Critical evaluations of the immunological mechanisms induced by 
these new constructs are essential to ascertain the protective response generated in gene 
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Appendix 1: Reagents for microarray study 
 
12X MES Stock 
 
MES-free acid monohydrate (Sigma-Aldrich) 1.22M  70.4g 
MES Sodium Salt (Sigma-Aldrich)   0.89M  193.3g 
Mix and adjust volume to 1L using DEPC water. Adjust pH to 6.5 and 6.7. Filter through 
a 0.2 µm filter. 
 
2X Hybridization Buffer 
 
MES     200 mM 8.3 ml of 12X MES Stock 
NaCl      2 M  17.7 ml of 5M NaCl 
EDTA     40mM  4.0 ml of 0.5 M 
Tween 20    0.02%  0.1 ml of 10% Tween 20 
DEPC water      19.9 ml 
Adjust to 50mls. Do not autoclave. Store at 2°C to 8°C. Shield from light.  
 
Non-Stringent Wash Buffer 
 
SSPE     6X SSPE 300 ml of 20X SSPE 
Tween-20    0.01%  1.0 ml of 10% Tween-20 
Top up with 699ml of DEPC water. Filter through a 0.2 µm filter 
 
Stringent Wash Buffer 
 
MES     100 mM 83.3 ml of 12X MES Stock  
NaCl     0.1M  5.2 ml of 5M NaCl 
Tween-20    0.01%  1.0 ml of 10% Tween 20 
Top up with 910.5ml of DEPC water to1L. Filter through a 0.2 µm filter. Store at 2°C to 
8°C and shield from light. 
 
2X Stain Buffer 
 
MES      200mM 41.7 ml of 12X MES Buffer 
NaCl     2M  92.5 ml of 5M NaCl 
Tween 20    0.05%  2.5 ml 10% Tween 20 
water 
Top up with 113.3ml of DEPC water to 250ml. Filter through a 0.2 µm filter. Store at 













LOG         LOG          LOG 
(D50/D10)  (D50/PBS)  (D10/PBS) 
BC031806  Smr1 
AB036743  Cst10 
AF276975  Swam2 
AK029642  Amy1 
AF079834  Car6 
AK009449  Crisp1 
BC024627  Dcpp 
BC014718  Dnase1 
AB017907  Pip 
AK009032  Psp 
XM_355790  Sec15l2 
AF288379  Klra20 
AF109633  Etv1 
AF257061  Mbp 
BC002039  Fxyd3 
BC095996  Tbrg3 
NM_029404  Phf14 
AF144133  Nisch 
AB057759  Mlph 
NM_201227  Dte 
AB001489  Pigr 
AF231125  Pcdh8 
AF148857   Peg12 
AF513619  Fancl 
NM_198634  Tigd3  
AY069926  Sox21 
AF474154  Mgat5 
BC011472  Kdelr3 
AK034795  Vat1 
NM_172829  St6gal2 
AK014880  Armc3 
AJ278069  Clstn2 
NM_011506  Sucla2 
AF249870  Perp 
AK007857  Sdro 
AJ005564  Sprr2f 
LOG         LOG          LOG 
(D50/D10)   (D50/PBS)  (D10/PBS) 
AK032132  Cbfa2t1h 
AK012493  Pax3 
AK008191  Gsta6 
AF260557  Tbx20 
BC005431  Anpep 
AK008118  Hrmt1l3 
AK007634  Snapc5 
AJ242929  Matn3 
AF020196  Pbx1 
AF458063  Il17d 
AK034181  
D10Bwg1379e 
AK032871  Adk 
AF190699  Ttyh1 
NM_172688  Map3k7 
AK004278  Fnbp1 
L01991  Cntn3 
AK028364  Adamts4 
NM_028880  Lrrtm1 
AK028341 Ddx1 
AK011188  Robo2 
L10385  Tgm3 
D29668  Igk-V8 
AF163315  Cml2 
AF040945  Mab21l1 
AJ292467  Wdr9 
BC012704  Car4 
AF221525  Cyp2d22 
AF214016  Mocs1 
BC017147  Klc3 
AK018094  Frcl1 
AF114378  Ldb3 
M83218  S100a8 
XM_356077  Nek1 
AB010151  Stxbp1 
 











        LOG            LOG            LOG 
(D50/D10)    (D50/PBS)   (D10/PBS) 
AB036838  Ndst4 
AF272847  Sfpq 
NM_170778  Dpyd 
AF028122  Klra12 
AF020738  Fgf12 
AK020863  Gng1 
AY004873  Pramel3 
NM_134014  Xpo1 
AF003870  Galc 
AF319173  Psca 
AK014491  Xrcc3 
AB026127  Cbx3 
AF483516  Snap25 
AF066075  Pth 
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Appendix 4: Tree cluster on genes downregulated by D50 immunization (47).  
            LOG            LOG               LOG 
 (D50/D10)     (D50/PBS)    (D10/PBS) 
 NM_019670  Diap3 
 M87801  Hoxa2 
BC032880  Aldh1a7  
NM_183428  Epb4.1  AF085696  Kcnj15 
 AF302503  Peli1 
 BC020177  Atp1a3 
 AK019553  Daf2 
NM_009071  Rock1  
XM_485570  Mll5  AK012463  Psmd7 
 NM_019550  Ptbp2 
 AK004594  Usp16 
 AF099187  Pde3a 
AF162853  Nfat5  
NM_008307  Htf9c  NM_177306  Rfxdc1 
 NM_194062  Nalp9c 
 AF090376  Gabre 
 AK013905  Wt1 
BC003475  Tubb2  
AK080899  Trpm6  BC061172  Tncc 
 NM_009535  Yes 
 AK032106  Syt4 
 AK004597  Icam1 
BC013459  Bmp4  
AF027503  Baiap1  NM_007904  Ednrb 
 NM_134048  Cbll1 
 AK052685  Ren1 
 NM_008608  Mmp14 
NM_031394  Sytl2  
AF365933  Zfp264  NM_016962  Spg4 
 AF213388  Abcc2 
 NM_144822  Cbara1 
 AK014887  Pde1c 
AF096867  Syn2  
AF176530  Fbxo15  AK010296  Zdhhc6 
 AK035987  Egfl5 
 NM_015823  Acvrinp1 
 AK011379  Rad51ap1 
AB041810  Bxdc1  
NM_011444 Sox5  AB003503  Gspt2 
 




 Appendix 5: Tree cluster on genes upregulated by D50 immunization (19). 
 
            LOG            LOG               LOG 
 
 
(D50/D10)     (D50/PBS)    (D10/PBS) 
AK036112  Kcna4 
 AF325263  Sfxn4 
 NM_181728  Art2 
 NM_011122  Plod1 
BC026463  Rerg  
NM_026201  Ccar1  NM_019628  Prpmp5  AJ621426  Sprn 
 AF051102  Ggh 
 AK036010  Vldlr 
AF073882  Mtmr7  
AF184981  Fmo2  AK043718  Pnma2  BC050965  Fzd3 
 AF406755  Tgfbr2 
 AB008160  Stat3 
AF201285  Tgfb1i4  
AB030729  Papolb  AB023631  Ces3  
 





















Appendix 6: Tree cluster on unknown genes downregulated in D10 group (50) 
         LOG              LOG             LOG  (D50/D10)     (D50/PBS)    (D10/PBS)  AK008407  2310057J18Rik 
 BE981626  EST 
 BB432990  EST 
 BB025438  EST 
 BG066476  EST 
 C76958   D7Ertd143e  
AV306186  EST  
AK014695  4833414E09Rik  
 AV229522  EST 
 BM238675  EST  
BB552737  EST  
NM_173432  AW539964  
 AW121529  EST 
 BG079055  EST  
AK015738  4930509K18Rik  
AK014370  3300002I10Rik  
 BG082689  EST 
 AK012378  6330407J23Rik  
BB035685  EST  
BB364961  EST  
 AK033891  A230055J12Rik 
 AK046123  AV344025  
AW491340  EST  
AK035504  AU041483  
 BG067121  EST 
 NM_183029  C330012H03Rik  
NM_010349  EST  
AI848860  1500002B03Rik  
 AK010213  2310079D11Rik 
 AW556170  EST  
AK054336  AI987712  
AI415201  1500011B03Rik  
 BB667258  4930563B10Rik 
 AK006268  1700023D19Rik  
BB383493  7530428D23Rik  
AV240479  EST  
 AK011587  2610028F08Rik 
 AK032438  6430546I09  
XM_484214  2900024P20Rik  
AI451419  EST  
AK020539  9530003O04Rik  
AK016643  4933403O03Rik  
BG063476  EST  
AU067727  D5Buc30e  
AK010727  2410077I05Rik  
BB087975   EST  
AK029473  E230016M11Rik  
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Appendix 7: Tree cluster on unknown genes upregulated in D10 group (37) 
           LOG            LOG            LOG 
(D50/D10)     (D50/PBS)    (D10/PBS) 
XM_483888  LOC432450 
BG079266  EST 
BG070345  EST 
AK003475  1110005L13Rik 
AK015639   4930487N04Rik 
AK016653  4933404K13Rik 
AK021311  D530037P16Rik 
XM_125968  1700034F02Rik 
BG074689  EST 
AW552105  EST 
AK015891  4930524O08Rik 
AF463524  2610510D13Rik 
AK012462  C330014O21Rik 
BB525091  D430002O22Rik 
AK014727  4833419G08Rik 
AK018926  1700094C09Rik 
AK037152  A030001H23Rik 
AK007164  1700110M21Rik 
BE957357  EST 
AK016521  4932412D23Rik 
AK004797  1200015N20Rik 
NM_029640  1810044A24Rik 
AK018558  9030618K22Rik 
BB150699  EST 
XM_354606  Gene model 877, (NCBI)  
BE957323  EST 
AK012462  C330014O21Rik 
AK079326  9630025B04Rik 
AK002675  0610025O11Rik 
C79309  EST 
BG071600  EST 
BB210907   EST 
AK006027  4930509O20Rik 
XM_112125  Gene model 47, (NCBI) 
AK011897  2610206C17Rik 
BQ175572   EST 
BB041915  EST 
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Appendix 8: Tree cluster on unknown genes downregulated in D50 group (62) 
               LOG              LOG              LOG 
XM_355193  LOC381251 
NM_028330  2810051F02Rik 
NM_172767  Loh11cr2a 
AK017960  5830431M20Rik 
XM_143339  EST 
AA589418  EST 
BG063769  EST 
AK077016  4932411A10 
XM_484154  4930512B01Rik 
AK039627  BC023106 
BG075036  EST 
AK006848  4933416O17Rik 
BE197105  A430093A21Rik 
BG069580  EST 
AK021247  C430039J16Rik 
AI428512  G630054C21Rik 
AK003346  1110003E08Rik 
BB525754   EST 
NM_177368  8430438D04Rik 
AK018072  6130400H19Rik 
BC026389  EST 
BB085975  A830082N09Rik 
AK076770  4930443F05Rik 
AK018247  6330571C24Rik 
BM239546  EST 
AI504701  9130020L07Rik 
AK004797  1200015N20Rik 
AU045440  EST 
AC079938  9030607J07Rik 
AK034150  B230343J05Rik 
AK015886  4930524J08Rik 
AK083486  D2Ertd173e 
AK002265  0610030G03Rik 
C80900  EST 
AK011513  2610022C02Rik 
XM_358416  Gm1567 
BB114080  EST 
BM240141  EST 
AK007269  1700124K17Rik 
XM_483987  LOC432536 
AV277898  EST 
AK020543  9530004M16Rik 
AK019903  5330422M15Rik 
AK020466  9430052A13Rik 
XM_484154  4930512B01Rik 
BB091346  EST 
BB473987  EST 
XM_354606  Gm877 
AK016186  4930560O18Rik 
BC060982  U46068 
NM_175205  4632419I22Rik 
BC010246  2810431N21Rik 
AK021083  C030015A19Rik 
AK018999  1700129O19Rik 
AV092359  EST 
AI429145  1700009N14Rik 
XM_145503  LOC243905 
AB016273  1700026P10Rik 
AK014995  4933437F24Rik 
AU022054  EST 
NM_001009980  2410193C02Rik 
XM_484525  BC031575 
 
(D50/D10)     (D50/PBS)     (D10/PBS) 
-3.0                    1:1                     3.0 
 250




 NM_026407  2610033C09Rik 
NM_172540  4732479N06Rik  
BG073657  EST  
BB797794  EST  BB267006  EST 
 AK043509  B230216G23Rik 
 R74675  D7Bwg0826e 
AK032648  9630011N22Rik  
AK009298  2310011G06Rik  
AK014037  3110009O07Rik  AK007203  1700113P08Rik 
 AK038386  A230001M10Rik 
 AK006804  1700055O19Rik 
AK029949  4933409K07Rik  
AV382158  EST  
AK017939  5830418G11Rik  BB271008  A830052D11Rik 
 XM_126551  9930033H14Rik 
 AK045684  B230303O12Rik 
AK084765  D330040H18Rik  
AV269323  EST  
AK045392  BC019943  AK033975  9330161F08Rik 
           LOG            LOG            LOG 
(D50/D10)     (D50/PBS)   (D10/PBS) 





















Appendix 10: Restriction map and multiple cloning site of pCI vector. 
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